{"matching_results": 29964, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1355, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1155}, {"key": "negative", "matching_results": 191}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "tickerreport.com", "matching_results": 775, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 698}, {"key": "negative", "matching_results": 76}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 766, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 684}, {"key": "negative", "matching_results": 82}]}]}, {"key": "dailypolitical.com", "matching_results": 765, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 673}, {"key": "negative", "matching_results": 92}]}]}, {"key": "watchlistnews.com", "matching_results": 759, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 681}, {"key": "negative", "matching_results": 78}]}]}, {"key": "thelincolnianonline.com", "matching_results": 703, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 622}, {"key": "negative", "matching_results": 81}]}]}, {"key": "zolmax.com", "matching_results": 663, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 588}, {"key": "negative", "matching_results": 75}]}]}, {"key": "freelancer.com.co", "matching_results": 657, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 598}, {"key": "negative", "matching_results": 50}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "theolympiareport.com", "matching_results": 573, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 498}, {"key": "negative", "matching_results": 74}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "openpr.com", "matching_results": 495, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 441}, {"key": "negative", "matching_results": 47}, {"key": "neutral", "matching_results": 7}]}]}]}], "results": [{"id": "jpg37umJah8HBxQSrVW66YfcfwWo9uBMfEh7IwKj9AsKjqR0qcBMblRN4Tidjl6y", "result_metadata": {"score": 37.011787}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.670187, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.492359, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.230595, "label": "negative"}, "relevance": 0.966282}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.8818}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240447}]}, "crawl_date": "2018-11-06T13:18:05Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45201182-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T12:52:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.63547, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.546544, "label": "/real estate/buying and selling homes"}, {"score": 0.482893, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.470469, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.963268}, {"text": "POSITION DISCLOSURE/DEALING DISCLOSURE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.835375}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.729269}, {"text": "disclosure Dealing Disclosure05/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6707}, {"text": "RELEVANT SECURITIES REPRESENTING", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642298}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552319}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514888}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501531}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470999}, {"text": "possible cash offer", "sentiment": {"score": 0.403939, "label": "positive"}, "relevance": 0.464383}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392215}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321408}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313157}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310819}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291474}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281263}, {"text": "vehicle companies", "sentiment": {"score": -0.502585, "label": "negative"}, "relevance": 0.277052}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260288}, {"text": "YesShire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2488}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237089}]}, "extracted_metadata": {"sha1": "6501627147f35912af04cfbdd0c9b4bff2cab733", "filename": "1541510285377.zip-b759f6f8cecf00545719c6e6ed44ea86.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: Nachrichten zu Aktien aus asien"}, {"id": "laN2ihOl3Awc6NoJ8G53ESTMAgiM3nOPq1lMm0wia3a0MLcco4lNYmHnMXaHjHrh", "result_metadata": {"score": 36.68119}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.227882, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.6599, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.515794, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.227882, "label": "negative"}, "relevance": 0.929457}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.867554}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360849}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355108}]}, "crawl_date": "2018-11-06T13:07:08Z", "url": "https://www.marketscreener.com/LONDON-STOCK-EXCHANGE-4005918/news/Norges-Bank-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-Amended-27555103/", "host": "marketscreener.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.607355, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.554693, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.535066, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.531799, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.518146, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501254, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.492199, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.466084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.466084, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.466084, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0157859, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree: N/A (e) Date position held/dealing", "keywords": [{"text": "Date position held/dealing"}, {"text": "N/A"}, {"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "02/11/2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 02/11/2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " Class of relevant security: Ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 7,012,558 0.88 (2) Cash-settled derivatives: 2,551,000 0.32 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "9,563,558 1.20 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " TOTAL: 9,563,558 1.20 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 06/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 06/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "+4724073297 Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Date of disclosure: 06/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.974937, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.53982, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.519965, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.515125, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.488407, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.435518, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.419439, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.408085, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.384516, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.37222, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.370318, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.362866, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.356231, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.355712, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.353701, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338907, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.730911, "label": "/real estate/buying and selling homes"}, {"score": 0.493973, "label": "/finance/financial news"}, {"score": 0.273856, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Sale 59,700 JPY 4,592.0000 Ordinary Sale 6,000 JPY 4,592.0000 Ordinary Sale 38,300 JPY 4,602.9121 Ordinary Sale 3,800 JPY 4,602.9121 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.763044, "arguments": [{"text": "i", "location": [3248, 3249], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Writing", "location": [3251, 3258], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3848, 3853], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3858, 3862], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4222, 4228], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4239, 4246], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 06/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5117, 5123], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5131, 5135], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5278, 5302], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5270, 5275], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5437, 5442], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5456, 5483], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.398424, "label": "positive"}, "relevance": 0.951806}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.826781}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.649315}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.640479}, {"text": "disclosure Dealing Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558024}, {"text": "short positions", "sentiment": {"score": -0.262887, "label": "negative"}, "relevance": 0.551023}, {"text": "Ordinary Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503793}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491826}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47416}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.474056}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467526}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.450498}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450447}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449921}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.445099}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4432}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43939}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436365}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433657}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433238}, {"text": "unit Ordinary Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432422}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431667}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.430782}, {"text": "long/short position Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429639}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.426063}, {"text": "possible cash offer", "sentiment": {"score": 0.410812, "label": "positive"}, "relevance": 0.4259}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425544}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.408511, "label": "negative"}, "relevance": 0.424139}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419222}, {"text": "Chiaroni Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419173}, {"text": "conversion Details Price", "sentiment": {"score": 0.287349, "label": "positive"}, "relevance": 0.4182}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415757}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414045}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403678}, {"text": "person", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.403098}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390925}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381665}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379073}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378561}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374382}, {"text": "vehicle companies", "sentiment": {"score": -0.671605, "label": "negative"}, "relevance": 0.372914}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370862}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369304}, {"text": "e.g. American", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369215}, {"text": "option arrangement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368789}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368293}, {"text": "Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36799}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367983}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367236}, {"text": "interests", "sentiment": {"score": -0.262887, "label": "negative"}, "relevance": 0.366644}]}, "extracted_metadata": {"sha1": "fa4c3fde19a7043f5488da960ad7a3592911b15c", "filename": "1541509628256.zip-7806391d0e8b732e1b44e361752931c2.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "Norges Bank : - Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "IcR6vMD8_73-weNEXmvDMp8pu5ylqXD2SrVqbK29f3VtmQ4s3FN2y_IM54-337aL", "result_metadata": {"score": 36.459457}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759689, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.989648}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.706937}]}, "crawl_date": "2018-11-06T13:26:06Z", "url": "https://www.euroinvestor.com/news/2018/11/06/form-83-takeda-pharmaceutical-co-ltd-amended/13924195", "host": "euroinvestor.com", "text": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended PR Newswire London, November 6 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T12:41:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.843315, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.265269, "label": "negative"}, "text": "Norges Bank", "relevance": 0.793929, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.562751, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555071, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.536524, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.535397, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.531584, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.516675, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.489322, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.489322, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.489322, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0858814, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.968333, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.531703, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.512334, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.507869, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.481832, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.429364, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.413451, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.402773, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.379419, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372159, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.371355, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Option contract", "relevance": 0.367087, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.362835, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.352296, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.351132, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.345614, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338842, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.718324, "label": "/real estate/buying and selling homes"}, {"score": 0.513091, "label": "/finance/financial news"}, {"score": 0.271201, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "populationOf", "sentence": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended PR Newswire London, November 6 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.226785, "arguments": [{"text": "8.3", "location": [100, 103], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "FORM", "location": [95, 99], "entities": [{"type": "Organization", "text": "Norges Bank - Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended PR Newswire London, November 6 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.594818, "arguments": [{"text": "PUBLIC", "location": [104, 110], "entities": [{"type": "Person", "text": "PUBLIC"}]}, {"text": "FORM", "location": [95, 99], "entities": [{"type": "Organization", "text": "Norges Bank - Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Sale 59,700 JPY 4,592.0000 Ordinary Sale 6,000 JPY 4,592.0000 Ordinary Sale 38,300 JPY 4,602.9121 Ordinary Sale 3,800 JPY 4,602.9121 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.763044, "arguments": [{"text": "i", "location": [3338, 3339], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Writing", "location": [3341, 3348], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3938, 3943], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3948, 3952], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4312, 4318], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4329, 4336], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 06/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5205, 5211], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5219, 5223], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5366, 5390], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5358, 5363], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5525, 5530], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5544, 5571], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.398424, "label": "positive"}, "relevance": 0.928617}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.794591}, {"text": "short positions", "sentiment": {"score": -0.446215, "label": "negative"}, "relevance": 0.52964}, {"text": "disclosure", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.464721}, {"text": "Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421466}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.412405}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405262}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.391462}, {"text": "Norges Bank", "sentiment": {"score": -0.265269, "label": "negative"}, "relevance": 0.376344}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.363709}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359068}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356537}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354516}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354056}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352903}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.347495}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.346202}, {"text": "derivative transactions", "sentiment": {"score": -0.426963, "label": "negative"}, "relevance": 0.343977}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342475}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.429787, "label": "negative"}, "relevance": 0.340154}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338213}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334976}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333567}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333236}, {"text": "person", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.332843}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32502}, {"text": "reference securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324371}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.298228}, {"text": "JPY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.296384}, {"text": "option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295776}, {"text": "PR Newswire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.293464}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.293331}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291763}, {"text": "vehicle companies", "sentiment": {"score": -0.671605, "label": "negative"}, "relevance": 0.291697}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291681}, {"text": "interests", "sentiment": {"score": -0.467783, "label": "negative"}, "relevance": 0.288732}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285905}, {"text": "Details", "sentiment": {"score": 0.256651, "label": "positive"}, "relevance": 0.285097}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285014}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280437}, {"text": "Option money", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279615}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279457}, {"text": "e.g. CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278736}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278598}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278136}, {"text": "Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278126}, {"text": "e.g. American", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277862}, {"text": "option relates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277573}, {"text": "Expiry date", "sentiment": {"score": -0.343513, "label": "negative"}, "relevance": 0.277272}, {"text": "agreements", "sentiment": {"score": 0.0297728, "label": "positive"}, "relevance": 0.277127}]}, "extracted_metadata": {"sha1": "7f3de75f64cffe8031651028c0da24c7b4aec5f6", "filename": "1541510766608.zip-3011e2d828b493787630bf6af9aa9b4e.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended", "forum_title": "Latest Financial News, Stock News, Forex News and Commodity Market News - Euroinvestor"}, {"id": "aaKsmMXUVdFyywCLHPRbJKNMfBsaunQeGr2_hYLaqhiYC-eIAYg81sKbACS2bilG", "result_metadata": {"score": 34.96812}, "author": "shweeta", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Immune system", "relevance": 0.883275, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Chemotherapy", "relevance": 0.817504, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Oncology", "relevance": 0.76464, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}], "categories": [{"score": 0.646959, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [], "keywords": [{"text": "Anticancer Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.946774}, {"text": "Record Sturdy Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.940954}]}, "crawl_date": "2018-11-05T23:06:11Z", "url": "https://www.findmarketresearch.org/2018/11/anticancer-drugs-market-to-record-sturdy-growth-by-2025/", "host": "findmarketresearch.org", "text": "Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T08:52:00+05:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.670335, "label": "negative"}, "text": "Cancer", "relevance": 0.21836, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.168329, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "executive", "relevance": 0.151952, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Geographical and Competitive Dynamics", "relevance": 0.139988, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.138784, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.133013, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "F. Hoffmann-La Roche Ltd", "relevance": 0.12761, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.125467, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.122288, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CELGENE CORPORATION", "relevance": 0.121551, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.120688, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.118474, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.11795, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.117193, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.116432, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.202534, "label": "positive"}, "text": "Amgen Inc", "relevance": 0.114163, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": -0.253321, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.113881, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.113208, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.113189, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.112954, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.112954, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.0650529, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "This report on the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "report"}, {"text": "market"}], "entities": []}, "sentence": " This report on the global anticancer drugs market analyzes the current and future prospects of the market.", "object": {"text": "the current and future prospects of the market", "keywords": [{"text": "future prospects"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.", "object": {"text": "an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments", "keywords": [{"text": "elaborate executive summary"}, {"text": "market snapshot"}, {"text": "various segments"}, {"text": "overall information"}], "entities": [{"type": "JobTitle", "text": "executive"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprises", "normalized": "comprise"}}, {"subject": {"text": "a market snapshot that provides overall information of various segments and sub-segments", "keywords": [{"text": "market snapshot"}, {"text": "various segments"}, {"text": "overall information"}, {"text": "sub-segments"}]}, "sentence": " The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.", "object": {"text": "an elaborate executive summary", "keywords": [{"text": "elaborate executive summary"}], "entities": [{"type": "JobTitle", "text": "executive"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "a market snapshot", "keywords": [{"text": "market snapshot"}]}, "sentence": " The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.", "object": {"text": "overall information of various segments and sub-segments", "keywords": [{"text": "various segments"}, {"text": "overall information"}, {"text": "sub-segments"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The research", "keywords": [{"text": "research"}]}, "sentence": " The research is a combination of primary and secondary research.", "object": {"text": "a combination of primary and secondary research", "keywords": [{"text": "secondary research"}, {"text": "combination"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Primary research", "keywords": [{"text": "Primary research"}]}, "sentence": " Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails.", "object": {"text": "the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails", "keywords": [{"text": "telephonic interviews"}, {"text": "research efforts"}, {"text": "e-mails"}, {"text": "bulk"}]}, "action": {"verb": {"text": "form", "tense": "past"}, "text": "formed", "normalized": "form"}}, {"subject": {"text": "study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases", "keywords": [{"text": "stock analysis presentations"}, {"text": "company websites"}, {"text": "annual reports"}, {"text": "press releases"}]}, "sentence": " Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases.", "object": {"text": "Secondary research", "keywords": [{"text": "Secondary research"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors.", "object": {"text": "$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors", "keywords": [{"text": "micro environmental factors"}, {"text": "segment"}, {"text": "macro"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Growth rates for each segment within the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "segment"}, {"text": "Growth rates"}, {"text": "market"}], "entities": []}, "sentence": " Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have been determined", "normalized": "have be determine"}}, {"subject": {"text": "Growth rates for each segment within the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "segment"}, {"text": "Growth rates"}, {"text": "market"}], "entities": []}, "sentence": " Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.", "object": {"text": "determined"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Growth rates for each segment within the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "segment"}, {"text": "Growth rates"}, {"text": "market"}], "entities": []}, "sentence": " Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.", "action": {"verb": {"text": "determine", "tense": "past"}, "text": "have been determined", "normalized": "have be determine"}}, {"subject": {"text": "A detailed qualitative analysis of factors", "keywords": [{"text": "qualitative analysis"}, {"text": "factors"}]}, "sentence": " A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section.", "object": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities", "keywords": [{"text": "qualitative analysis"}, {"text": "market growth"}, {"text": "future opportunities"}, {"text": "factors"}]}, "sentence": " A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section.", "object": {"text": "provided in the market overview section", "keywords": [{"text": "market overview section"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "overall competitive scenario"}, {"text": "market attractiveness analysis"}, {"text": "thorough analysis"}], "entities": []}, "sentence": " This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.", "object": {"text": "This section of the report", "keywords": [{"text": "section"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "market attractiveness analysis", "keywords": [{"text": "market attractiveness analysis"}]}, "sentence": " This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.", "object": {"text": "a thorough analysis of the overall competitive scenario", "keywords": [{"text": "overall competitive scenario"}, {"text": "thorough analysis"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025", "keywords": [{"text": "compound annual growth"}, {"text": "Mn"}, {"text": "rate"}, {"text": "period"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.", "object": {"text": "provided for all the segments", "keywords": [{"text": "segments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "2025"}, "sentence": " Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.", "object": {"text": "for all the segments", "keywords": [{"text": "segments"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "2016"}, "sentence": " Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.", "action": {"verb": {"text": "consider", "tense": "present"}, "text": "considering", "normalized": "consider"}}, {"subject": {"text": "market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer,", "keywords": [{"text": "high prevalence rate"}, {"text": "preference"}, {"text": "rise"}, {"text": "therapies"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.", "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth", "keywords": [{"text": "historical year-on-year growth"}, {"text": "various geographies"}, {"text": "healthcare expenditure"}, {"text": "capita"}], "entities": []}, "sentence": " Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.", "object": {"text": "into consideration", "keywords": [{"text": "consideration"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "have been taken", "normalized": "have be take"}}, {"subject": {"text": "market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth", "keywords": [{"text": "high prevalence rate"}, {"text": "historical year-on-year growth"}, {"text": "various geographies"}, {"text": "healthcare expenditure"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.", "object": {"text": "the market size", "keywords": [{"text": "market size"}]}, "action": {"verb": {"text": "estimate", "tense": "present"}, "text": "estimating", "normalized": "estimate"}}, {"subject": {"text": "Anticancer drugs", "keywords": [{"text": "Anticancer drugs"}]}, "sentence": " Anticancer drugs are also known as antineoplastic drugs.", "object": {"text": "as antineoplastic drugs", "keywords": [{"text": "antineoplastic drugs"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are also known", "normalized": "be also know"}}, {"subject": {"text": "These drugs", "keywords": [{"text": "drugs"}]}, "sentence": " These drugs prevents and inhibits the growth of cancer cells.", "object": {"text": "the growth of cancer cells", "keywords": [{"text": "cancer cells"}, {"text": "growth"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibits", "normalized": "inhibit"}}, {"subject": {"text": "global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}], "entities": []}, "sentence": " Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs.", "object": {"text": "segmented into cytotoxic drugs, targeted drugs, and hormonal drugs", "keywords": [{"text": "cytotoxic drugs"}, {"text": "hormonal drugs"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}], "entities": []}, "sentence": " Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs.", "object": {"text": "into cytotoxic drugs, targeted drugs, and hormonal drugs", "keywords": [{"text": "cytotoxic drugs"}, {"text": "hormonal drugs"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The targeted drugs segment", "keywords": [{"text": "targeted drugs segment"}]}, "sentence": " The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others.", "object": {"text": "further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others", "keywords": [{"text": "tyrosine kinase inhibitors"}, {"text": "monoclonal antibodies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The targeted drugs segment", "keywords": [{"text": "targeted drugs segment"}]}, "sentence": " The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others.", "object": {"text": "into monoclonal antibodies", "keywords": [{"text": "monoclonal antibodies"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "The segment", "keywords": [{"text": "segment"}]}, "sentence": " The segment is anticipated to hold a significant share of the global market.", "object": {"text": "anticipated to hold a significant share of the global market", "keywords": [{"text": "significant share"}, {"text": "global market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The segment", "keywords": [{"text": "segment"}]}, "sentence": " The segment is anticipated to hold a significant share of the global market.", "object": {"text": "a significant share of the global market", "keywords": [{"text": "significant share"}, {"text": "global market"}], "entities": []}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "is anticipated to hold", "normalized": "be anticipate to hold"}}, {"subject": {"text": "The targeted drugs", "keywords": [{"text": "targeted drugs"}]}, "sentence": " The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.", "object": {"text": "a significant demand", "keywords": [{"text": "significant demand"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "The targeted drugs", "keywords": [{"text": "targeted drugs"}]}, "sentence": " The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.", "action": {"verb": {"text": "continue", "tense": "future"}, "text": "is expected to continue dominating", "normalized": "be expect to continue dominate"}}, {"subject": {"text": "The targeted drugs", "keywords": [{"text": "targeted drugs"}]}, "sentence": " The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "is expected to continue dominating", "normalized": "be expect to continue dominate"}}, {"subject": {"text": "therapy type, global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}, {"text": "therapy type"}], "entities": []}, "sentence": " Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others.", "object": {"text": "segmented into chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}], "entities": []}, "sentence": " Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others.", "object": {"text": "into chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "therapy", "keywords": [{"text": "therapy"}]}, "sentence": " Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period.", "object": {"text": "the highest share of the market", "keywords": [{"text": "highest share"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "Targeted therapy", "keywords": [{"text": "therapy"}]}, "sentence": " Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period.", "object": {"text": "anticipated to dominate the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Targeted therapy", "keywords": [{"text": "therapy"}]}, "sentence": " Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "is anticipated to dominate", "normalized": "be anticipate to dominate"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "sentence": " Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period.", "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "is anticipated to dominate", "normalized": "be anticipate to dominate"}}, {"subject": {"text": "Side effects of chemotherapy and specificity of the targeted drug", "keywords": [{"text": "specificity"}, {"text": "chemotherapy"}, {"text": "effects"}, {"text": "drug"}]}, "sentence": " Side effects of chemotherapy and specificity of the targeted drug are the factors driving the growth of global market.", "object": {"text": "the factors driving the growth of global market", "keywords": [{"text": "global market"}, {"text": "factors"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}], "entities": []}, "sentence": " Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others.", "object": {"text": "segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others", "keywords": [{"text": "colorectal cancer"}, {"text": "lung cancer"}, {"text": "breast cancer"}, {"text": "leukemia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global anticancer drugs market", "keywords": [{"text": "global anticancer drugs"}], "entities": []}, "sentence": " Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others.", "object": {"text": "into lung cancer, breast cancer, leukemia, colorectal cancer and others", "keywords": [{"text": "colorectal cancer"}, {"text": "lung cancer"}, {"text": "breast cancer"}, {"text": "leukemia"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "anticancer drugs market", "keywords": [{"text": "anticancer drugs"}, {"text": "market"}], "entities": []}, "sentence": " anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "object": {"text": "been segmented into five regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "anticancer drugs market", "keywords": [{"text": "anticancer drugs"}, {"text": "market"}], "entities": []}, "sentence": " anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "object": {"text": "segmented into five regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "anticancer drugs market", "keywords": [{"text": "anticancer drugs"}, {"text": "market"}], "entities": []}, "sentence": " anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "object": {"text": "into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the regions", "keywords": [{"text": "regions"}]}, "sentence": " In addition, the regions have been further segmented by major countries from each region.", "object": {"text": "further segmented by major countries from each region", "keywords": [{"text": "major countries"}, {"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by major countries from each region", "keywords": [{"text": "major countries"}, {"text": "region"}]}, "sentence": " In addition, the regions have been further segmented by major countries from each region.", "object": {"text": "the regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "have been further segmented", "normalized": "have be far segment"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments.", "object": {"text": "major players", "keywords": [{"text": "major players"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "the anticancer drugs market", "keywords": [{"text": "anticancer drugs"}, {"text": "market"}], "entities": []}, "sentence": " The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments.", "object": {"text": "on various attributes such as company overview", "keywords": [{"text": "various attributes"}, {"text": "company overview"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Key companies", "keywords": [{"text": "Key companies"}]}, "sentence": " Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "action": {"verb": {"text": "profile", "tense": "past"}, "text": "profiled", "normalized": "profile"}}, {"subject": {"text": "F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc", "keywords": [{"text": "Bayer AG"}, {"text": "Hoffmann-La Roche"}, {"text": "CELGENE CORPORATION"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "F. Hoffmann-La Roche Ltd"}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "CELGENE CORPORATION", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Pfizer Inc", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Amgen Inc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "object": {"text": "Key companies profiled in the report", "keywords": [{"text": "Key companies"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Cancer", "relevance": 0.960491, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Chemotherapy", "relevance": 0.70299, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Oncology", "relevance": 0.636511, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Metastasis", "relevance": 0.553137, "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}, {"text": "Targeted therapy", "relevance": 0.547111, "dbpedia_resource": "http://dbpedia.org/resource/Targeted_therapy"}, {"text": "Breast cancer", "relevance": 0.517342, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.473101, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Chemotherapeutic agents", "relevance": 0.435893, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapeutic_agents"}, {"text": "Immune system", "relevance": 0.423661, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Leukemia", "relevance": 0.42106, "dbpedia_resource": "http://dbpedia.org/resource/Leukemia"}, {"text": "Lung cancer", "relevance": 0.381548, "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}, {"text": "Cancer staging", "relevance": 0.377359, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Compound annual growth rate", "relevance": 0.365248, "dbpedia_resource": "http://dbpedia.org/resource/Compound_annual_growth_rate"}, {"text": "Lymphoma", "relevance": 0.343147, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Epidemiology", "relevance": 0.339681, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Disease", "relevance": 0.337893, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Pleural effusion", "relevance": 0.332464, "dbpedia_resource": "http://dbpedia.org/resource/Pleural_effusion"}, {"text": "Colorectal cancer", "relevance": 0.332045, "dbpedia_resource": "http://dbpedia.org/resource/Colorectal_cancer"}, {"text": "Radiation therapy", "relevance": 0.331453, "dbpedia_resource": "http://dbpedia.org/resource/Radiation_therapy"}, {"text": "Chemotherapy regimens", "relevance": 0.329459, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy_regimens"}, {"text": "Bone marrow", "relevance": 0.322864, "dbpedia_resource": "http://dbpedia.org/resource/Bone_marrow"}], "categories": [{"score": 0.562161, "label": "/health and fitness"}, {"score": 0.482469, "label": "/health and fitness/therapy"}, {"score": 0.455175, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "participantIn", "sentence": "Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails.", "score": 0.639841, "arguments": [{"text": "our", "location": [424, 427], "entities": [{"type": "Person", "text": "our"}]}, {"text": "interviews", "location": [494, 504], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "locatedAt", "sentence": "Anticancer drugs Market: Geographical and Competitive Dynamics  anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.", "score": 0.701766, "arguments": [{"text": "Asia", "location": [3546, 3550], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3551, 3558], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "In addition, the regions have been further segmented by major countries from each region.", "score": 0.390588, "arguments": [{"text": "countries", "location": [3662, 3671], "entities": [{"type": "GeopoliticalEntity", "text": "countries"}]}, {"text": "region", "location": [3682, 3688], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "score": 0.686042, "arguments": [{"text": "F. Hoffmann-La Roche Ltd", "location": [3963, 3987], "entities": [{"type": "Organization", "text": "F. Hoffmann-La Roche Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3922, 3931], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "score": 0.719066, "arguments": [{"text": "Eli Lilly and Company", "location": [3989, 4010], "entities": [{"type": "Organization", "text": "Eli Lilly and Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3922, 3931], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.", "score": 0.473557, "arguments": [{"text": "Pfizer Inc", "location": [4046, 4056], "entities": [{"type": "Organization", "text": "Pfizer Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3922, 3931], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "anticancer drugs market", "sentiment": {"score": -0.0692363, "label": "negative"}, "relevance": 0.905074}, {"text": "global anticancer drugs", "sentiment": {"score": -0.0692363, "label": "negative"}, "relevance": 0.781759}, {"text": "targeted drugs segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372309}, {"text": "cytotoxic drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314553}, {"text": "antineoplastic drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313565}, {"text": "global market", "sentiment": {"score": -0.611932, "label": "negative"}, "relevance": 0.313056}, {"text": "hormonal drugs", "sentiment": {"score": -0.344745, "label": "negative"}, "relevance": 0.312618}, {"text": "market attractiveness analysis", "sentiment": {"score": 0.492025, "label": "positive"}, "relevance": 0.305153}, {"text": "market overview section", "sentiment": {"score": 0.555741, "label": "positive"}, "relevance": 0.300418}, {"text": "Market size estimations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.298901}, {"text": "lung cancer segment", "sentiment": {"score": -0.848319, "label": "negative"}, "relevance": 0.28624}, {"text": "elaborate executive summary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.282265}, {"text": "stock analysis presentations", "sentiment": {"score": 0.279604, "label": "positive"}, "relevance": 0.281256}, {"text": "thorough analysis", "sentiment": {"score": 0.492025, "label": "positive"}, "relevance": 0.279329}, {"text": "annual growth rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278614}, {"text": "historical year-on-year growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277652}, {"text": "high prevalence", "sentiment": {"score": -0.676397, "label": "negative"}, "relevance": 0.276333}, {"text": "micro environmental factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275964}, {"text": "cancer types", "sentiment": {"score": -0.59136, "label": "negative"}, "relevance": 0.27507}, {"text": "secondary research", "sentiment": {"score": -0.381398, "label": "negative"}, "relevance": 0.273856}, {"text": "tyrosine kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.273722}, {"text": "high prevalence rate", "sentiment": {"score": -0.504475, "label": "negative"}, "relevance": 0.27345}, {"text": "market snapshot", "sentiment": {"score": 0.421669, "label": "positive"}, "relevance": 0.272263}, {"text": "market growth", "sentiment": {"score": 0.555741, "label": "positive"}, "relevance": 0.271938}, {"text": "Download Sample Copy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271539}, {"text": "overall competitive scenario", "sentiment": {"score": 0.492025, "label": "positive"}, "relevance": 0.27131}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270123}, {"text": "key business strategies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267643}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267166}, {"text": "forecast period", "sentiment": {"score": -0.572992, "label": "negative"}, "relevance": 0.264463}, {"text": "Market revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26338}, {"text": "Targeted therapy", "sentiment": {"score": -0.534052, "label": "negative"}, "relevance": 0.2528}, {"text": "Research Methodology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248508}, {"text": "Growth rates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247241}, {"text": "various segments", "sentiment": {"score": 0.421669, "label": "positive"}, "relevance": 0.247152}, {"text": "Primary research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24674}, {"text": "report", "sentiment": {"score": 0.0762216, "label": "positive"}, "relevance": 0.246698}, {"text": "cancer cells", "sentiment": {"score": -0.575481, "label": "negative"}, "relevance": 0.244709}, {"text": "abnormal growth", "sentiment": {"score": -0.836194, "label": "negative"}, "relevance": 0.24469}, {"text": "qualitative analysis", "sentiment": {"score": 0.555741, "label": "positive"}, "relevance": 0.244465}, {"text": "research efforts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244423}, {"text": "colorectal cancer", "sentiment": {"score": -0.699158, "label": "negative"}, "relevance": 0.244385}, {"text": "future prospects", "sentiment": {"score": -0.415804, "label": "negative"}, "relevance": 0.244214}, {"text": "SWOT analysis", "sentiment": {"score": 0.293005, "label": "positive"}, "relevance": 0.244147}, {"text": "company websites", "sentiment": {"score": -0.381398, "label": "negative"}, "relevance": 0.243714}, {"text": "telephonic interviews", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.243192}, {"text": "various geographies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242767}, {"text": "overall information", "sentiment": {"score": 0.421669, "label": "positive"}, "relevance": 0.242461}, {"text": "breast cancer", "sentiment": {"score": -0.690647, "label": "negative"}, "relevance": 0.242124}, {"text": "press releases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24158}]}, "extracted_metadata": {"sha1": "64898f674edac255e87975da832ecef93028e88e", "filename": "1541459171192.zip-f0167dde1ee4ea21321cd311997a55ba.xml", "file_type": "json"}, "external_links": ["https://www.xploremr.com/connectus/sample/202", "https://www.xploremr.com/report/202/anticancer-drugs-market"], "title": "Anticancer Drugs to Record Sturdy Growth by 2025", "forum_title": "Research Insights \u2013 Page 29 \u2013 Find Market Research"}, {"id": "h5TnBjRzY8YWhJqpnuu1HBJ-IxnzSqB-11Q1RuDbK67Lj2egOB38EkedatiqwfnV", "result_metadata": {"score": 33.64091}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Crescendo Biologics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody", "object": {"text": "early licensing by Takeda of first oncology-targeted Humabody", "keywords": [{"text": "early licensing"}, {"text": "Takeda"}, {"text": "oncology-targeted Humabody"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}], "concepts": [], "categories": [{"score": 0.547557, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.478632, "label": "/health and fitness"}, {"score": 0.473704, "label": "/health and fitness/drugs"}], "relations": [{"type": "agentOf", "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody", "score": 0.951316, "arguments": [{"text": "Crescendo Biologics", "location": [0, 19], "entities": [{"type": "Organization", "text": "Crescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [20, 29], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}], "keywords": [{"text": "Crescendo Biologics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960139}, {"text": "early licensing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.768598}, {"text": "oncology-targeted Humabody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.608925}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.60793}]}, "crawl_date": "2018-11-06T11:05:32Z", "url": "https://www.cambridgenetwork.co.uk/news/crescendo-biologics-licensing-takeda-oncology-targeted-humabody/", "host": "cambridgenetwork.co.uk", "text": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target", "main_image_url": "http://www.cambridgenetwork.co.uk/public/news/3humabody-1.png", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T00:00:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.635587, "label": "positive"}, "text": "Takeda", "relevance": 0.882165, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.6151, "label": "positive"}, "text": "Crescendo Biologics", "relevance": 0.480232, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.440019, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Crescendo Biologics Ltd", "relevance": 0.366678, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Humabody Crescendo Biologics", "relevance": 0.36434, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.555134, "label": "positive"}, "text": "Crescendo", "relevance": 0.364306, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology Drug Discovery Unit & Immunology Unit", "relevance": 0.189611, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.382552, "label": "positive"}, "text": "Humabody", "relevance": 0.13044, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Humabodies", "relevance": 0.129564, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.359399, "label": "negative"}, "text": "developer", "relevance": 0.124813, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.665548, "label": "positive"}, "text": "Chris Arendt", "relevance": 0.120454, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.635587, "label": "positive"}, "text": "Peter Pack", "relevance": 0.119237, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.116994, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$754 million", "relevance": 0.116994, "type": "Quantity"}], "sentiment": {"document": {"score": 0.794345, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "object": {"text": "early licensing", "keywords": [{"text": "early licensing"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "Biologics", "keywords": [{"text": "Biologics"}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "object": {"text": "early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics", "keywords": [{"text": "Crescendo Biologics"}, {"text": "early licensing"}, {"text": "oncology-targeted Humabody"}, {"text": "drug developer"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Company", "text": "Crescendo Biologics Ltd"}, {"type": "JobTitle", "text": "developer"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "therapeutics", "keywords": [{"text": "therapeutics"}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "object": {"text": "T-cell", "keywords": [{"text": "T-cell"}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhancing", "normalized": "enhance"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited", "keywords": [{"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "object": {"text": "exercised an option under its existing, multi-target collaboration and licence agreement", "keywords": [{"text": "multi-target collaboration"}, {"text": "licence agreement"}, {"text": "option"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited", "keywords": [{"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "object": {"text": "an option under its existing, multi-target collaboration and licence agreement", "keywords": [{"text": "multi-target collaboration"}, {"text": "licence agreement"}, {"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "has exercised", "normalized": "have exercise"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has taken an exclusive licence to Humabodies directed to one of its oncology targets.", "object": {"text": "an exclusive licence to Humabodies directed to one of its oncology targets", "keywords": [{"text": "exclusive licence"}, {"text": "oncology targets"}, {"text": "Humabodies"}], "entities": [{"type": "Location", "text": "Humabodies", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "has taken", "normalized": "have take"}}, {"subject": {"text": "This licence", "keywords": [{"text": "licence"}]}, "sentence": " This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae leads meeting its stringent criteria.Dr Peter Pack, CEO of Crescendo, commented: \u201cThe team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae", "keywords": [{"text": "highly successful delivery"}, {"text": "pre-clinical evaluation"}, {"text": "Takeda"}, {"text": "Humabody\u00ae"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "mark", "tense": "present"}, "text": "earlier than planned and marks", "normalized": "early than plan and mark"}}, {"subject": {"text": "The team at Crescendo", "keywords": [{"text": "Crescendo"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae leads meeting its stringent criteria.Dr Peter Pack, CEO of Crescendo, commented: \u201cThe team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "made great progress on our Humabody programmes", "keywords": [{"text": "great progress"}, {"text": "Humabody programmes"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The team at Crescendo", "keywords": [{"text": "Crescendo"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae leads meeting its stringent criteria.Dr Peter Pack, CEO of Crescendo, commented: \u201cThe team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "great progress", "keywords": [{"text": "great progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "has made", "normalized": "have make"}}, {"subject": {"text": "we"}, "sentence": " To date, we have met all the technical milestones on time or earlier than planned, which is proof of our excellent collaboration.", "object": {"text": "met all the technical milestones on time", "keywords": [{"text": "technical milestones"}, {"text": "time"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " To date, we have met all the technical milestones on time or earlier than planned, which is proof of our excellent collaboration.", "object": {"text": "all the technical milestones", "keywords": [{"text": "technical milestones"}]}, "action": {"verb": {"text": "meet", "tense": "past"}, "text": "have met", "normalized": "have meet"}}, {"subject": {"text": "We"}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit", "keywords": [{"text": "Oncology Drug Discovery"}, {"text": "Chris Arendt"}, {"text": "Immunology Unit"}, {"text": "future successes."}], "entities": [{"type": "Person", "text": "Chris Arendt"}, {"type": "JobTitle", "text": "Oncology Drug Discovery Unit & Immunology Unit"}]}, "action": {"verb": {"text": "delight", "tense": "past"}, "text": "delighted", "normalized": "delight"}}, {"subject": {"text": "the option to license", "keywords": [{"text": "option"}]}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "taken by Takeda", "keywords": [{"text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "the option to license", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "has been taken", "normalized": "have be take"}}, {"subject": {"text": "we"}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "to research diverse modalities to bring transformative treatments to patients with cancer", "keywords": [{"text": "research diverse modalities"}, {"text": "transformative treatments"}, {"text": "patients"}, {"text": "cancer"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "we"}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "diverse modalities", "keywords": [{"text": "diverse modalities"}]}, "action": {"verb": {"text": "research", "tense": "future"}, "text": "continue to research", "normalized": "continue to research"}}, {"subject": {"text": "we"}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.\u201dChris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \u201cAt Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "transformative treatments", "keywords": [{"text": "transformative treatments"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "to bring", "normalized": "to bring"}}, {"subject": {"text": "the licence", "keywords": [{"text": "licence"}]}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.\u201dTakeda\u2019s option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "on the quality of the Humabody", "keywords": [{"text": "quality"}, {"text": "Humabody"}], "entities": [{"type": "Location", "text": "Humabody", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "was based", "normalized": "be base"}}, {"subject": {"text": "we"}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.\u201dTakeda\u2019s option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "improved and differentiated immuno-oncology therapies.", "keywords": [{"text": "differentiated immuno-oncology therapies"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "see to develop", "normalized": "see to develop"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.\u201dTakeda\u2019s option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "immuno-oncology therapies.\u201dTakeda\u2019s option", "keywords": [{"text": "Takeda\u2019s option"}, {"text": "immuno-oncology therapies."}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.\u201dTakeda\u2019s option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "part of the existing multi-target collaboration", "keywords": [{"text": "multi-target collaboration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "licence agreement", "keywords": [{"text": "licence agreement"}]}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.\u201dTakeda\u2019s option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration", "keywords": [{"text": "Humabody\u00ae-based therapeutics"}, {"text": "Takeda"}, {"text": "collaboration"}, {"text": "right"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Crescendo", "keywords": [{"text": "Crescendo"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " Under the agreement, Crescendo is eligible to receive clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda.", "object": {"text": "eligible to receive clinical development", "keywords": [{"text": "clinical development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Crescendo", "keywords": [{"text": "Crescendo"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " Under the agreement, Crescendo is eligible to receive clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda.", "object": {"text": "clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda", "keywords": [{"text": "sales-based milestone payments"}, {"text": "Humabody\u00ae-based product sales"}, {"text": "clinical development"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Quantity", "text": "$754 million"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "to receive", "normalized": "to receive"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Crescendo Biologics is a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.", "object": {"text": "a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics", "keywords": [{"text": "next-generation antibody"}, {"text": "Cambridge-based company"}, {"text": "therapeutics"}, {"text": "vision"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "next-generation antibody therapeutics", "keywords": [{"text": "next-generation antibody"}, {"text": "therapeutics"}]}, "sentence": " Crescendo Biologics is a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.", "object": {"text": "on novel class-leading platforms", "keywords": [{"text": "novel class-leading platforms"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}], "concepts": [{"text": "License", "relevance": 0.910296, "dbpedia_resource": "http://dbpedia.org/resource/License"}, {"text": "Royalties", "relevance": 0.894455, "dbpedia_resource": "http://dbpedia.org/resource/Royalties"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.8811, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.779667, "label": "/science/medicine/oncology"}, {"score": 0.416813, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "agentOf", "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "score": 0.98642, "arguments": [{"text": "Crescendo Biologics", "location": [0, 19], "entities": [{"type": "Organization", "text": "Crescendo Biologics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [20, 29], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "partOfMany", "sentence": "\"Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \"At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.851828, "arguments": [{"text": "Takeda", "location": [1252, 1258], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "we", "location": [1260, 1262], "entities": [{"type": "Person", "text": "our"}]}]}, {"type": "hasAttribute", "sentence": "\"Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \"At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.894458, "arguments": [{"text": "patients", "location": [1341, 1349], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1355, 1361], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "agentOf", "sentence": "\"Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.800183, "arguments": [{"text": "Takeda", "location": [1538, 1544], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announced", "location": [1627, 1636], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "\"Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.773885, "arguments": [{"text": "October 2016 where", "location": [1640, 1658], "entities": [{"type": "Date", "text": "October 2016 where"}]}, {"text": "announced", "location": [1627, 1636], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "\"Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.648673, "arguments": [{"text": "Takeda", "location": [1659, 1665], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "collaboration", "location": [1762, 1775], "entities": [{"type": "Crime", "text": "collaboration"}]}]}, {"type": "agentOf", "sentence": "\"Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.861352, "arguments": [{"text": "Humabody\u00ae", "location": [1714, 1723], "entities": [{"type": "Person", "text": "Humabody\u00ae"}]}, {"text": "collaboration", "location": [1762, 1775], "entities": [{"type": "Crime", "text": "collaboration"}]}]}, {"type": "employedBy", "sentence": "Crescendo Biologics is a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.", "score": 0.438629, "arguments": [{"text": "whose", "location": [2029, 2034], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "company", "location": [2021, 2028], "entities": [{"type": "Organization", "text": "developer"}]}]}, {"type": "agentOf", "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "score": 0.893653, "arguments": [{"text": "Crescendo Biologics", "location": [92, 111], "entities": [{"type": "Organization", "text": "Crescendo Biologics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [112, 121], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "timeOf", "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "score": 0.841305, "arguments": [{"text": "today", "location": [288, 293], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announces", "location": [294, 303], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "affectedBy", "sentence": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody 6/11/2018 Crescendo Biologics Ltd, the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited has exercised an option under its existing, multi-target collaboration and licence agreement.", "score": 0.519225, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [309, 346], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [294, 303], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "agentOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: \"The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.73462, "arguments": [{"text": "Peter Pack", "location": [744, 754], "entities": [{"type": "Person", "text": "Peter Pack"}]}, {"text": "commented", "location": [774, 783], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "managerOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: \"The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.700442, "arguments": [{"text": "CEO", "location": [756, 759], "entities": [{"type": "Person", "text": "Peter Pack"}]}, {"text": "Crescendo", "location": [763, 772], "entities": [{"type": "Organization", "text": "Crescendo Biologics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: \"The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.670905, "arguments": [{"text": "team", "location": [790, 794], "entities": [{"type": "Organization", "text": "developer"}]}, {"text": "Crescendo", "location": [798, 807], "entities": [{"type": "Organization", "text": "Crescendo Biologics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "\"Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \"At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.72811, "arguments": [{"text": "Chris Arendt", "location": [1161, 1173], "entities": [{"type": "Person", "text": "Chris Arendt"}]}, {"text": "commented", "location": [1237, 1246], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "partOfMany", "sentence": "\"Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: \"At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.865756, "arguments": [{"text": "Chris Arendt", "location": [1161, 1173], "entities": [{"type": "Person", "text": "Chris Arendt"}]}, {"text": "we", "location": [1260, 1262], "entities": [{"type": "Person", "text": "our"}]}]}], "keywords": [{"text": "Crescendo Biologics", "sentiment": {"score": 0.6151, "label": "positive"}, "relevance": 0.979585}, {"text": "Takeda", "sentiment": {"score": 0.726948, "label": "positive"}, "relevance": 0.93389}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.930216}, {"text": "Humabody Crescendo Biologics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.839704}, {"text": "Takeda team", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.780563}, {"text": "licence agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.686249}, {"text": "multi-target collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676104}, {"text": "early licensing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622296}, {"text": "stringent criteria.Dr Peter", "sentiment": {"score": 0.635587, "label": "positive"}, "relevance": 0.622267}, {"text": "oncology-targeted Humabody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611573}, {"text": "highly successful delivery", "sentiment": {"score": 0.635587, "label": "positive"}, "relevance": 0.61022}, {"text": "differentiated immuno-oncology therapies.", "sentiment": {"score": 0.382552, "label": "positive"}, "relevance": 0.602138}, {"text": "Oncology Drug Discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602088}, {"text": "sales-based milestone payments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594171}, {"text": "novel class-leading platforms", "sentiment": {"score": 0.6151, "label": "positive"}, "relevance": 0.592533}, {"text": "licence option", "sentiment": {"score": 0.635587, "label": "positive"}, "relevance": 0.58945}, {"text": "Humabody\u00ae-based product sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586888}, {"text": "exclusive licence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571736}, {"text": "excellent collaboration", "sentiment": {"score": 0.650341, "label": "positive"}, "relevance": 0.527783}, {"text": "drug developer", "sentiment": {"score": -0.359399, "label": "negative"}, "relevance": 0.526374}, {"text": "pre-clinical evaluation", "sentiment": {"score": 0.635587, "label": "positive"}, "relevance": 0.525021}, {"text": "Humabody\u00ae-based therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522654}, {"text": "oncology targets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52248}, {"text": "transformative treatments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516447}, {"text": "technical milestones", "sentiment": {"score": 0.559271, "label": "positive"}, "relevance": 0.516092}, {"text": "Chris Arendt", "sentiment": {"score": 0.665548, "label": "positive"}, "relevance": 0.516028}, {"text": "next-generation antibody", "sentiment": {"score": 0.6151, "label": "positive"}, "relevance": 0.514121}, {"text": "Cambridge-based company", "sentiment": {"score": 0.6151, "label": "positive"}, "relevance": 0.51358}, {"text": "Humabody programmes", "sentiment": {"score": 0.556185, "label": "positive"}, "relevance": 0.513325}, {"text": "great progress", "sentiment": {"score": 0.556185, "label": "positive"}, "relevance": 0.512779}, {"text": "future successes.", "sentiment": {"score": 0.81831, "label": "positive"}, "relevance": 0.510984}, {"text": "diverse modalities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508523}, {"text": "Immunology Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507698}, {"text": "clinical development", "sentiment": {"score": 0.554082, "label": "positive"}, "relevance": 0.504017}, {"text": "announces", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446633}, {"text": "T-cell", "sentiment": {"score": -0.491732, "label": "negative"}, "relevance": 0.432293}, {"text": "royalties", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422755}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421785}, {"text": "CEO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421674}, {"text": "Humabodies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420289}, {"text": "Pack", "sentiment": {"score": 0.635587, "label": "positive"}, "relevance": 0.419781}, {"text": "date", "sentiment": {"score": 0.484168, "label": "positive"}, "relevance": 0.419331}, {"text": "time", "sentiment": {"score": 0.559271, "label": "positive"}, "relevance": 0.419265}, {"text": "schedule", "sentiment": {"score": 0.81831, "label": "positive"}, "relevance": 0.418828}, {"text": "Head", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418751}, {"text": "patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418563}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41855}, {"text": "proof", "sentiment": {"score": 0.650341, "label": "positive"}, "relevance": 0.418295}]}, "extracted_metadata": {"sha1": "a7f60d73d813cf4b94a0cbc5392561c76769f21e", "filename": "1541502332084.zip-4f983304f9f8dcdfa58936dbded0f102.xml", "file_type": "json"}, "title": "Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody", "forum_title": "Cambridge Network - News"}, {"id": "x4gbQyfe5B9qjZcWzEFBXaK6kAEAEnQiKI4dTmLCKofnhL92f4LN-r1ILppB_ZuZ", "result_metadata": {"score": 32.077835}, "author": "researchinsights", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Grand View Research", "relevance": 0.33, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$77.5 Billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Vaccine Market", "keywords": [{"text": "Vaccine Market"}]}, "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc.", "object": {"text": "$77.5 Billion By 2024", "entities": [{"type": "Quantity", "text": "$77.5 Billion"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}], "concepts": [], "categories": [{"score": 0.541949, "label": "/health and fitness/disease/cold and flu"}, {"score": 0.478988, "label": "/finance/investing"}, {"score": 0.478988, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "basedIn", "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc.", "score": 0.548325, "arguments": [{"text": "Inc.", "location": [73, 77], "entities": [{"type": "Organization", "text": "Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Grand View Research", "location": [52, 71], "entities": [{"type": "GeopoliticalEntity", "text": "Grand View Research"}]}]}], "keywords": [{"text": "Vaccine Market Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.918169}, {"text": "Grand View Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.783177}]}, "crawl_date": "2018-11-06T12:37:07Z", "url": "https://express-press-release.net/news/2018/11/06/340475", "host": "express-press-release.net", "text": "Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.", "main_image_url": "https://express-press-release.net/news/wp-content/uploads/2015/11/epr-network-big-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T11:16:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Pasteur, Inc.", "relevance": 0.778379, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.266256, "label": "positive"}, "text": "Grand View Research", "relevance": 0.510607, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "polio vaccine", "relevance": 0.457934, "type": "Drug"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.449906, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.427479, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.403963, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "\u2018Immunize Australia Program", "relevance": 0.379233, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.362472, "label": "negative"}, "text": "Janssen Pharmaceuticals", "relevance": 0.367035, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Report of Biotechnology", "relevance": 0.366375, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "San Francisco", "relevance": 0.365941, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"count": 1, "sentiment": {"score": -0.712745, "label": "negative"}, "text": "colorectal cancers", "relevance": 0.350656, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.400003, "label": "negative"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.348989, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.347998, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.337214, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.333674, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson", "relevance": 0.325552, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.315145, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Ltd.", "relevance": 0.309356, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.241194, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.303037, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.302921, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.295167, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.288846, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.284531, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.275188, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Emergent BioSolutions, Inc.", "relevance": 0.270622, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CSL Ltd.", "relevance": 0.267397, "type": "Company", "disambiguation": {"subtype": [], "name": "CSL Limited", "dbpedia_resource": "http://dbpedia.org/resource/CSL_Limited"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.260692, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$77.5 Billion", "relevance": 0.260692, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.7%", "relevance": 0.260692, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.8%", "relevance": 0.260692, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14.5%", "relevance": 0.260692, "type": "Quantity"}], "sentiment": {"document": {"score": -0.238026, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Vaccine Market", "keywords": [{"text": "Vaccine Market"}]}, "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc.", "object": {"text": "$77.5 Billion By 2024", "entities": [{"type": "Quantity", "text": "$77.5 Billion"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}, {"subject": {"text": "by researchinsights in Biotech // 0 Comments", "keywords": [{"text": "Biotech"}, {"text": "researchinsights"}, {"text": "Comments"}]}, "sentence": " Posted on 2018-11-06 by researchinsights in Biotech // 0 Comments", "object": {"text": "on 2018-11-06"}, "action": {"verb": {"text": "Posted", "tense": "past"}, "text": "Posted", "normalized": "Posted"}}, {"subject": {"text": "San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation", "keywords": [{"text": "vaccine market valuation"}, {"text": "San Francisco"}, {"text": "United States"}, {"text": "/EPR Network/"}], "entities": [{"type": "Location", "text": "San Francisco", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "USCounty", "CityTown", "FilmScreeningVenue", "City"], "name": "San Francisco", "dbpedia_resource": "http://dbpedia.org/resource/San_Francisco"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc.", "object": {"text": "USD 77.5 billion", "keywords": [{"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "exceed", "tense": "future"}, "text": "is expected to exceed", "normalized": "be expect to exceed"}}, {"subject": {"text": "vaccine development", "keywords": [{"text": "vaccine development"}]}, "sentence": " Majority of the key players are focused on vaccine development to gain an edge over competitors.", "object": {"text": "an edge over competitors", "keywords": [{"text": "competitors"}, {"text": "edge"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "to gain", "normalized": "to gain"}}, {"subject": {"text": "Pfizer, Inc.,", "keywords": [{"text": "Pfizer"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}]}, "sentence": " For instance, Pfizer, Inc., is developing vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B.", "object": {"text": "vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B", "keywords": [{"text": "Clostridium difficile"}, {"text": "Staphylococcus aureus"}, {"text": "Meningococcal"}, {"text": "vaccines"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is developing", "normalized": "be develop"}}, {"subject": {"text": "the broad coalition of governments", "keywords": [{"text": "broad coalition"}, {"text": "governments"}]}, "sentence": " Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "object": {"text": "to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality", "keywords": [{"text": "immunization programs"}, {"text": "communicable diseases"}, {"text": "high morbidity"}, {"text": "vaccination benefits"}], "entities": []}, "action": {"verb": {"text": "work", "tense": "present"}, "text": "working", "normalized": "work"}}, {"subject": {"text": "the broad coalition of governments", "keywords": [{"text": "broad coalition"}, {"text": "governments"}]}, "sentence": " Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "object": {"text": "the awareness of vaccination benefits through immunization programs", "keywords": [{"text": "immunization programs"}, {"text": "vaccination benefits"}, {"text": "awareness"}]}, "action": {"verb": {"text": "promote", "tense": "future"}, "text": "working to promote", "normalized": "work to promote"}}, {"subject": {"text": "the propagation of communicable diseases", "keywords": [{"text": "communicable diseases"}, {"text": "propagation"}], "entities": []}, "sentence": " Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "object": {"text": "associated with high morbidity and mortality", "keywords": [{"text": "high morbidity"}, {"text": "mortality"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "communicable diseases", "keywords": [{"text": "communicable diseases"}], "entities": []}, "sentence": " Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "object": {"text": "with high morbidity and mortality", "keywords": [{"text": "high morbidity"}, {"text": "mortality"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "are associated", "normalized": "be associate"}}, {"subject": {"text": "the \u2018Immunize Australia Program\u2019", "keywords": [{"text": "\u2018Immunize Australia Program"}], "entities": [{"type": "Organization", "text": "\u2018Immunize Australia Program"}]}, "sentence": " For instance, the \u2018Immunize Australia Program\u2019 sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases.", "object": {"text": "the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases", "keywords": [{"text": "checks rampant disease"}, {"text": "preventative action"}, {"text": "severe diseases"}, {"text": "disease occurrence"}]}, "action": {"verb": {"text": "sponsor", "tense": "present"}, "text": "sponsors", "normalized": "sponsor"}}, {"subject": {"text": "the \u2018Immunize Australia Program\u2019 sponsors the immunization of individuals", "keywords": [{"text": "\u2018Immunize Australia Program"}, {"text": "immunization"}, {"text": "individuals"}], "entities": [{"type": "Organization", "text": "\u2018Immunize Australia Program"}]}, "sentence": " For instance, the \u2018Immunize Australia Program\u2019 sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases.", "object": {"text": "as a preventative action", "keywords": [{"text": "preventative action"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acts", "normalized": "act"}}, {"subject": {"text": "millions of Australians", "keywords": [{"text": "Australians"}, {"text": "millions"}]}, "sentence": " For instance, the \u2018Immunize Australia Program\u2019 sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases.", "object": {"text": "from severe diseases", "keywords": [{"text": "severe diseases"}]}, "action": {"verb": {"text": "protect", "tense": "present"}, "text": "thus protecting", "normalized": "thus protect"}}, {"subject": {"text": "Another program", "keywords": [{"text": "program"}]}, "sentence": " Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "object": {"text": "involved in achieving extensive immunization coverage on the Indian continent", "keywords": [{"text": "extensive immunization coverage"}, {"text": "Indian continent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Another program", "keywords": [{"text": "program"}]}, "sentence": " Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "object": {"text": "in achieving extensive immunization coverage on the Indian continent", "keywords": [{"text": "extensive immunization coverage"}, {"text": "Indian continent"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Another program", "keywords": [{"text": "program"}]}, "sentence": " Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "object": {"text": "extensive immunization coverage on the Indian continent", "keywords": [{"text": "extensive immunization coverage"}, {"text": "Indian continent"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "Another program that has been involved in achieving extensive immunization coverage on the Indian continent", "keywords": [{"text": "extensive immunization coverage"}, {"text": "Indian continent"}, {"text": "program"}]}, "sentence": " Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "object": {"text": "the National Immunization Program", "keywords": [{"text": "National Immunization Program"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a government program", "keywords": [{"text": "government program"}]}, "sentence": " Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "object": {"text": "strong preventive measures", "keywords": [{"text": "strong preventive measures"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "taking", "normalized": "take"}}, {"subject": {"text": "www.grandviewresearch.com/industry-analysis/vaccine-market", "keywords": [{"text": "www.grandviewresearch.com/industry-analysis/vaccine-market"}]}, "sentence": " To view a summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/vaccine-market", "object": {"text": "a summary of this report", "keywords": [{"text": "summary"}, {"text": "report"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "To view", "normalized": "To view"}}, {"subject": {"text": "Further key findings from the study", "keywords": [{"text": "key findings"}, {"text": "study"}]}, "sentence": " Further key findings from the study suggest: The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines.", "object": {"text": "The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines", "keywords": [{"text": "vaccine type segment"}, {"text": "highly stable nature"}, {"text": "market share"}, {"text": "easy storage"}], "entities": [{"type": "Quantity", "text": "14.5"}]}, "action": {"verb": {"text": "suggest", "tense": "present"}, "text": "suggest", "normalized": "suggest"}}, {"subject": {"text": "The inactivated vaccine type segment", "keywords": [{"text": "vaccine type segment"}]}, "sentence": " Further key findings from the study suggest: The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines.", "object": {"text": "to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines", "keywords": [{"text": "highly stable nature"}, {"text": "market share"}, {"text": "easy storage"}, {"text": "vaccines"}], "entities": [{"type": "Quantity", "text": "14.5"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "easy storage and transport due to the highly stable nature of these vaccines", "keywords": [{"text": "highly stable nature"}, {"text": "easy storage"}, {"text": "vaccines"}, {"text": "transport"}]}, "sentence": " Further key findings from the study suggest: The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines.", "object": {"text": "the related advantages", "keywords": [{"text": "advantages"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Sanofi Pasteur, Inc.", "keywords": [{"text": "Sanofi Pasteur"}], "entities": [{"type": "Company", "text": "Sanofi Pasteur, Inc."}]}, "sentence": " In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.", "object": {"text": "a new trivalent, inactivated polio vaccine in India", "keywords": [{"text": "inactivated polio vaccine"}, {"text": "India"}], "entities": [{"type": "Drug", "text": "polio vaccine"}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "The DNA vaccine segment", "keywords": [{"text": "DNA vaccine segment"}], "entities": []}, "sentence": " The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area.", "object": {"text": "presumed to be the fastest growing type over the forecast period", "keywords": [{"text": "fastest growing type"}, {"text": "forecast period"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The DNA vaccine segment", "keywords": [{"text": "DNA vaccine segment"}], "entities": []}, "sentence": " The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area.", "object": {"text": "the fastest growing type", "keywords": [{"text": "fastest growing type"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is presumed to be", "normalized": "be presume to be"}}, {"subject": {"text": "production", "keywords": [{"text": "production"}]}, "sentence": " The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area.", "object": {"text": "to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area", "keywords": [{"text": "cell-based vaccines"}, {"text": "immunization outcomes"}, {"text": "continual developments"}, {"text": "biotechnology area"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "The cancer application segment", "keywords": [{"text": "cancer application segment"}]}, "sentence": " The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.", "object": {"text": "the fastest growth", "keywords": [{"text": "fastest growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "immunization against cancer", "keywords": [{"text": "immunization"}, {"text": "cancer"}]}, "sentence": " The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.", "object": {"text": "with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers", "keywords": [{"text": "colorectal cancers"}, {"text": "various types"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "colorectal cancers"}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "past"}, "text": "dominated", "normalized": "dominate"}}, {"subject": {"text": "the existence of key participants of the industry in this region Asia Pacific", "keywords": [{"text": "region Asia Pacific"}, {"text": "key participants"}, {"text": "existence"}, {"text": "industry"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "object": {"text": "identified to witness a lucrative growth with a CAGR of around 10.7%", "keywords": [{"text": "lucrative growth"}, {"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "10.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific", "keywords": [{"text": "region Asia Pacific"}, {"text": "key participants"}, {"text": "extensive research"}, {"text": "development activities"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "object": {"text": "to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India", "keywords": [{"text": "lucrative growth"}, {"text": "forecast period"}, {"text": "population base"}, {"text": "economic growth"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Quantity", "text": "10.7"}]}, "action": {"verb": {"text": "identify", "tense": "past"}, "text": "is identified", "normalized": "be identify"}}, {"subject": {"text": "the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific", "keywords": [{"text": "region Asia Pacific"}, {"text": "key participants"}, {"text": "extensive research"}, {"text": "development activities"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "object": {"text": "a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India", "keywords": [{"text": "lucrative growth"}, {"text": "forecast period"}, {"text": "population base"}, {"text": "economic growth"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Quantity", "text": "10.7"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "to witness", "normalized": "to witness"}}, {"subject": {"text": "the availability of skilled labors at a lower cost and the low manufacturing operations cost", "keywords": [{"text": "skilled labors"}, {"text": "low manufacturing operations"}, {"text": "lower cost"}, {"text": "availability"}]}, "sentence": " Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.", "object": {"text": "a platform", "keywords": [{"text": "platform"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "clinical trial", "keywords": [{"text": "clinical trial"}]}, "sentence": " Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.", "object": {"text": "of the vaccinations", "keywords": [{"text": "vaccinations"}]}, "action": {"verb": {"text": "outsource", "tense": "present"}, "text": "outsourcing", "normalized": "outsource"}}, {"subject": {"text": "Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc", "keywords": [{"text": "Takeda Pharmaceuticals Company"}, {"text": "Janssen Pharmaceuticals"}, {"text": "Valeant Pharmaceuticals International"}, {"text": "AstraZeneca plc"}], "entities": [{"type": "Company", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "Janssen Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "Takeda Pharmaceuticals Company Ltd."}, {"type": "Company", "text": "Valeant Pharmaceuticals International", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}]}, "sentence": " Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.", "object": {"text": "Other prominent players", "keywords": [{"text": "prominent players"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "VBI vaccines, Inc.", "keywords": [{"text": "VBI vaccines"}], "entities": [{"type": "Company", "text": "Inc."}]}, "sentence": " In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its \u201cLipid Particle Vaccine\u201d formulation technology to better the stability of the Sanofi vaccines.", "object": {"text": "into a collaborative agreement with Sanofi Pasteur, Inc. to employ its \u201cLipid Particle Vaccine\u201d formulation technology to better the stability of the Sanofi vaccines", "keywords": [{"text": "Sanofi Pasteur"}, {"text": "Lipid Particle Vaccine"}, {"text": "Sanofi vaccines"}, {"text": "collaborative agreement"}], "entities": [{"type": "Company", "text": "Sanofi Pasteur, Inc."}]}, "action": {"verb": {"text": "enter", "tense": "past"}, "text": "entered", "normalized": "enter"}}], "concepts": [{"text": "Vaccine", "relevance": 0.962892, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "Vaccination", "relevance": 0.773497, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "Immune system", "relevance": 0.509667, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Vaccination schedule", "relevance": 0.498106, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination_schedule"}, {"text": "Polio vaccine", "relevance": 0.484377, "dbpedia_resource": "http://dbpedia.org/resource/Polio_vaccine"}, {"text": "Influenza vaccine", "relevance": 0.44111, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_vaccine"}, {"text": "Louis Pasteur", "relevance": 0.421213, "dbpedia_resource": "http://dbpedia.org/resource/Louis_Pasteur"}, {"text": "HPV vaccine", "relevance": 0.402819, "dbpedia_resource": "http://dbpedia.org/resource/HPV_vaccine"}, {"text": "Infectious disease", "relevance": 0.382404, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Tuberculosis", "relevance": 0.375877, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Economic growth", "relevance": 0.372267, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Microbiology", "relevance": 0.367078, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "Biotechnology", "relevance": 0.365387, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Smallpox", "relevance": 0.36223, "dbpedia_resource": "http://dbpedia.org/resource/Smallpox"}, {"text": "Ribavirin", "relevance": 0.337363, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Pharmaceutical industry", "relevance": 0.330058, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Economics", "relevance": 0.322219, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "DNA vaccination", "relevance": 0.318709, "dbpedia_resource": "http://dbpedia.org/resource/DNA_vaccination"}, {"text": "Johnson & Johnson", "relevance": 0.312709, "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}, {"text": "2016", "relevance": 0.308407, "dbpedia_resource": "http://dbpedia.org/resource/2016"}, {"text": "Disease", "relevance": 0.307806, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}], "categories": [{"score": 0.875084, "label": "/health and fitness/disease"}, {"score": 0.308916, "label": "/health and fitness/disease/epidemic"}], "relations": [{"type": "timeOf", "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc. Posted on 2018-11-06 by researchinsights in Biotech // 0 Comments San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. Development of various molecules to cater to the growing demand for vaccines can drive market demand.", "score": 0.51084, "arguments": [{"text": "2024", "location": [46, 50], "entities": [{"type": "Date", "text": "2024"}]}, {"text": "Grand", "location": [52, 57], "entities": [{"type": "SportingEvent", "text": "Grand"}]}]}, {"type": "residesIn", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.516907, "arguments": [{"text": "participants", "location": [2875, 2887], "entities": [{"type": "Person", "text": "participants"}]}, {"text": "region", "location": [2912, 2918], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}, {"type": "locatedAt", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.403979, "arguments": [{"text": "region", "location": [2912, 2918], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "Asia", "location": [2919, 2923], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.79467, "arguments": [{"text": "Asia", "location": [2919, 2923], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2924, 2931], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOfMany", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.468956, "arguments": [{"text": "China", "location": [3123, 3128], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3104, 3113], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.709653, "arguments": [{"text": "Japan", "location": [3130, 3135], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3104, 3113], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India.", "score": 0.583123, "arguments": [{"text": "India", "location": [3141, 3146], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3104, 3113], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc. In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its \"Lipid Particle Vaccine\" formulation technology to better the stability of the Sanofi vaccines.", "score": 0.962112, "arguments": [{"text": "Sanofi Pasteur, Inc.", "location": [3845, 3865], "entities": [{"type": "Organization", "text": "Sanofi Pasteur, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "employ", "location": [3869, 3875], "entities": [{"type": "EventCommunication", "text": "employ"}]}]}, {"type": "participantIn", "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc. Posted on 2018-11-06 by researchinsights in Biotech // 0 Comments San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. Development of various molecules to cater to the growing demand for vaccines can drive market demand.", "score": 0.510296, "arguments": [{"text": "View Research, Inc.", "location": [58, 77], "entities": [{"type": "Organization", "text": "View Research, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Grand", "location": [52, 57], "entities": [{"type": "SportingEvent", "text": "Grand"}]}]}, {"type": "agentOf", "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc. Posted on 2018-11-06 by researchinsights in Biotech // 0 Comments San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. Development of various molecules to cater to the growing demand for vaccines can drive market demand.", "score": 0.946805, "arguments": [{"text": "View Research, Inc.", "location": [58, 77], "entities": [{"type": "Organization", "text": "View Research, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Posted", "location": [78, 84], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "timeOf", "sentence": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc. Posted on 2018-11-06 by researchinsights in Biotech // 0 Comments San Francisco, United States, 2018-Nov-06 \u2014 /EPR Network/ \u2014 The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. Development of various molecules to cater to the growing demand for vaccines can drive market demand.", "score": 0.985059, "arguments": [{"text": "2018-11-06", "location": [88, 98], "entities": [{"type": "Date", "text": "2018-11-06"}]}, {"text": "Posted", "location": [78, 84], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "partOfMany", "sentence": "Majority of the key players are focused on vaccine development to gain an edge over competitors.", "score": 0.879425, "arguments": [{"text": "Majority", "location": [445, 453], "entities": [{"type": "Cardinal", "text": "Majority"}]}, {"text": "players", "location": [465, 472], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "employedBy", "sentence": "For instance, Pfizer, Inc., is developing vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B. Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "score": 0.487666, "arguments": [{"text": "Meningococcal B.\nFurthermore", "location": [647, 675], "entities": [{"type": "Person", "text": "Meningococcal B.\nFurthermore"}]}, {"text": "Pfizer, Inc.", "location": [556, 568], "entities": [{"type": "Organization", "text": "Pfizer, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "For instance, Pfizer, Inc., is developing vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B. Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "score": 0.429699, "arguments": [{"text": "Meningococcal B.\nFurthermore", "location": [647, 675], "entities": [{"type": "Person", "text": "Meningococcal B.\nFurthermore"}]}, {"text": "communicable diseases", "location": [863, 884], "entities": [{"type": "HealthCondition", "text": "communicable diseases"}]}]}, {"type": "partOf", "sentence": "For instance, Pfizer, Inc., is developing vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B. Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.", "score": 0.819224, "arguments": [{"text": "coalition", "location": [687, 696], "entities": [{"type": "Organization", "text": "Grand View Research, Inc. Development"}]}, {"text": "governments", "location": [700, 711], "entities": [{"type": "GeopoliticalEntity", "text": "National Immunization Program"}]}]}, {"type": "hasAttribute", "sentence": "Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.", "score": 0.844903, "arguments": [{"text": "children", "location": [1520, 1528], "entities": [{"type": "Person", "text": "children"}]}, {"text": "diseases", "location": [1494, 1502], "entities": [{"type": "HealthCondition", "text": "communicable diseases"}]}]}], "keywords": [{"text": "Grand View Research", "sentiment": {"score": 0.266256, "label": "positive"}, "relevance": 0.952297}, {"text": "Sanofi Pasteur", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.907069}, {"text": "Vaccine Market Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.843698}, {"text": "global vaccine market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.83823}, {"text": "vaccine type segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.794273}, {"text": "National Immunization Program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.791579}, {"text": "extensive immunization coverage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.784303}, {"text": "DNA vaccine segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781449}, {"text": "inactivated polio vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.772847}, {"text": "Lipid Particle Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.755933}, {"text": "Sanofi vaccines", "sentiment": {"score": 0.477881, "label": "positive"}, "relevance": 0.724521}, {"text": "\u2018Immunize Australia Program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.719124}, {"text": "cancer application segment", "sentiment": {"score": -0.843535, "label": "negative"}, "relevance": 0.717092}, {"text": "fastest growing type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711191}, {"text": "Takeda Pharmaceuticals Company", "sentiment": {"score": -0.315145, "label": "negative"}, "relevance": 0.709789}, {"text": "checks rampant disease", "sentiment": {"score": -0.642585, "label": "negative"}, "relevance": 0.709006}, {"text": "forecast period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.708948}, {"text": "long lasting immunogenicity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.705925}, {"text": "Valeant Pharmaceuticals International", "sentiment": {"score": -0.400003, "label": "negative"}, "relevance": 0.704819}, {"text": "vaccine development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.702636}, {"text": "strong preventive measures", "sentiment": {"score": -0.450799, "label": "negative"}, "relevance": 0.693173}, {"text": "immunization programs", "sentiment": {"score": -0.503573, "label": "negative"}, "relevance": 0.692752}, {"text": "highly stable nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.692017}, {"text": "region Asia Pacific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.69174}, {"text": "low manufacturing operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.688807}, {"text": "immunization outcomes", "sentiment": {"score": -0.566356, "label": "negative"}, "relevance": 0.678068}, {"text": "cell-based vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.670201}, {"text": "VBI vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662098}, {"text": "market growth", "sentiment": {"score": -0.503573, "label": "negative"}, "relevance": 0.646242}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.645748}, {"text": "market demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64022}, {"text": "vaccinations market", "sentiment": {"score": -0.843535, "label": "negative"}, "relevance": 0.632623}, {"text": "market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632128}, {"text": "new report", "sentiment": {"score": 0.266256, "label": "positive"}, "relevance": 0.631536}, {"text": "key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626797}, {"text": "San Francisco", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626306}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626243}, {"text": "/EPR Network/", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626138}, {"text": "Clostridium difficile", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625501}, {"text": "vaccine-preventable diseases", "sentiment": {"score": -0.450799, "label": "negative"}, "relevance": 0.62466}, {"text": "communicable diseases", "sentiment": {"score": -0.503573, "label": "negative"}, "relevance": 0.622267}, {"text": "Staphylococcus aureus", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621587}, {"text": "government program", "sentiment": {"score": -0.450799, "label": "negative"}, "relevance": 0.621243}, {"text": "fastest growth", "sentiment": {"score": -0.843535, "label": "negative"}, "relevance": 0.620674}, {"text": "high morbidity", "sentiment": {"score": -0.503573, "label": "negative"}, "relevance": 0.618551}, {"text": "lucrative growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618548}, {"text": "Janssen Pharmaceuticals", "sentiment": {"score": -0.362472, "label": "negative"}, "relevance": 0.617254}, {"text": "various molecules", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616577}, {"text": "severe diseases", "sentiment": {"score": -0.642585, "label": "negative"}, "relevance": 0.61457}, {"text": "vaccination benefits", "sentiment": {"score": -0.503573, "label": "negative"}, "relevance": 0.614043}]}, "extracted_metadata": {"sha1": "0c77747859eb0bca3c57c438c172a5b896eee9a3", "filename": "1541507827222.zip-e32fa923581705faf689d9d04b6c7e30.xml", "file_type": "json"}, "external_links": ["https://www.grandviewresearch.com/industry-analysis/vaccine-market?utm_source=express&utm_medium=referral&utm_campaign=express_nov06&utm_content=Content"], "title": "Vaccine Market Size to Reach $77.5 Billion By 2024: Grand View Research, Inc.", "forum_title": "Express Press Release Distribution"}, {"id": "CRjM6B-_ZgUEGlLfRfORUIBGIGLiY4VBARuMvmJdEuXchH0DpPMZZCsHt-_JeGCY", "result_metadata": {"score": 31.985954}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.517806, "label": "positive"}, "text": "CEO", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.517806, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.517806, "label": "positive"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.641283, "label": "/finance/investing"}, {"score": 0.641283, "label": "/finance/investing/beginning investing"}, {"score": 0.238327, "label": "/business and industrial/company/merger and acquisition"}], "relations": [{"type": "colleague", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal", "score": 0.578246, "arguments": [{"text": "CEO", "location": [7, 10], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda"}]}]}], "keywords": [{"text": "Takeda CEO", "sentiment": {"score": 0.517806, "label": "positive"}, "relevance": 0.97858}, {"text": "investor backing", "sentiment": {"score": 0.517806, "label": "positive"}, "relevance": 0.78999}, {"text": "Shire deal", "sentiment": {"score": 0.517806, "label": "positive"}, "relevance": 0.735009}]}, "crawl_date": "2018-11-05T15:29:41Z", "url": "https://www.channelnewsasia.com/news/business/takeda-ceo-confident-of-investor-backing-for-us-62-billion-shire-deal-10900278", "host": "channelnewsasia.com", "text": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "http://www.channelnewsasia.com/image/10900276/16x9/991/557/4f49de2def6f95d9ebb8b46b4f689420/QE/file-photo---takeda-pharmaceutical-co-president-and-chief-executive-officer-christophe-weber-attends-an-opening-ceremony-for-its-new-headquarters-in-tokyo-1.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T15:11:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.658218, "label": "positive"}, "text": "Takeda", "relevance": 0.927633, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.581614, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 7, "sentiment": {"score": 0.488797, "label": "positive"}, "text": "Christophe Weber", "relevance": 0.535348, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.466717, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.673205, "label": "positive"}, "text": "Business Takeda", "relevance": 0.426572, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "London-listed Shire", "relevance": 0.398971, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": -0.424801, "label": "negative"}, "text": "Shire", "relevance": 0.349928, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.313172, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.513485, "label": "negative"}, "text": "Shire", "relevance": 0.288259, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 5, "sentiment": {"score": 0.348189, "label": "positive"}, "text": "U.S.", "relevance": 0.287026, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.242941, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.23375, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.311781, "label": "positive"}, "text": "President Donald Trump", "relevance": 0.229744, "type": "Person", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}, {"count": 2, "sentiment": {"score": 0.673205, "label": "positive"}, "text": "CEO", "relevance": 0.222047, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.21806, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FT Global Pharmaceutical and Biotechnology", "relevance": 0.218019, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EGM", "relevance": 0.202472, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.197014, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive", "relevance": 0.196398, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.179313, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ben Hirschler", "relevance": 0.177872, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.557971, "label": "positive"}, "text": "Novartis", "relevance": 0.162048, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0.557971, "label": "positive"}, "text": "Pfizer", "relevance": 0.154393, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.551229, "label": "positive"}, "text": "Mark Potter", "relevance": 0.149206, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "three-month", "relevance": 0.149206, "type": "Quantity"}], "sentiment": {"document": {"score": 0.630195, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The boss of Japan's Takeda Pharmaceutical", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "boss"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "object": {"text": "he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "investor backing"}, {"text": "acquisition"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he"}, "sentence": " The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "object": {"text": "investor backing", "keywords": [{"text": "investor backing"}]}, "action": {"verb": {"text": "secure", "tense": "future"}, "text": "securing", "normalized": "secure"}}, {"subject": {"text": "Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber", "keywords": [{"text": "Officer Christophe Weber"}, {"text": "Takeda Pharmaceutical"}, {"text": "Chief"}, {"text": "President"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "opening ceremony"}, {"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "attend", "tense": "present"}, "text": "attends", "normalized": "attend"}}, {"subject": {"text": "The boss of Japan's Takeda Pharmaceutical", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "boss"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "object": {"text": "he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "investor backing"}, {"text": "acquisition"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he"}, "sentence": " LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "object": {"text": "investor backing", "keywords": [{"text": "investor backing"}]}, "action": {"verb": {"text": "secure", "tense": "future"}, "text": "securing", "normalized": "secure"}}, {"subject": {"text": "Chief Executive Christophe Weber", "keywords": [{"text": "Executive Christophe Weber"}], "entities": [{"type": "JobTitle", "text": "Chief Executive"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move.", "object": {"text": "that buying rare diseases specialist Shire was not a defensive move", "keywords": [{"text": "diseases specialist Shire"}], "entities": [{"type": "Organization", "text": "Shire"}, {"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "insist", "tense": "past"}, "text": "insisted", "normalized": "insist"}}, {"subject": {"text": "with our current progress at Takeda", "keywords": [{"text": "current progress"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " \"We are quite satisfied with our current progress at Takeda.", "object": {"text": "We"}, "action": {"verb": {"text": "satisfy", "tense": "past"}, "text": "quite satisfied", "normalized": "quite satisfy"}}, {"subject": {"text": "Our business", "keywords": [{"text": "business"}]}, "sentence": " Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "object": {"text": "doing well"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "object": {"text": "Our business is doing well", "keywords": [{"text": "business"}]}, "action": {"verb": {"text": "tell", "tense": "past"}, "text": "told", "normalized": "tell"}}, {"subject": {"text": "We"}, "sentence": " \"We don't have to do this Shire acquisition.", "object": {"text": "this Shire acquisition", "keywords": [{"text": "Shire acquisition"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "do", "tense": "future"}, "text": "don't have to do", "normalized": "don't have to do"}}, {"subject": {"text": "We"}, "sentence": " We just feel it is a way to accelerate our progress and our evolution.\"", "object": {"text": "it is a way to accelerate our progress and our evolution", "keywords": [{"text": "progress"}, {"text": "way"}, {"text": "evolution"}]}, "action": {"verb": {"text": "feel", "tense": "present"}, "text": "feel", "normalized": "feel"}}, {"subject": {"text": "We"}, "sentence": " We just feel it is a way to accelerate our progress and our evolution.\"", "object": {"text": "our progress and our evolution", "keywords": [{"text": "progress"}, {"text": "evolution"}]}, "action": {"verb": {"text": "accelerate", "tense": "future"}, "text": "to accelerate", "normalized": "to accelerate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "object": {"text": "already gained approval", "keywords": [{"text": "approval"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "object": {"text": "approval", "keywords": [{"text": "approval"}]}, "action": {"verb": {"text": "gain", "tense": "past"}, "text": "gained", "normalized": "gain"}}, {"subject": {"text": "it"}, "sentence": " Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "object": {"text": "still waiting for the nod from European authorities", "keywords": [{"text": "European authorities"}, {"text": "nod"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "object": {"text": "for the nod from European authorities", "keywords": [{"text": "European authorities"}, {"text": "nod"}]}, "action": {"verb": {"text": "wait", "tense": "present"}, "text": "waiting", "normalized": "wait"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Crucially, Takeda also needs two-thirds support from shareholders.", "object": {"text": "two-thirds support from shareholders", "keywords": [{"text": "two-thirds"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "It"}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "object": {"text": "set Oct. 19", "keywords": [{"text": "Oct."}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "It"}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "object": {"text": "Oct. 19", "keywords": [{"text": "Oct."}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "has set", "normalized": "have set"}}, {"subject": {"text": "the record date", "keywords": [{"text": "record date"}]}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "object": {"text": "to vote in an extraordinary general meeting (EGM) on the deal", "keywords": [{"text": "extraordinary general meeting"}, {"text": "EGM"}, {"text": "deal"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "entitle", "tense": "present"}, "text": "entitling", "normalized": "entitle"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "object": {"text": "on the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "to vote", "normalized": "to vote"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "object": {"text": "it to hold the meeting within a three-month period ending Jan. 18", "keywords": [{"text": "three-month period"}, {"text": "meeting"}, {"text": "Jan."}], "entities": [{"type": "Quantity", "text": "three-month"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allowing", "normalized": "allow"}}, {"subject": {"text": "a three-month period", "keywords": [{"text": "three-month period"}], "entities": [{"type": "Quantity", "text": "three-month"}]}, "sentence": " It has set Oct. 19 as the record date entitling investors to vote in an extraordinary general meeting (EGM) on the deal, allowing it to hold the meeting within a three-month period ending Jan. 18.", "action": {"verb": {"text": "end", "tense": "present"}, "text": "ending", "normalized": "end"}}, {"subject": {"text": "it"}, "sentence": " Alternatively, it could set a new record date.", "object": {"text": "a new record date", "keywords": [{"text": "new record date"}]}, "action": {"verb": {"text": "set", "tense": "future"}, "text": "could set", "normalized": "could set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a market value of around US$32 billion", "keywords": [{"text": "market value"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around US$32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "secured a US$30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around US$32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "$30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "has secured", "normalized": "have secure"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "concerned as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "object": {"text": "he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held", "keywords": [{"text": "Takeda shareholders"}, {"text": "EGM date"}, {"text": "company"}], "entities": [{"type": "Person", "text": "Christophe Weber"}, {"type": "Person", "text": "Christophe Weber"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, a deal that will propel it into the top 10 rankings of global drugmakers by sales, alongside the likes of Novartis and Pfizer .", "object": {"text": "its agreement to take over Shire in May", "keywords": [{"text": "agreement"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "strike", "tense": "past"}, "text": "struck", "normalized": "strike"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, a deal that will propel it into the top 10 rankings of global drugmakers by sales, alongside the likes of Novartis and Pfizer .", "object": {"text": "its agreement", "keywords": [{"text": "agreement"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The Japanese company struck its agreement to take over Shire in May, a deal that will propel it into the top 10 rankings of global drugmakers by sales, alongside the likes of Novartis and Pfizer .", "object": {"text": "it"}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "will propel", "normalized": "will propel"}}, {"subject": {"text": "It"}, "sentence": " It will also increase Takeda's exposure to the U.S. drugs market - the world's biggest - which will account for around half of the enlarged group's business, just as President Donald Trump puts a squeeze on drugmakers to cut their prices. sentifi.com Channel NewsAsia - Sentifi topic widget", "object": {"text": "Takeda's exposure", "keywords": [{"text": "Takeda"}, {"text": "exposure"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "will also increase", "normalized": "will also increase"}}, {"subject": {"text": "the world's biggest -", "keywords": [{"text": "world"}]}, "sentence": " It will also increase Takeda's exposure to the U.S. drugs market - the world's biggest - which will account for around half of the enlarged group's business, just as President Donald Trump puts a squeeze on drugmakers to cut their prices. sentifi.com Channel NewsAsia - Sentifi topic widget", "object": {"text": "for around half of the enlarged group's business", "keywords": [{"text": "enlarged group"}]}, "action": {"verb": {"text": "account", "tense": "future"}, "text": "will account", "normalized": "will account"}}, {"subject": {"text": "President Donald Trump", "keywords": [{"text": "Trump"}, {"text": "President"}], "entities": [{"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}]}, "sentence": " It will also increase Takeda's exposure to the U.S. drugs market - the world's biggest - which will account for around half of the enlarged group's business, just as President Donald Trump puts a squeeze on drugmakers to cut their prices. sentifi.com Channel NewsAsia - Sentifi topic widget", "object": {"text": "a squeeze", "keywords": [{"text": "squeeze"}]}, "action": {"verb": {"text": "put", "tense": "present"}, "text": "puts", "normalized": "put"}}, {"subject": {"text": "drugmakers", "keywords": [{"text": "drugmakers"}]}, "sentence": " It will also increase Takeda's exposure to the U.S. drugs market - the world's biggest - which will account for around half of the enlarged group's business, just as President Donald Trump puts a squeeze on drugmakers to cut their prices. sentifi.com Channel NewsAsia - Sentifi topic widget", "object": {"text": "their prices. sentifi.com Channel NewsAsia - Sentifi topic widget", "keywords": [{"text": "prices. sentifi.com Channel"}, {"text": "Sentifi topic"}, {"text": "widget"}, {"text": "NewsAsia"}]}, "action": {"verb": {"text": "cut", "tense": "future"}, "text": "to cut", "normalized": "to cut"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "object": {"text": "Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace", "keywords": [{"text": "Medicare program"}, {"text": "fundamental attractions"}, {"text": "lower prices"}, {"text": "U.S. marketplace"}], "entities": [{"type": "Company", "text": "President Donald Trump"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Trump", "keywords": [{"text": "Trump"}], "entities": [{"type": "Company", "text": "President Donald Trump"}]}, "sentence": " Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "object": {"text": "the price", "keywords": [{"text": "price"}]}, "action": {"verb": {"text": "base", "tense": "future"}, "text": "to base", "normalized": "to base"}}, {"subject": {"text": "the lower prices", "keywords": [{"text": "lower prices"}]}, "sentence": " Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "action": {"verb": {"text": "pay", "tense": "past"}, "text": "paid", "normalized": "pay"}}, {"subject": {"text": "the price the government's Medicare program", "keywords": [{"text": "Medicare program"}, {"text": "price"}, {"text": "government"}]}, "sentence": " Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "object": {"text": "the fundamental attractions of the U.S. marketplace", "keywords": [{"text": "fundamental attractions"}, {"text": "U.S. marketplace"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "undermine", "tense": "future", "negated": true}, "text": "undermine", "normalized": "undermine"}}, {"subject": {"text": "This"}, "sentence": " \"This is still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine,\" he said.", "object": {"text": "still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine", "keywords": [{"text": "new innovative medicine"}, {"text": "fastest access"}, {"text": "latest medicine"}, {"text": "willingness"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " \"This is still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine,\" he said.", "object": {"text": "with the latest medicine", "keywords": [{"text": "latest medicine"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "to treat", "normalized": "to treat"}}, {"subject": {"text": "he"}, "sentence": " \"This is still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine,\" he said.", "object": {"text": "This is still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine", "keywords": [{"text": "new innovative medicine"}, {"text": "fastest access"}, {"text": "latest medicine"}, {"text": "willingness"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "My assumption", "keywords": [{"text": "assumption"}]}, "sentence": " \"My assumption always has been there would be more price pressure in the U.S. and we have to deal with it.\"", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "more price pressure", "keywords": [{"text": "price pressure"}]}, "sentence": " \"My assumption always has been there would be more price pressure in the U.S. and we have to deal with it.\"", "object": {"text": "in the U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "would be", "normalized": "would be"}}, {"subject": {"text": "we"}, "sentence": " \"My assumption always has been there would be more price pressure in the U.S. and we have to deal with it.\"", "object": {"text": "with it"}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "have to deal", "normalized": "have to deal"}}], "concepts": [{"text": "Chief executive officer", "relevance": 0.976532, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Executive officer", "relevance": 0.812707, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Chief executives", "relevance": 0.654213, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Donald Trump", "relevance": 0.57415, "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}, {"text": "Management occupations", "relevance": 0.478887, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.47348, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Boss", "relevance": 0.470147, "dbpedia_resource": "http://dbpedia.org/resource/Boss"}, {"text": "Stock", "relevance": 0.467031, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Ivana Trump", "relevance": 0.440886, "dbpedia_resource": "http://dbpedia.org/resource/Ivana_Trump"}], "categories": [{"score": 0.505106, "label": "/finance/investing"}, {"score": 0.505106, "label": "/finance/investing/beginning investing"}, {"score": 0.489789, "label": "/finance/financial news"}], "relations": [{"type": "colleague", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.577452, "arguments": [{"text": "CEO", "location": [7, 10], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}]}, {"type": "colleague", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.485719, "arguments": [{"text": "CEO", "location": [106, 109], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Takeda", "location": [99, 105], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}]}, {"type": "agentOf", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.609191, "arguments": [{"text": "Takeda Pharmaceutical Co", "location": [410, 434], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "attends", "location": [490, 497], "entities": [{"type": "EventCommunication", "text": "attends"}]}]}, {"type": "agentOf", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.99478, "arguments": [{"text": "Christophe Weber", "location": [473, 489], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "attends", "location": [490, 497], "entities": [{"type": "EventCommunication", "text": "attends"}]}]}, {"type": "agentOf", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.702136, "arguments": [{"text": "Christophe Weber", "location": [473, 489], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "opening ceremony", "location": [501, 517], "entities": [{"type": "EventPerformance", "text": "opening ceremony"}]}]}, {"type": "partOf", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.198181, "arguments": [{"text": "attends", "location": [490, 497], "entities": [{"type": "EventCommunication", "text": "attends"}]}, {"text": "opening ceremony", "location": [501, 517], "entities": [{"type": "EventPerformance", "text": "opening ceremony"}]}]}, {"type": "ownerOf", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.638509, "arguments": [{"text": "its", "location": [522, 525], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "headquarters", "location": [530, 542], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.970809, "arguments": [{"text": "headquarters", "location": [530, 542], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [546, 551], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "FILE PHOTO - Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.964711, "arguments": [{"text": "Tokyo", "location": [546, 551], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [553, 558], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.287177, "arguments": [{"text": "boss", "location": [629, 633], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Japan", "location": [637, 642], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.975517, "arguments": [{"text": "Monday", "location": [675, 681], "entities": [{"type": "Date", "text": "Monday"}]}, {"text": "said", "location": [667, 671], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.652487, "arguments": [{"text": "its", "location": [732, 735], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "62 billion", "location": [739, 749], "entities": [{"type": "Money", "text": "62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "residesIn", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.303142, "arguments": [{"text": "boss", "location": [173, 177], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Japan", "location": [181, 186], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move.", "score": 0.432864, "arguments": [{"text": "Chief Executive", "location": [958, 973], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "its", "location": [937, 940], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}]}, {"type": "agentOf", "sentence": "Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move.", "score": 0.993918, "arguments": [{"text": "Christophe Weber", "location": [974, 990], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "insisted", "location": [991, 999], "entities": [{"type": "EventCommunication", "text": "insisted"}]}]}, {"type": "hasAttribute", "sentence": "Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move.", "score": 0.680113, "arguments": [{"text": "specialist", "location": [1026, 1036], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "diseases", "location": [1017, 1025], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "affectedBy", "sentence": "Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "score": 0.8368, "arguments": [{"text": "FT Global Pharmaceutical", "location": [1185, 1209], "entities": [{"type": "Organization", "text": "FT Global Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [1176, 1180], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "score": 0.566056, "arguments": [{"text": "Biotechnology conference", "location": [1214, 1238], "entities": [{"type": "Organization", "text": "Biotechnology conference", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [1176, 1180], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "score": 0.637812, "arguments": [{"text": "Biotechnology conference", "location": [1214, 1238], "entities": [{"type": "Organization", "text": "Biotechnology conference", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "London", "location": [1242, 1248], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "agentOf", "sentence": "\"We don't have to do this Shire acquisition.", "score": 0.455767, "arguments": [{"text": "Shire", "location": [1276, 1281], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [1282, 1293], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "\" Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "score": 0.516859, "arguments": [{"text": "company", "location": [1472, 1479], "entities": [{"type": "Organization", "text": "FT Global Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1446, 1457], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "\" Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "score": 0.989268, "arguments": [{"text": "company", "location": [1472, 1479], "entities": [{"type": "Organization", "text": "FT Global Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [1463, 1471], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "score": 0.7179, "arguments": [{"text": "regulators", "location": [1512, 1522], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "Japanese", "location": [1491, 1499], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.391602, "arguments": [{"text": "Takeda Pharmaceutical", "location": [189, 210], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "Japan", "location": [181, 186], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "score": 0.959425, "arguments": [{"text": "regulators", "location": [1512, 1522], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "Chinese", "location": [1504, 1511], "entities": [{"type": "GeopoliticalEntity", "text": "Chinese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "\" Takeda has already gained approval for what would be the biggest-ever overseas acquisition by a Japanese company from U.S., Japanese and Chinese regulators - but it is still waiting for the nod from European authorities.", "score": 0.997799, "arguments": [{"text": "authorities", "location": [1575, 1586], "entities": [{"type": "Organization", "text": "authorities", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "European", "location": [1566, 1574], "entities": [{"type": "GeopoliticalEntity", "text": "European"}]}]}, {"type": "hasAttribute", "sentence": "Advertisement Advertisement Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.632065, "arguments": [{"text": "Advertisement Advertisement\nTakeda", "location": [1899, 1933], "entities": [{"type": "Organization", "text": "Advertisement Advertisement\nTakeda"}]}, {"text": "30.9 billion", "location": [2002, 2014], "entities": [{"type": "Money", "text": "30.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "score": 0.69517, "arguments": [{"text": "Weber", "location": [2148, 2153], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2164, 2168], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "sentifi.com Channel NewsAsia - Sentifi topic widget Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "score": 0.993629, "arguments": [{"text": "Weber", "location": [2811, 2816], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2817, 2821], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\"This is still the country where new innovative medicine has the fastest access - there is this willingness to treat patients with the latest medicine,\" he said.", "score": 0.985655, "arguments": [{"text": "he", "location": [3210, 3212], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [3213, 3217], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "score": 0.448668, "arguments": [{"text": "he", "location": [2169, 2171], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2164, 2168], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "score": 0.936657, "arguments": [{"text": "he", "location": [2186, 2188], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "persuaded", "location": [2193, 2202], "entities": [{"type": "EventCommunication", "text": "persuaded"}]}]}, {"type": "affectedBy", "sentence": "Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "score": 0.854167, "arguments": [{"text": "shareholders", "location": [2210, 2222], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "persuaded", "location": [2193, 2202], "entities": [{"type": "EventCommunication", "text": "persuaded"}]}]}, {"type": "agentOf", "sentence": "Weber, however, said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date, without specifying exactly when it would be held.", "score": 0.432627, "arguments": [{"text": "company", "location": [2244, 2251], "entities": [{"type": "Organization", "text": "FT Global Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "persuaded", "location": [2193, 2202], "entities": [{"type": "EventCommunication", "text": "persuaded"}]}]}, {"type": "basedIn", "sentence": "The Japanese company struck its agreement to take over Shire in May, a deal that will propel it into the top 10 rankings of global drugmakers by sales, alongside the likes of Novartis and Pfizer .", "score": 0.981252, "arguments": [{"text": "company", "location": [2336, 2343], "entities": [{"type": "Organization", "text": "Advertisement Advertisement\nTakeda"}]}, {"text": "Japanese", "location": [2327, 2335], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "sentifi.com Channel NewsAsia - Sentifi topic widget Weber said Trump's plans to base the price the government's Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U.S. marketplace.", "score": 0.82854, "arguments": [{"text": "Medicare", "location": [2871, 2879], "entities": [{"type": "Organization", "text": "Medicare", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "government", "location": [2858, 2868], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.935574, "arguments": [{"text": "Takeda Pharmaceutical", "location": [189, 210], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [211, 215], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.963933, "arguments": [{"text": "Takeda Pharmaceutical", "location": [645, 666], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [667, 671], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Our business is doing well,\" he told the FT Global Pharmaceutical and Biotechnology conference in London.", "score": 0.976376, "arguments": [{"text": "he", "location": [1173, 1175], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "told", "location": [1176, 1180], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "residesIn", "sentence": "\" (Reporting by Ben Hirschler; Editing by Mark Potter) Source: Reuters", "score": 0.865545, "arguments": [{"text": "Ben Hirschler", "location": [3341, 3354], "entities": [{"type": "Person", "text": "Ben Hirschler"}]}, {"text": "Editing", "location": [3356, 3363], "entities": [{"type": "GeopoliticalEntity", "text": "Editing"}]}]}, {"type": "timeOf", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.982494, "arguments": [{"text": "Monday", "location": [219, 225], "entities": [{"type": "Date", "text": "Monday"}]}, {"text": "said", "location": [211, 215], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.737669, "arguments": [{"text": "he", "location": [226, 228], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "62 billion", "location": [283, 293], "entities": [{"type": "Money", "text": "62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.387631, "arguments": [{"text": "he", "location": [226, 228], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "acquisition", "location": [294, 305], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.849042, "arguments": [{"text": "London-listed Shire", "location": [309, 328], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "62 billion", "location": [283, 293], "entities": [{"type": "Money", "text": "62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "Takeda CEO confident of investor backing for US$62 billion Shire deal close breaking news Business Takeda CEO confident of investor backing for US$62 billion Shire deal The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.846268, "arguments": [{"text": "London-listed Shire", "location": [309, 328], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "acquisition", "location": [294, 305], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.484642, "arguments": [{"text": "its", "location": [732, 735], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "acquisition", "location": [750, 761], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "REUTERS/Kim Kyung-Hoon 05 Nov 2018 11:11PM LONDON: The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its US$62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.", "score": 0.645296, "arguments": [{"text": "London-listed Shire", "location": [765, 784], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "acquisition", "location": [750, 761], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Advertisement Advertisement Takeda, which has a market value of around US$32 billion, has secured a US$30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.600443, "arguments": [{"text": "Shire", "location": [2047, 2052], "entities": [{"type": "Organization", "text": "London-listed Shire"}]}, {"text": "acquisition", "location": [2053, 2064], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0.661965, "label": "positive"}, "relevance": 0.984844}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.97911}, {"text": "Business Takeda CEO", "sentiment": {"score": 0.673205, "label": "positive"}, "relevance": 0.832009}, {"text": "investor backing", "sentiment": {"score": 0.673205, "label": "positive"}, "relevance": 0.799712}, {"text": "Takeda shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64553}, {"text": "London-listed Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641026}, {"text": "Shire deal", "sentiment": {"score": 0.673205, "label": "positive"}, "relevance": 0.586205}, {"text": "diseases specialist Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580487}, {"text": "Shire acquisition", "sentiment": {"score": -0.513485, "label": "negative"}, "relevance": 0.577655}, {"text": "Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554088}, {"text": "Officer Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547267}, {"text": "Executive Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526197}, {"text": "debt burden", "sentiment": {"score": -0.64151, "label": "negative"}, "relevance": 0.525885}, {"text": "Chief Executive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508906}, {"text": "biggest-ever overseas acquisition", "sentiment": {"score": 0.348189, "label": "positive"}, "relevance": 0.489126}, {"text": "record date", "sentiment": {"score": 0.473764, "label": "positive"}, "relevance": 0.476718}, {"text": "FT Global Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475198}, {"text": "Japanese company", "sentiment": {"score": -0.0766125, "label": "negative"}, "relevance": 0.468943}, {"text": "new record date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463705}, {"text": "extraordinary general meeting", "sentiment": {"score": 0.473763, "label": "positive"}, "relevance": 0.462754}, {"text": "new innovative medicine", "sentiment": {"score": 0.745341, "label": "positive"}, "relevance": 0.456829}, {"text": "President Donald Trump", "sentiment": {"score": 0.311781, "label": "positive"}, "relevance": 0.45079}, {"text": "U.S. drugs market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449768}, {"text": "prices. sentifi.com Channel", "sentiment": {"score": 0.311781, "label": "positive"}, "relevance": 0.449009}, {"text": "Advertisement Advertisement", "sentiment": {"score": -0.434386, "label": "negative"}, "relevance": 0.384276}, {"text": "EGM date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37318}, {"text": "new headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367214}, {"text": "FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366412}, {"text": "Pharmaceutical Co President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364023}, {"text": "REUTERS/Kim Kyung-Hoon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358253}, {"text": "opening ceremony", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356547}, {"text": "two-thirds support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355088}, {"text": "quarterly results", "sentiment": {"score": 0.732697, "label": "positive"}, "relevance": 0.35374}, {"text": "three-month period", "sentiment": {"score": -0.432785, "label": "negative"}, "relevance": 0.352133}, {"text": "debt repayments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350124}, {"text": "current progress", "sentiment": {"score": 0.953259, "label": "positive"}, "relevance": 0.348708}, {"text": "strong set", "sentiment": {"score": 0.732697, "label": "positive"}, "relevance": 0.348544}, {"text": "Chinese regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344596}, {"text": "Ben Hirschler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344042}, {"text": "European authorities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343793}, {"text": "Biotechnology conference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343788}, {"text": "strong demand", "sentiment": {"score": 0.484852, "label": "positive"}, "relevance": 0.342478}, {"text": "market value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340241}, {"text": "fastest access", "sentiment": {"score": 0.745341, "label": "positive"}, "relevance": 0.34017}, {"text": "enlarged group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338999}, {"text": "latest medicine", "sentiment": {"score": 0.745893, "label": "positive"}, "relevance": 0.338247}, {"text": "price pressure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335935}, {"text": "global drugmakers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335275}, {"text": "bridge loan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334465}, {"text": "Medicare program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333253}]}, "extracted_metadata": {"sha1": "15d202637b17bf4cc37d0477714ee372ba58b000", "filename": "1541431781977.zip-e05e4a348393187d49e87b156909872f.xml", "file_type": "json"}, "title": "Takeda CEO confident of investor backing for US$62 billion Shire deal", "forum_title": "Channel NewsAsia"}, {"id": "Dx70cMOjgFktnCUOGM91wTUL0zEmeV7RJu7xG_Rpd6tT-Muiq3AUIQLu9-MXIU3N", "result_metadata": {"score": 31.91645}, "author": "No Author", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.58896, "label": "negative"}, "text": "Japan", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.58896, "label": "negative"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.58896, "label": "negative"}, "text": "Shire", "relevance": 0.33, "type": "Person"}], "sentiment": {"document": {"score": -0.58896, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": "Japan\u2019s Takeda Pharmaceutical pushes back as dissident shareholders seek to stop Shire deal", "object": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "dissident shareholders", "keywords": [{"text": "dissident shareholders"}]}, "sentence": "Japan\u2019s Takeda Pharmaceutical pushes back as dissident shareholders seek to stop Shire deal", "object": {"text": "to stop Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seek", "normalized": "seek"}}, {"subject": {"text": "dissident shareholders", "keywords": [{"text": "dissident shareholders"}]}, "sentence": "Japan\u2019s Takeda Pharmaceutical pushes back as dissident shareholders seek to stop Shire deal", "object": {"text": "Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "stop", "tense": "future"}, "text": "seek to stop", "normalized": "seek to stop"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.635192, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.479202, "label": "/business and industrial/company"}, {"score": 0.384305, "label": "/business and industrial/company/merger and acquisition"}], "relations": [{"type": "partOf", "sentence": "Japan's Takeda Pharmaceutical pushes back as dissident shareholders seek to stop Shire deal", "score": 0.62307, "arguments": [{"text": "Takeda Pharmaceutical", "location": [8, 29], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "dissident shareholders", "sentiment": {"score": -0.58896, "label": "negative"}, "relevance": 0.919859}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.58896, "label": "negative"}, "relevance": 0.819261}, {"text": "Shire deal", "sentiment": {"score": -0.58896, "label": "negative"}, "relevance": 0.808963}, {"text": "Japan", "sentiment": {"score": -0.58896, "label": "negative"}, "relevance": 0.37195}]}, "crawl_date": "2018-11-06T06:02:27Z", "url": "https://www.japantimes.co.jp/news/2018/11/06/business/corporate-business/takeda-pushes-back-dissident-shareholders-seek-stop-shire-deal/", "host": "japantimes.co.jp", "text": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May. | REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON \u2013 Takeda", "main_image_url": "https://cdn.japantimes.2xx.jp/wp-content/uploads/2018/11/b-takeda-a-20181107-870x604.jpg", "country": "JP", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T05:32:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": 0.177191, "label": "positive"}, "text": "Christophe Weber", "relevance": 0.92263, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.27838, "label": "negative"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.673922, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 5, "sentiment": {"score": -0.077448, "label": "negative"}, "text": "Takeda", "relevance": 0.615057, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.27838, "label": "negative"}, "text": "REUTERS Takeda", "relevance": 0.590177, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.582273, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.565952, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "sue Takeda", "relevance": 0.555841, "type": "Person"}, {"count": 4, "sentiment": {"score": -0.077448, "label": "negative"}, "text": "Shire", "relevance": 0.38724, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.375131, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.27838, "label": "negative"}, "text": "Shire", "relevance": 0.363397, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.387899, "label": "positive"}, "text": "London", "relevance": 0.319558, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 1, "sentiment": {"score": -0.27838, "label": "negative"}, "text": "Bloomberg", "relevance": 0.280838, "type": "Company", "disambiguation": {"subtype": [], "name": "Bloomberg L.P.", "dbpedia_resource": "http://dbpedia.org/resource/Bloomberg_L.P."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.25945, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.27838, "label": "negative"}, "text": "Tokyo", "relevance": 0.249788, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.258411, "label": "negative"}, "text": "DealReporter", "relevance": 0.248491, "type": "Company", "disambiguation": {"subtype": [], "name": "Mergermarket", "dbpedia_resource": "http://dbpedia.org/resource/Mergermarket"}}, {"count": 1, "sentiment": {"score": -0.221605, "label": "negative"}, "text": "European Union", "relevance": 0.244639, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.242968, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.395589, "label": "positive"}, "text": "Ninlaro", "relevance": 0.238152, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.619951, "label": "negative"}, "text": "Crohn\u2019s disease", "relevance": 0.233816, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.228399, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": -0.620168, "label": "negative"}, "text": "representative", "relevance": 0.226702, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.421171, "label": "positive"}, "text": "European Commission", "relevance": 0.222214, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.209398, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.191198, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.180542, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.180542, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "19 percent", "relevance": 0.180542, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "47 percent", "relevance": 0.180542, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 percent", "relevance": 0.180542, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0973688, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "your browser", "keywords": [{"text": "browser"}]}, "sentence": "Sorry, but your browser needs Javascript to use this site.", "object": {"text": "Javascript", "keywords": [{"text": "Javascript"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "you"}, "sentence": " If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May. | REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE", "object": {"text": "it"}, "action": {"verb": {"text": "activate", "tense": "future"}, "text": "to activate", "normalized": "to activate"}}, {"subject": {"text": "http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co.", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May. | REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE", "object": {"text": "at the company's news conference venue in Tokyo", "keywords": [{"text": "news conference venue"}, {"text": "Tokyo"}, {"text": "company"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "display", "tense": "past"}, "text": "is displayed", "normalized": "be display"}}, {"subject": {"text": "dissident shareholders", "keywords": [{"text": "dissident shareholders"}]}, "sentence": " If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May. | REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE", "object": {"text": "to stop Shire deal Bloomberg SHARE", "keywords": [{"text": "Shire deal"}, {"text": "Bloomberg SHARE"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Company", "text": "Bloomberg", "disambiguation": {"subtype": ["Company"], "name": "Bloomberg L.P.", "dbpedia_resource": "http://dbpedia.org/resource/Bloomberg_L.P."}}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seek", "normalized": "seek"}}, {"subject": {"text": "dissident shareholders", "keywords": [{"text": "dissident shareholders"}]}, "sentence": " If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May. | REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE", "object": {"text": "Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "stop", "tense": "future"}, "text": "seek to stop", "normalized": "seek to stop"}}, {"subject": {"text": "dissident shareholders", "keywords": [{"text": "dissident shareholders"}]}, "sentence": " Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker\u2019s acquisition of Shire PLC, saying he won\u2019t release minutes of boardroom discussions.", "object": {"text": "to stop the Japanese drugmaker\u2019s acquisition of Shire PLC", "keywords": [{"text": "Shire PLC"}, {"text": "drugmaker\u2019s acquisition"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seeking", "normalized": "seek"}}, {"subject": {"text": "Chief Executive Officer Christophe Weber", "keywords": [{"text": "Officer Christophe Weber"}], "entities": [{"type": "JobTitle", "text": "Chief Executive Officer"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker\u2019s acquisition of Shire PLC, saying he won\u2019t release minutes of boardroom discussions.", "object": {"text": "he won\u2019t release minutes of boardroom discussions", "keywords": [{"text": "boardroom discussions"}, {"text": "release"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "saying", "normalized": "say"}}, {"subject": {"text": "members of Takeda\u2019s founding family", "keywords": [{"text": "Takeda"}, {"text": "members"}, {"text": "family"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " A group including members of Takeda\u2019s founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "object": {"text": "A group", "keywords": [{"text": "group"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the U.K.-listed biotech", "keywords": [{"text": "U.K.-listed biotech"}]}, "sentence": " A group including members of Takeda\u2019s founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "object": {"text": "as the biggest overseas acquisition", "keywords": [{"text": "biggest overseas acquisition"}]}, "action": {"verb": {"text": "rank", "tense": "future"}, "text": "would rank", "normalized": "would rank"}}, {"subject": {"text": "The investors", "keywords": [{"text": "investors"}]}, "sentence": " The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "object": {"text": "to sue Takeda in a bid to obtain details of the board talks leading up to the May deal", "keywords": [{"text": "board talks"}, {"text": "Takeda"}, {"text": "bid"}, {"text": "deal"}], "entities": [{"type": "Person", "text": "sue Takeda"}]}, "action": {"verb": {"text": "plan", "tense": "present"}, "text": "plan", "normalized": "plan"}}, {"subject": {"text": "The investors", "keywords": [{"text": "investors"}]}, "sentence": " The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "object": {"text": "Takeda", "keywords": [{"text": "Takeda"}]}, "action": {"verb": {"text": "sue", "tense": "future"}, "text": "plan to sue", "normalized": "plan to sue"}}, {"subject": {"text": "trade publication DealReporter", "keywords": [{"text": "trade publication"}, {"text": "DealReporter"}], "entities": [{"type": "Company", "text": "DealReporter", "disambiguation": {"subtype": [], "name": "Mergermarket", "dbpedia_resource": "http://dbpedia.org/resource/Mergermarket"}}]}, "sentence": " The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "object": {"text": "The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal", "keywords": [{"text": "board talks"}, {"text": "Takeda"}, {"text": "bid"}, {"text": "investors"}], "entities": [{"type": "Person", "text": "sue Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe discuss many confidential topics, and we think board minutes should remain confidential,\u201d Weber said in an interview in London.", "object": {"text": "many confidential topics", "keywords": [{"text": "confidential topics"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discuss", "normalized": "discuss"}}, {"subject": {"text": "we"}, "sentence": " \u201cWe discuss many confidential topics, and we think board minutes should remain confidential,\u201d Weber said in an interview in London.", "object": {"text": "board minutes should remain confidential", "keywords": [{"text": "board"}]}, "action": {"verb": {"text": "think", "tense": "present"}, "text": "think", "normalized": "think"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " \u201cWe discuss many confidential topics, and we think board minutes should remain confidential,\u201d Weber said in an interview in London.", "object": {"text": "We discuss many confidential topics, and we think board minutes should remain confidential", "keywords": [{"text": "confidential topics"}, {"text": "board"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The planned transaction", "keywords": [{"text": "planned transaction"}]}, "sentence": " The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "object": {"text": "the maker of cancer drug Ninlaro", "keywords": [{"text": "cancer drug Ninlaro"}, {"text": "maker"}], "entities": [{"type": "Person", "text": "Ninlaro"}]}, "action": {"verb": {"text": "vault", "tense": "future"}, "text": "would vault", "normalized": "would vault"}}, {"subject": {"text": "largest pharma giants", "keywords": [{"text": "largest pharma giants"}]}, "sentence": " The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "object": {"text": "the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines,", "keywords": [{"text": "largest pharma giants"}, {"text": "cancer drug Ninlaro"}, {"text": "planned transaction"}, {"text": "new medicines"}], "entities": [{"type": "Person", "text": "Ninlaro"}]}, "sentence": " The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "object": {"text": "on track", "keywords": [{"text": "track"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "object": {"text": "The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world\u2019s largest pharma giants and boost its pipeline of new medicines, is on track", "keywords": [{"text": "largest pharma giants"}, {"text": "cancer drug Ninlaro"}, {"text": "planned transaction"}, {"text": "new medicines"}], "entities": [{"type": "Person", "text": "Ninlaro"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Authorities in China, the U.S., Brazil and Japan", "keywords": [{"text": "Authorities"}, {"text": "Brazil"}, {"text": "China"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": " Authorities in China, the U.S., Brazil and Japan have cleared the deal, leaving the European Union as the last major regulator to issue a decision.", "object": {"text": "cleared the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Authorities in China, the U.S., Brazil and Japan", "keywords": [{"text": "Authorities"}, {"text": "Brazil"}, {"text": "China"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": " Authorities in China, the U.S., Brazil and Japan have cleared the deal, leaving the European Union as the last major regulator to issue a decision.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "clear", "tense": "past"}, "text": "have cleared", "normalized": "have clear"}}, {"subject": {"text": "Authorities in China, the U.S., Brazil and Japan", "keywords": [{"text": "Authorities"}, {"text": "Brazil"}, {"text": "China"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "sentence": " Authorities in China, the U.S., Brazil and Japan have cleared the deal, leaving the European Union as the last major regulator to issue a decision.", "object": {"text": "the European Union", "keywords": [{"text": "European Union"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "leave", "tense": "present"}, "text": "leaving", "normalized": "leave"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "object": {"text": "offered to dispose of an experimental Shire treatment for Crohn\u2019s disease", "keywords": [{"text": "experimental Shire treatment"}, {"text": "Crohn"}, {"text": "disease"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "object": {"text": "of an experimental Shire treatment", "keywords": [{"text": "experimental Shire treatment"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "dispose", "tense": "future"}, "text": "has offered to dispose", "normalized": "have offer to dispose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "object": {"text": "approval", "keywords": [{"text": "approval"}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "to win", "normalized": "to win"}}, {"subject": {"text": "a malady of the digestive system", "keywords": [{"text": "malady"}]}, "sentence": " Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "object": {"text": "in discussions with the European Commission", "keywords": [{"text": "European Commission"}, {"text": "discussions"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "object": {"text": "Takeda has offered to dispose of an experimental Shire treatment for Crohn\u2019s disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter", "keywords": [{"text": "experimental Shire treatment"}, {"text": "Crohn\u2019s disease"}, {"text": "European Commission"}, {"text": "malady"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Crohn\u2019s disease"}, {"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "object": {"text": "to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}, {"text": "deal"}, {"text": "Jan."}], "entities": []}, "action": {"verb": {"text": "plan", "tense": "present"}, "text": "plans", "normalized": "plan"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "object": {"text": "an extraordinary general meeting", "keywords": [{"text": "extraordinary general meeting"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "plans to hold", "normalized": "plan to hold"}}, {"subject": {"text": "Shire investors", "keywords": [{"text": "Shire investors"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "object": {"text": "a separate vote", "keywords": [{"text": "separate vote"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "would get", "normalized": "would get"}}, {"subject": {"text": "the Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the Japanese company\u2019s shares", "keywords": [{"text": "Japanese company"}, {"text": "shares"}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "down about 19 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "19 percent"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "its intentions", "keywords": [{"text": "intentions"}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "first made public"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "its intentions", "keywords": [{"text": "intentions"}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "public", "keywords": [{"text": "public"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Shire\u2019s stock", "keywords": [{"text": "Shire"}, {"text": "stock"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " While the Japanese company\u2019s shares are down about 19 percent since its intentions were first made public at the end of March, Shire\u2019s stock has gained 47 percent.", "object": {"text": "47 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "47 percent"}]}, "action": {"verb": {"text": "gain", "tense": "past"}, "text": "has gained", "normalized": "have gain"}}, {"subject": {"text": "The dissident group", "keywords": [{"text": "dissident group"}]}, "sentence": " The dissident group represents fewer than 100 people and holds less than 1 percent of Takeda, Weber said.", "object": {"text": "fewer than 100 people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "The dissident group", "keywords": [{"text": "dissident group"}]}, "sentence": " The dissident group represents fewer than 100 people and holds less than 1 percent of Takeda, Weber said.", "object": {"text": "less than 1 percent of Takeda", "keywords": [{"text": "Takeda"}, {"text": "percent"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "1 percent"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " The dissident group represents fewer than 100 people and holds less than 1 percent of Takeda, Weber said.", "object": {"text": "The dissident group represents fewer than 100 people and holds less than 1 percent of Takeda", "keywords": [{"text": "dissident group"}, {"text": "Takeda"}, {"text": "percent"}, {"text": "people"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "1 percent"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "A representative for the investors", "keywords": [{"text": "representative"}, {"text": "investors"}], "entities": [{"type": "JobTitle", "text": "representative"}]}, "sentence": " A representative for the investors did not immediately reply to an email seeking comment.", "action": {"verb": {"text": "do", "tense": "past", "negated": true}, "text": "did", "normalized": "do"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda last week said Weber\u2019s management team informed the board of its interest in Shire as early as September 2017.", "object": {"text": "Weber\u2019s management team informed the board of its interest in Shire as early as September 2017", "keywords": [{"text": "Weber\u2019s management"}, {"text": "Shire"}, {"text": "team"}, {"text": "board"}], "entities": [{"type": "Person", "text": "Christophe Weber"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Takeda last week said Weber\u2019s management team informed the board of its interest in Shire as early as September 2017.", "object": {"text": "management team informed the board of its interest in Shire as early as September 2017", "keywords": [{"text": "management team"}, {"text": "Shire"}, {"text": "board"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "Directors", "keywords": [{"text": "Directors"}]}, "sentence": " Directors were regularly briefed on the Japanese company\u2019s due-diligence procedures and the takeover talks, according to Weber.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Directors", "keywords": [{"text": "Directors"}]}, "sentence": " Directors were regularly briefed on the Japanese company\u2019s due-diligence procedures and the takeover talks, according to Weber.", "action": {"verb": {"text": "brief", "tense": "past"}, "text": "briefed", "normalized": "brief"}}, {"subject": {"text": "the Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " Directors were regularly briefed on the Japanese company\u2019s due-diligence procedures and the takeover talks, according to Weber.", "object": {"text": "due-diligence procedures", "keywords": [{"text": "due-diligence procedures"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Directors were regularly briefed on the Japanese company\u2019s due-diligence procedures and the takeover talks", "keywords": [{"text": "takeover talks"}, {"text": "due-diligence procedures"}, {"text": "Japanese company"}, {"text": "Directors"}]}, "sentence": " Directors were regularly briefed on the Japanese company\u2019s due-diligence procedures and the takeover talks, according to Weber.", "object": {"text": "to Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "They"}, "sentence": " \u201cThey have a different vision of what Takeda should become,\u201d Weber said.", "object": {"text": "a different vision of what Takeda should become", "keywords": [{"text": "Takeda"}, {"text": "different vision"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " \u201cThey have a different vision of what Takeda should become,\u201d Weber said.", "object": {"text": "They have a different vision of what Takeda should become", "keywords": [{"text": "Takeda"}, {"text": "different vision"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "future"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "It"}, "sentence": " \u201cIt\u2019s a question of being a global company versus a local company.\u201d", "object": {"text": "a question of being a global company versus a local company", "keywords": [{"text": "global company"}, {"text": "local company"}, {"text": "question"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " The only way the company would relent on the request to release the board minutes, the CEO said, is if a court orders it.", "object": {"text": "on the request to release the board minutes", "keywords": [{"text": "request"}, {"text": "board"}]}, "action": {"verb": {"text": "relent", "tense": "future"}, "text": "would relent", "normalized": "would relent"}}], "concepts": [{"text": "Chief executive officer", "relevance": 0.964578, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "European Union", "relevance": 0.961409, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.835399, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Board of directors", "relevance": 0.781543, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Executive officer", "relevance": 0.694254, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Pharmacology", "relevance": 0.675768, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Digestion", "relevance": 0.645821, "dbpedia_resource": "http://dbpedia.org/resource/Digestion"}, {"text": "Stock", "relevance": 0.623313, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Corporate governance", "relevance": 0.593112, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Pharmaceutical drug", "relevance": 0.568775, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Dissident", "relevance": 0.558661, "dbpedia_resource": "http://dbpedia.org/resource/Dissident"}, {"text": "Human gastrointestinal tract", "relevance": 0.556746, "dbpedia_resource": "http://dbpedia.org/resource/Human_gastrointestinal_tract"}, {"text": "Japan", "relevance": 0.556163, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Dissidents", "relevance": 0.533461, "dbpedia_resource": "http://dbpedia.org/resource/Dissidents"}, {"text": "Corporation", "relevance": 0.525409, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}, {"text": "Corporate title", "relevance": 0.51093, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Chief executives", "relevance": 0.510531, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Dissent", "relevance": 0.508261, "dbpedia_resource": "http://dbpedia.org/resource/Dissent"}], "categories": [{"score": 0.617542, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.511591, "label": "/finance/financial news"}, {"score": 0.371567, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May.", "score": 0.602546, "arguments": [{"text": "company", "location": [217, 224], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "news conference", "location": [227, 242], "entities": [{"type": "EventMeeting", "text": "news conference"}]}]}, {"type": "affectedBy", "sentence": "| REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON - Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.", "score": 0.792505, "arguments": [{"text": "Shire PLC", "location": [536, 545], "entities": [{"type": "Organization", "text": "Shire PLC"}]}, {"text": "acquisition", "location": [521, 532], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "A group including members of Takeda's founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "score": 0.33228, "arguments": [{"text": "members", "location": [623, 630], "entities": [{"type": "Person", "text": "dissidents"}]}, {"text": "Takeda", "location": [634, 640], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "A group including members of Takeda's founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "score": 0.871773, "arguments": [{"text": "members", "location": [623, 630], "entities": [{"type": "Person", "text": "dissidents"}]}, {"text": "family", "location": [652, 658], "entities": [{"type": "Person", "text": "family"}]}]}, {"type": "employedBy", "sentence": "A group including members of Takeda's founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "score": 0.688004, "arguments": [{"text": "family", "location": [652, 658], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Takeda", "location": [634, 640], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "A group including members of Takeda's founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "score": 0.777241, "arguments": [{"text": "Takeda", "location": [634, 640], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$62 billion", "location": [679, 690], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "basedIn", "sentence": "A group including members of Takeda's founding family opposes the planned $62 billion acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.", "score": 0.955646, "arguments": [{"text": "company", "location": [803, 810], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [794, 802], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "score": 0.772555, "arguments": [{"text": "board", "location": [879, 884], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "talks", "location": [885, 890], "entities": [{"type": "EventMeeting", "text": "news conference"}]}]}, {"type": "timeOf", "sentence": "The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "score": 0.91137, "arguments": [{"text": "May deal", "location": [909, 917], "entities": [{"type": "Date", "text": "May deal"}]}, {"text": "talks", "location": [885, 890], "entities": [{"type": "EventMeeting", "text": "news conference"}]}]}, {"type": "timeOf", "sentence": "The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.", "score": 0.965179, "arguments": [{"text": "last week", "location": [955, 964], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "said", "location": [950, 954], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "\"We discuss many confidential topics, and we think board minutes should remain confidential,\" Weber said in an interview in London.", "score": 0.859447, "arguments": [{"text": "We", "location": [967, 969], "entities": [{"type": "Person", "text": "dissidents"}]}, {"text": "discuss", "location": [970, 977], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "locatedAt", "sentence": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May.", "score": 0.712421, "arguments": [{"text": "news conference", "location": [227, 242], "entities": [{"type": "EventMeeting", "text": "news conference"}]}, {"text": "venue", "location": [243, 248], "entities": [{"type": "Facility", "text": "venue"}]}]}, {"type": "agentOf", "sentence": "\"We discuss many confidential topics, and we think board minutes should remain confidential,\" Weber said in an interview in London.", "score": 0.997446, "arguments": [{"text": "Weber", "location": [1060, 1065], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1066, 1070], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world's largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "score": 0.99784, "arguments": [{"text": "Weber", "location": [1280, 1285], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1286, 1290], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to dispose of an experimental Shire treatment for Crohn's disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "score": 0.997192, "arguments": [{"text": "Weber", "location": [1642, 1647], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1648, 1652], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "The dissident group represents fewer than 100 people and holds less than 1 percent of Takeda, Weber said.", "score": 0.936549, "arguments": [{"text": "Weber", "location": [2079, 2084], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2085, 2089], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\"They have a different vision of what Takeda should become,\" Weber said.", "score": 0.997792, "arguments": [{"text": "Weber", "location": [2488, 2493], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2494, 2498], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "\" The only way the company would relent on the request to release the board minutes, the CEO said, is if a court orders it.", "score": 0.990826, "arguments": [{"text": "CEO", "location": [2655, 2658], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2659, 2663], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "So far, he said, he's unaware of any legal action by the dissidents, who argue that Weber railroaded the deal past directors with insufficient scrutiny.", "score": 0.998145, "arguments": [{"text": "he", "location": [2698, 2700], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2701, 2705], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "\"We discuss many confidential topics, and we think board minutes should remain confidential,\" Weber said in an interview in London.", "score": 0.688783, "arguments": [{"text": "Weber", "location": [1060, 1065], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "interview", "location": [1077, 1086], "entities": [{"type": "EventMeeting", "text": "interview"}]}]}, {"type": "partOf", "sentence": "\"We discuss many confidential topics, and we think board minutes should remain confidential,\" Weber said in an interview in London.", "score": 0.950946, "arguments": [{"text": "said", "location": [1066, 1070], "entities": [{"type": "EventCommunication", "text": "said"}]}, {"text": "interview", "location": [1077, 1086], "entities": [{"type": "EventMeeting", "text": "interview"}]}]}, {"type": "locatedAt", "sentence": "\"We discuss many confidential topics, and we think board minutes should remain confidential,\" Weber said in an interview in London.", "score": 0.968029, "arguments": [{"text": "interview", "location": [1077, 1086], "entities": [{"type": "EventMeeting", "text": "interview"}]}, {"text": "London", "location": [1090, 1096], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "hasAttribute", "sentence": "The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world's largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "score": 0.818878, "arguments": [{"text": "Ninlaro", "location": [1166, 1173], "entities": [{"type": "Person", "text": "Ninlaro"}]}, {"text": "cancer", "location": [1154, 1160], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "basedIn", "sentence": "The planned transaction, which would vault the maker of cancer drug Ninlaro into the ranks of the world's largest pharma giants and boost its pipeline of new medicines, is on track, Weber said.", "score": 0.507671, "arguments": [{"text": "pharma giants", "location": [1212, 1225], "entities": [{"type": "Organization", "text": "pharma giants"}]}, {"text": "world", "location": [1196, 1201], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Authorities in China, the U.S., Brazil and Japan have cleared the deal, leaving the European Union as the last major regulator to issue a decision.", "score": 0.346151, "arguments": [{"text": "Authorities", "location": [1292, 1303], "entities": [{"type": "Organization", "text": "Authorities", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "China", "location": [1307, 1312], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Authorities in China, the U.S., Brazil and Japan have cleared the deal, leaving the European Union as the last major regulator to issue a decision.", "score": 0.5701, "arguments": [{"text": "European Union", "location": [1376, 1390], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "regulator", "location": [1409, 1418], "entities": [{"type": "Facility", "text": "regulator"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to dispose of an experimental Shire treatment for Crohn's disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "score": 0.931455, "arguments": [{"text": "Takeda", "location": [1440, 1446], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "offered", "location": [1451, 1458], "entities": [{"type": "EventCommunication", "text": "offered"}]}]}, {"type": "hasAttribute", "sentence": "Takeda has offered to dispose of an experimental Shire treatment for Crohn's disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "score": 0.904186, "arguments": [{"text": "Crohn", "location": [1509, 1514], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [1517, 1524], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "locatedAt", "sentence": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May.", "score": 0.797799, "arguments": [{"text": "news conference", "location": [227, 242], "entities": [{"type": "EventMeeting", "text": "news conference"}]}, {"text": "Tokyo", "location": [252, 257], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "participantIn", "sentence": "Takeda has offered to dispose of an experimental Shire treatment for Crohn's disease, a malady of the digestive system, to win approval and is in discussions with the European Commission on the matter, Weber said.", "score": 0.838563, "arguments": [{"text": "European Commission", "location": [1607, 1626], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "discussions", "location": [1586, 1597], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "participantIn", "sentence": "Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "score": 0.577264, "arguments": [{"text": "Takeda", "location": [1654, 1660], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "meeting", "location": [1700, 1707], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "score": 0.842265, "arguments": [{"text": "Jan. 18", "location": [1711, 1718], "entities": [{"type": "Date", "text": "Jan. 18"}]}, {"text": "meeting", "location": [1700, 1707], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "score": 0.865608, "arguments": [{"text": "shareholders", "location": [1723, 1735], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [1700, 1707], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "employedBy", "sentence": "Takeda plans to hold an extraordinary general meeting by Jan. 18 for shareholders to vote on the deal; Shire investors would get a separate vote around the same time.", "score": 0.503048, "arguments": [{"text": "investors", "location": [1763, 1772], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Shire", "location": [1757, 1762], "entities": [{"type": "Organization", "text": "Shire PLC"}]}]}, {"type": "basedIn", "sentence": "While the Japanese company's shares are down about 19 percent since its intentions were first made public at the end of March, Shire's stock has gained 47 percent.", "score": 0.979139, "arguments": [{"text": "company", "location": [1840, 1847], "entities": [{"type": "Organization", "text": "Shire PLC"}]}, {"text": "Japanese", "location": [1831, 1839], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Directors were regularly briefed on the Japanese company's due-diligence procedures and the takeover talks, according to Weber.", "score": 0.981165, "arguments": [{"text": "company", "location": [2348, 2355], "entities": [{"type": "Organization", "text": "Shire PLC"}]}, {"text": "Japanese", "location": [2339, 2347], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "A representative for the investors did not immediately reply to an email seeking comment.", "score": 0.753358, "arguments": [{"text": "representative", "location": [2093, 2107], "entities": [{"type": "Person", "text": "representative"}]}, {"text": "reply", "location": [2146, 2151], "entities": [{"type": "EventCommunication", "text": "reply"}]}]}, {"type": "agentOf", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.839955, "arguments": [{"text": "Takeda", "location": [2181, 2187], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "said", "location": [2198, 2202], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.89359, "arguments": [{"text": "last week", "location": [2188, 2197], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "said", "location": [2198, 2202], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOfMany", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.320473, "arguments": [{"text": "Weber", "location": [2203, 2208], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "management team", "location": [2211, 2226], "entities": [{"type": "Person", "text": "management team"}]}]}, {"type": "timeOf", "sentence": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May.", "score": 0.716165, "arguments": [{"text": "May", "location": [261, 264], "entities": [{"type": "Date", "text": "May"}]}, {"text": "news conference", "location": [227, 242], "entities": [{"type": "EventMeeting", "text": "news conference"}]}]}, {"type": "agentOf", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.934601, "arguments": [{"text": "management team", "location": [2211, 2226], "entities": [{"type": "Person", "text": "management team"}]}, {"text": "informed", "location": [2227, 2235], "entities": [{"type": "EventCommunication", "text": "informed"}]}]}, {"type": "affectedBy", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.934522, "arguments": [{"text": "board", "location": [2240, 2245], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "informed", "location": [2227, 2235], "entities": [{"type": "EventCommunication", "text": "informed"}]}]}, {"type": "partOf", "sentence": "Takeda last week said Weber's management team informed the board of its interest in Shire as early as September 2017.", "score": 0.646825, "arguments": [{"text": "board", "location": [2240, 2245], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [2249, 2252], "entities": [{"type": "Organization", "text": "Shire PLC"}]}]}, {"type": "participantIn", "sentence": "Directors were regularly briefed on the Japanese company's due-diligence procedures and the takeover talks, according to Weber.", "score": 0.739667, "arguments": [{"text": "Directors", "location": [2299, 2308], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "briefed", "location": [2324, 2331], "entities": [{"type": "EventMeeting", "text": "news conference"}]}]}, {"type": "partOf", "sentence": "\"It's a question of being a global company versus a local company.", "score": 0.677765, "arguments": [{"text": "global company", "location": [2528, 2542], "entities": [{"type": "Organization", "text": "global company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2558, 2565], "entities": [{"type": "Organization", "text": "Shire PLC"}]}]}, {"type": "partOf", "sentence": "\" The only way the company would relent on the request to release the board minutes, the CEO said, is if a court orders it.", "score": 0.469209, "arguments": [{"text": "company", "location": [2585, 2592], "entities": [{"type": "Organization", "text": "global company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "board", "location": [2636, 2641], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "agentOf", "sentence": "So far, he said, he's unaware of any legal action by the dissidents, who argue that Weber railroaded the deal past directors with insufficient scrutiny.", "score": 0.977112, "arguments": [{"text": "who", "location": [2759, 2762], "entities": [{"type": "Person", "text": "dissidents"}]}, {"text": "argue", "location": [2763, 2768], "entities": [{"type": "EventCommunication", "text": "argue"}]}]}, {"type": "locatedAt", "sentence": "If you're not sure how to activate it, please refer to this site: http://www.enable-javascript.com/ The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo in May.", "score": 0.981026, "arguments": [{"text": "venue", "location": [243, 248], "entities": [{"type": "Facility", "text": "venue"}]}, {"text": "Tokyo", "location": [252, 257], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "managerOf", "sentence": "| REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON - Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.", "score": 0.702058, "arguments": [{"text": "Chief Executive Officer", "location": [396, 419], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Takeda Pharmaceutical Co.", "location": [370, 395], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "| REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON - Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.", "score": 0.758732, "arguments": [{"text": "drugmaker", "location": [509, 518], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "Japanese", "location": [500, 508], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "| REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON - Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.", "score": 0.49382, "arguments": [{"text": "drugmaker", "location": [509, 518], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "acquisition", "location": [521, 532], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "| REUTERS Takeda pushes back as dissident shareholders seek to stop Shire deal Bloomberg SHARE LONDON - Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the Japanese drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.", "score": 0.510946, "arguments": [{"text": "drugmaker", "location": [509, 518], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "Shire PLC", "location": [536, 545], "entities": [{"type": "Organization", "text": "Shire PLC"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0.0728181, "label": "positive"}, "relevance": 0.94586}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.8005}, {"text": "REUTERS Takeda", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.642244}, {"text": "Weber", "sentiment": {"score": -0.223949, "label": "negative"}, "relevance": 0.615032}, {"text": "Officer Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607106}, {"text": "LONDON \u2013 Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605145}, {"text": "dissident shareholders", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.564541}, {"text": "Japanese company", "sentiment": {"score": -0.479941, "label": "negative"}, "relevance": 0.559655}, {"text": "experimental Shire treatment", "sentiment": {"score": -0.619951, "label": "negative"}, "relevance": 0.486486}, {"text": "news conference venue", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.449937}, {"text": "Shire deal", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.4276}, {"text": "biggest overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42662}, {"text": "trade publication DealReporter", "sentiment": {"score": -0.258411, "label": "negative"}, "relevance": 0.424174}, {"text": "largest pharma giants", "sentiment": {"score": 0.395588, "label": "positive"}, "relevance": 0.420938}, {"text": "cancer drug Ninlaro", "sentiment": {"score": 0.395589, "label": "positive"}, "relevance": 0.418031}, {"text": "Weber\u2019s management", "sentiment": {"score": 0.465055, "label": "positive"}, "relevance": 0.41396}, {"text": "extraordinary general meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406309}, {"text": "Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356583}, {"text": "Shire investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345564}, {"text": "dissident group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.312699}, {"text": "Bloomberg SHARE", "sentiment": {"score": -0.27838, "label": "negative"}, "relevance": 0.301369}, {"text": "drugmaker\u2019s acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.286393}, {"text": "boardroom discussions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.284428}, {"text": "insufficient scrutiny", "sentiment": {"score": -0.621337, "label": "negative"}, "relevance": 0.279837}, {"text": "confidential topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27962}, {"text": "U.K.-listed biotech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277156}, {"text": "board talks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275215}, {"text": "major regulator", "sentiment": {"score": -0.221605, "label": "negative"}, "relevance": 0.273737}, {"text": "new medicines", "sentiment": {"score": 0.395588, "label": "positive"}, "relevance": 0.272765}, {"text": "Crohn\u2019s disease", "sentiment": {"score": -0.619951, "label": "negative"}, "relevance": 0.271928}, {"text": "global company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271564}, {"text": "local company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271411}, {"text": "due-diligence procedures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270346}, {"text": "planned transaction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270168}, {"text": "European Union", "sentiment": {"score": -0.221605, "label": "negative"}, "relevance": 0.268714}, {"text": "European Commission", "sentiment": {"score": 0.421171, "label": "positive"}, "relevance": 0.266298}, {"text": "separate vote", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26565}, {"text": "legal action", "sentiment": {"score": -0.565658, "label": "negative"}, "relevance": 0.259996}, {"text": "takeover talks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25877}, {"text": "different vision", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258503}, {"text": "percent", "sentiment": {"score": -0.479941, "label": "negative"}, "relevance": 0.206061}]}, "extracted_metadata": {"sha1": "0d7f87a192cf298b486d602d72d9b194e90e9550", "filename": "1541484147099.zip-bcec6d92bcff9e8c70c72e86d3205d7e.xml", "file_type": "json"}, "external_links": ["http://www.enable-javascript.com/", "http://www.addthis.com/bookmark.php?v=300&pubid=jtimes"], "title": "Japan\u2019s Takeda Pharmaceutical pushes back as dissident shareholders seek to stop Shire deal", "forum_title": "Business \u2013 The Japan Times"}, {"id": "nNsDA6GfzeDMhCf8CCHHpYA3JNAdejaMxDiWpu_b-VIJYItmV53L7ZdfTYKDkkwt", "result_metadata": {"score": 31.784336}, "author": "Lisa Pomrenke", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acorda Therapeutics", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Acorda Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Acorda_Therapeutics"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denali Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DNLI", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.848654, "label": "/finance/financial news"}], "relations": [{"type": "hasAttribute", "sentence": "Financial Review: Acorda Therapeutics (ACOR) and Denali Therapeutics (DNLI)", "score": 0.941675, "arguments": [{"text": "Denali Therapeutics", "location": [49, 68], "entities": [{"type": "Organization", "text": "Denali Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "DNLI", "location": [70, 74], "entities": [{"type": "Ticker", "text": "DNLI"}]}]}], "keywords": [{"text": "Denali Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.965942}, {"text": "Acorda Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801493}, {"text": "DNLI", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52287}, {"text": "Financial Review", "sentiment": {"score": -0.343168, "label": "negative"}, "relevance": 0.497422}]}, "crawl_date": "2018-11-05T21:13:23Z", "url": "https://www.wkrb13.com/2018/11/05/financial-review-acorda-therapeutics-acor-and-denali-therapeutics-dnli.html", "host": "wkrb13.com", "text": "Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics.", "main_image_url": "https://www.marketbeat.com/logos/denali-therapeutics-inc-logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T20:52:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.349853, "label": "negative"}, "text": "Denali Therapeutics", "relevance": 0.889543, "type": "Company"}, {"count": 5, "sentiment": {"score": 0.385954, "label": "positive"}, "text": "Acorda Therapeutics", "relevance": 0.818229, "type": "Company", "disambiguation": {"subtype": [], "name": "Acorda Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Acorda_Therapeutics"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denali Therapeutics Inc.", "relevance": 0.672433, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acorda Therapeutics, Inc.", "relevance": 0.519896, "type": "Company"}, {"count": 7, "sentiment": {"score": -0.508586, "label": "negative"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.498811, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acorda Therapeutics Daily", "relevance": 0.411151, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.514983, "label": "negative"}, "text": "Parkinson", "relevance": 0.294899, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.466411, "label": "negative"}, "text": "Alzheimer's disease", "relevance": 0.285918, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": -0.27797, "label": "negative"}, "text": "United States", "relevance": 0.236659, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.508586, "label": "negative"}, "text": "Parkinson's disease", "relevance": 0.223177, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "primary sclerosing cholangitis", "relevance": 0.195649, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Primary sclerosing cholangitis", "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SPR Pharma Inc.", "relevance": 0.187515, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.182241, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "neurodegeneration", "relevance": 0.181568, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Neurodegeneration", "dbpedia_resource": "http://dbpedia.org/resource/Neurodegeneration"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Qutenza", "relevance": 0.181401, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ardsley", "relevance": 0.179504, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "City"], "name": "Ardsley, New York", "dbpedia_resource": "http://dbpedia.org/resource/Ardsley,_New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "South San Francisco", "relevance": 0.175633, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "South San Francisco, California", "dbpedia_resource": "http://dbpedia.org/resource/South_San_Francisco,_California"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canadian Spinal Research Organization", "relevance": 0.173105, "type": "Organization", "disambiguation": {"subtype": [], "name": "Canadian Spinal Research Organization", "dbpedia_resource": "http://dbpedia.org/resource/Canadian_Spinal_Research_Organization"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.169566, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.168858, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ALS", "relevance": 0.168342, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Europe Ltd.", "relevance": 0.167665, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gamma Limited", "relevance": 0.165023, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.524542, "label": "negative"}, "text": "ARCUS", "relevance": 0.164418, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.282781, "label": "negative"}, "text": "Brigham and Women's Hospital", "relevance": 0.161247, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen International GmbH", "relevance": 0.161195, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.455935, "label": "positive"}, "text": "MarketBeat.com", "relevance": 0.160062, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "St. Luke's Medical Center", "relevance": 0.158786, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biotechnology Limited", "relevance": 0.157468, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "aSyn", "relevance": 0.156041, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.155912, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes, Inc.", "relevance": 0.155197, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Paion AG", "relevance": 0.15463, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbCellera Biologics", "relevance": 0.15357, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.358366, "label": "negative"}, "text": "triptan", "relevance": 0.15353, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes plc", "relevance": 0.152706, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.207225, "label": "negative"}, "text": "zolmitriptan", "relevance": 0.151414, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0.403372, "label": "positive"}, "text": "Americas", "relevance": 0.15071, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mayo Foundation for Education and Research", "relevance": 0.150144, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medarex, Inc.", "relevance": 0.148048, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech, Inc.", "relevance": 0.147817, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.508586, "label": "negative"}, "text": "Inbrija", "relevance": 0.146337, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.89", "relevance": 0.146337, "type": "Quantity"}], "sentiment": {"document": {"score": -0.319628, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Denali Therapeutics", "keywords": [{"text": "Denali Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics"}]}, "sentence": " Denali Therapeutics has lower revenue, but higher earnings than Acorda Therapeutics.", "object": {"text": "lower revenue", "keywords": [{"text": "lower revenue"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Denali Therapeutics", "keywords": [{"text": "Denali Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics"}]}, "sentence": " Denali Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.", "object": {"text": "trading at a lower price-to-earnings ratio than Acorda Therapeutics", "keywords": [{"text": "lower price-to-earnings ratio"}, {"text": "Acorda Therapeutics"}, {"text": "trading"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics", "disambiguation": {"subtype": [], "name": "Acorda Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Acorda_Therapeutics"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Denali Therapeutics", "keywords": [{"text": "Denali Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics"}]}, "sentence": " Denali Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.", "object": {"text": "that it is currently the more affordable of the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicating", "normalized": "indicate"}}, {"subject": {"text": "Denali Therapeutics", "keywords": [{"text": "Denali Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics"}]}, "sentence": " Denali Therapeutics beats Acorda Therapeutics on 6 of the 11 factors compared between the two stocks.", "object": {"text": "Acorda Therapeutics", "keywords": [{"text": "Acorda Therapeutics"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics", "disambiguation": {"subtype": [], "name": "Acorda Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Acorda_Therapeutics"}}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 11 factors", "keywords": [{"text": "factors"}]}, "sentence": " Denali Therapeutics beats Acorda Therapeutics on 6 of the 11 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Acorda Therapeutics, Inc., a biopharmaceutical company,", "keywords": [{"text": "Acorda Therapeutics"}, {"text": "biopharmaceutical company"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Acorda Therapeutics, Inc."}]}, "sentence": " Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.", "object": {"text": "therapies", "keywords": [{"text": "therapies"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "commercializes", "normalized": "commercialize"}}, {"subject": {"text": "neuropathic pain", "keywords": [{"text": "neuropathic pain"}]}, "sentence": " The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.", "object": {"text": "with post-herpetic neuralgia", "keywords": [{"text": "post-herpetic neuralgia"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "It"}, "sentence": " It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.", "object": {"text": "Ampyra", "keywords": [{"text": "Ampyra"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis.", "object": {"text": "Inbrija", "keywords": [{"text": "Inbrija"}], "entities": [{"type": "Company", "text": "Inbrija"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "SYN120", "keywords": [{"text": "SYN120"}]}, "sentence": " In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis.", "object": {"text": "completed Phase II clinical trial", "keywords": [{"text": "clinical trial"}, {"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "SYN120", "keywords": [{"text": "SYN120"}]}, "sentence": " In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis.", "object": {"text": "Phase II clinical trial to treat Parkinson's disease-related dementia", "keywords": [{"text": "disease-related dementia"}, {"text": "clinical trial"}, {"text": "Parkinson"}, {"text": "Phase"}], "entities": [{"type": "Person", "text": "Parkinson"}]}, "action": {"verb": {"text": "complete", "tense": "past"}, "text": "is completed", "normalized": "be complete"}}, {"subject": {"text": "BTT1023 (timolumab)", "keywords": [{"text": "timolumab"}]}, "sentence": " In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis.", "object": {"text": "in Phase II clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients.", "object": {"text": "rHIgM22", "keywords": [{"text": "rHIgM22"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "Cimaglermin alfa", "keywords": [{"text": "Cimaglermin alfa"}]}, "sentence": " Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients.", "object": {"text": "in Phase Ib clinical trial", "keywords": [{"text": "Phase Ib"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc.", "object": {"text": "collaborations and license agreements with Biogen International GmbH", "keywords": [{"text": "Biogen International GmbH"}, {"text": "license agreements"}, {"text": "collaborations"}], "entities": [{"type": "Company", "text": "Biogen International GmbH"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Acorda Therapeutics, Inc.", "keywords": [{"text": "Acorda Therapeutics"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics, Inc."}]}, "sentence": " Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "object": {"text": "founded in 1995"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Acorda Therapeutics, Inc.", "keywords": [{"text": "Acorda Therapeutics"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics, Inc."}]}, "sentence": " Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "Acorda Therapeutics", "keywords": [{"text": "Acorda Therapeutics"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics, Inc."}]}, "sentence": " Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "object": {"text": "headquartered in Ardsley, New York", "keywords": [{"text": "Ardsley"}, {"text": "New York"}], "entities": [{"type": "Location", "text": "Ardsley", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "CityTown", "City"], "name": "Ardsley, New York", "dbpedia_resource": "http://dbpedia.org/resource/Ardsley,_New_York"}}, {"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Acorda Therapeutics, Inc.", "keywords": [{"text": "Acorda Therapeutics"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics, Inc."}]}, "sentence": " Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Denali Therapeutics Inc., a biopharmaceutical company,", "keywords": [{"text": "Denali Therapeutics Inc."}, {"text": "biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.", "object": {"text": "therapeutic candidates for neurodegenerative diseases in the United States", "keywords": [{"text": "therapeutic candidates"}, {"text": "neurodegenerative diseases"}, {"text": "United States"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "discover", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "Denali Therapeutics Inc., a biopharmaceutical company,", "keywords": [{"text": "Denali Therapeutics Inc."}, {"text": "biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.", "object": {"text": "therapeutic candidates", "keywords": [{"text": "therapeutic candidates"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "discovers and develops", "normalized": "discover and develop"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "object": {"text": "leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease", "keywords": [{"text": "leucine-rich repeat kinase"}, {"text": "inhibitor product candidates"}, {"text": "clinical trials"}, {"text": "Parkinson"}], "entities": [{"type": "Person", "text": "Parkinson"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease", "keywords": [{"text": "clinical trials"}, {"text": "Parkinson"}, {"text": "Phase"}, {"text": "DNL151"}], "entities": [{"type": "Person", "text": "Parkinson"}]}, "sentence": " The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "object": {"text": "kinase 2 (LRRK2) inhibitor product candidates", "keywords": [{"text": "inhibitor product candidates"}, {"text": "kinase"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate", "keywords": [{"text": "inhibitor product candidate"}, {"text": "brain-penetrant small molecule"}]}, "sentence": " It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "object": {"text": "in Phase 1 clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS.", "object": {"text": "LF1, a protein to treat neurodegeneration", "keywords": [{"text": "neurodegeneration"}, {"text": "protein"}], "entities": [{"type": "HealthCondition", "text": "neurodegeneration", "disambiguation": {"subtype": [], "name": "Neurodegeneration", "dbpedia_resource": "http://dbpedia.org/resource/Neurodegeneration"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is developing", "normalized": "be develop"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development.", "object": {"text": "various seed program, which are under the research, discovery, and preclinical stages of development", "keywords": [{"text": "various seed program"}, {"text": "preclinical stages"}, {"text": "research"}, {"text": "discovery"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "various seed program", "keywords": [{"text": "various seed program"}]}, "sentence": " Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development.", "object": {"text": "under the research, discovery", "keywords": [{"text": "research"}, {"text": "discovery"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Denali Therapeutics Inc.", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics.", "object": {"text": "collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Forschungs-Und Entwicklungsges M.B.H"}, {"text": "F-star Biotechnology Limited"}, {"text": "collaboration agreement"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Genentech, Inc."}, {"type": "Company", "text": "Gamma Limited"}, {"type": "Company", "text": "Biotechnology Limited"}, {"type": "Company", "text": "AbCellera Biologics"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.", "object": {"text": "as SPR Pharma Inc.", "keywords": [{"text": "SPR Pharma"}], "entities": [{"type": "Company", "text": "SPR Pharma Inc."}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.", "object": {"text": "its name"}, "action": {"verb": {"text": "change", "tense": "past"}, "text": "changed", "normalized": "change"}}, {"subject": {"text": "Denali Therapeutics Inc.", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.", "object": {"text": "incorporated in 2013"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Denali Therapeutics Inc.", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.", "action": {"verb": {"text": "incorporate", "tense": "past"}, "text": "was incorporated", "normalized": "be incorporate"}}, {"subject": {"text": "Denali Therapeutics Inc.", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.", "object": {"text": "headquartered in South San Francisco, California", "keywords": [{"text": "South San Francisco"}, {"text": "California"}], "entities": [{"type": "Location", "text": "South San Francisco", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "South San Francisco, California", "dbpedia_resource": "http://dbpedia.org/resource/South_San_Francisco,_California"}}, {"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Denali Therapeutics Inc.", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Denali Therapeutics Inc."}]}, "sentence": " Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "News & Ratings for Acorda Therapeutics Daily -", "keywords": [{"text": "Acorda Therapeutics Daily"}, {"text": "Ratings"}, {"text": "News"}], "entities": [{"type": "Company", "text": "Acorda Therapeutics Daily"}]}, "sentence": " Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .", "object": {"text": "your email address", "keywords": [{"text": "email address"}]}, "action": {"verb": {"text": "Enter", "tense": "present"}, "text": "Enter", "normalized": "Enter"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.948964, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Alzheimer's disease", "relevance": 0.846551, "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}, {"text": "Parkinson's disease", "relevance": 0.709175, "dbpedia_resource": "http://dbpedia.org/resource/Parkinson's_disease"}, {"text": "Neurodegenerative disorders", "relevance": 0.707951, "dbpedia_resource": "http://dbpedia.org/resource/Neurodegenerative_disorders"}, {"text": "Neurology", "relevance": 0.690618, "dbpedia_resource": "http://dbpedia.org/resource/Neurology"}, {"text": "Amyotrophic lateral sclerosis", "relevance": 0.613368, "dbpedia_resource": "http://dbpedia.org/resource/Amyotrophic_lateral_sclerosis"}, {"text": "Pharmacology", "relevance": 0.611249, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.529725, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Acorda Therapeutics", "relevance": 0.516291, "dbpedia_resource": "http://dbpedia.org/resource/Acorda_Therapeutics"}, {"text": "Enzyme inhibitor", "relevance": 0.482606, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Signal transduction", "relevance": 0.481478, "dbpedia_resource": "http://dbpedia.org/resource/Signal_transduction"}, {"text": "Therapy", "relevance": 0.480168, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.470747, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Lysosomal storage disease", "relevance": 0.454498, "dbpedia_resource": "http://dbpedia.org/resource/Lysosomal_storage_disease"}, {"text": "Dementia", "relevance": 0.45099, "dbpedia_resource": "http://dbpedia.org/resource/Dementia"}, {"text": "Medicine", "relevance": 0.425358, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "4-Aminopyridine", "relevance": 0.420086, "dbpedia_resource": "http://dbpedia.org/resource/4-Aminopyridine"}, {"text": "Pre-clinical development", "relevance": 0.404645, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Protein", "relevance": 0.393348, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.389656, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Beta amyloid", "relevance": 0.379236, "dbpedia_resource": "http://dbpedia.org/resource/Beta_amyloid"}, {"text": "The Canon of Medicine", "relevance": 0.375899, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Jean-Martin Charcot", "relevance": 0.375555, "dbpedia_resource": "http://dbpedia.org/resource/Jean-Martin_Charcot"}, {"text": "Clinical research", "relevance": 0.371774, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "LRRK2", "relevance": 0.353789, "dbpedia_resource": "http://dbpedia.org/resource/LRRK2"}, {"text": "Informed consent", "relevance": 0.347843, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}, {"text": "Epidemiology", "relevance": 0.346028, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Apomorphine", "relevance": 0.344162, "dbpedia_resource": "http://dbpedia.org/resource/Apomorphine"}], "categories": [{"score": 0.57732, "label": "/health and fitness/disease"}, {"score": 0.47911, "label": "/health and fitness/disorders"}, {"score": 0.443203, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients.", "score": 0.886614, "arguments": [{"text": "patients", "location": [1416, 1424], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "heart failure", "location": [1402, 1415], "entities": [{"type": "HealthCondition", "text": "Parkinson's disease"}]}]}, {"type": "employedBy", "sentence": "The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "score": 0.484318, "arguments": [{"text": "candidates", "location": [2106, 2116], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "DNL151", "location": [2139, 2145], "entities": [{"type": "Organization", "text": "DNL151"}]}]}, {"type": "hasAttribute", "sentence": "The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "score": 0.596096, "arguments": [{"text": "candidates", "location": [2106, 2116], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "Parkinson's disease", "location": [2188, 2207], "entities": [{"type": "HealthCondition", "text": "Parkinson's disease"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "score": 0.558837, "arguments": [{"text": "candidates", "location": [2302, 2312], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "Alzheimer's disease", "location": [2449, 2468], "entities": [{"type": "HealthCondition", "text": "Alzheimer's disease"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "score": 0.712572, "arguments": [{"text": "candidates", "location": [2302, 2312], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "amyotrophic lateral sclerosis", "location": [2473, 2502], "entities": [{"type": "HealthCondition", "text": "amyotrophic lateral sclerosis"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "score": 0.646977, "arguments": [{"text": "candidate", "location": [2401, 2410], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "Alzheimer's disease", "location": [2449, 2468], "entities": [{"type": "HealthCondition", "text": "Alzheimer's disease"}]}]}, {"type": "hasAttribute", "sentence": "In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau.", "score": 0.784631, "arguments": [{"text": "candidate", "location": [2907, 2916], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "Alzheimer's disease", "location": [2959, 2978], "entities": [{"type": "HealthCondition", "text": "Alzheimer's disease"}]}]}, {"type": "hasAttribute", "sentence": "Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS.", "score": 0.646999, "arguments": [{"text": "candidate", "location": [3205, 3214], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "Alzheimer's disease", "location": [3236, 3255], "entities": [{"type": "HealthCondition", "text": "Alzheimer's disease"}]}]}, {"type": "hasAttribute", "sentence": "It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "score": 0.431939, "arguments": [{"text": "candidate", "location": [2401, 2410], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "amyotrophic lateral sclerosis", "location": [2473, 2502], "entities": [{"type": "HealthCondition", "text": "amyotrophic lateral sclerosis"}]}]}, {"type": "educatedAt", "sentence": "Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS.", "score": 0.394289, "arguments": [{"text": "candidate", "location": [3205, 3214], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "ALS", "location": [3260, 3263], "entities": [{"type": "Organization", "text": "ALS"}]}]}, {"type": "managerOf", "sentence": "Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics.", "score": 0.645598, "arguments": [{"text": "F-star", "location": [3602, 3608], "entities": [{"type": "Person", "text": "Biotechnologische Forschungs-Und Entwicklungsges M.B.H"}]}, {"text": "Biotechnology Limited", "location": [3609, 3630], "entities": [{"type": "Organization", "text": "Biotechnology Limited"}]}]}, {"type": "partOf", "sentence": "The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.", "score": 0.546824, "arguments": [{"text": "its", "location": [3719, 3722], "entities": [{"type": "Organization", "text": "Acorda Therapeutics\nAcorda Therapeutics, Inc."}]}, {"text": "Denali Therapeutics Inc.", "location": [3731, 3755], "entities": [{"type": "Organization", "text": "Denali Therapeutics\nDenali Therapeutics Inc."}]}]}, {"type": "locatedAt", "sentence": "Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.", "score": 0.996568, "arguments": [{"text": "South San Francisco", "location": [3845, 3864], "entities": [{"type": "GeopoliticalEntity", "text": "South San Francisco"}]}, {"text": "California", "location": [3866, 3876], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "partOf", "sentence": "The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "score": 0.279798, "arguments": [{"text": "company", "location": [1430, 1437], "entities": [{"type": "Organization", "text": "Acorda Therapeutics\nAcorda Therapeutics, Inc."}]}, {"text": "Biogen International GmbH; Alkermes plc", "location": [1485, 1524], "entities": [{"type": "Organization", "text": "Biogen International GmbH; Alkermes plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.279892, "arguments": [{"text": "your", "location": [3939, 3943], "entities": [{"type": "Person", "text": "your"}]}, {"text": "Acorda Therapeutics Daily", "location": [3905, 3930], "entities": [{"type": "Organization", "text": "Acorda Therapeutics\nAcorda Therapeutics, Inc."}]}]}, {"type": "partOf", "sentence": "The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "score": 0.437337, "arguments": [{"text": "Spinal Research Organization", "location": [1625, 1653], "entities": [{"type": "Organization", "text": "Spinal Research Organization"}]}, {"text": "Canadian", "location": [1616, 1624], "entities": [{"type": "GeopoliticalEntity", "text": "Canadian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "score": 0.329132, "arguments": [{"text": "Women", "location": [1740, 1745], "entities": [{"type": "Person", "text": "Women"}]}, {"text": "Hospital, Inc. Acorda Therapeutics, Inc.", "location": [1748, 1788], "entities": [{"type": "Organization", "text": "Hospital, Inc. Acorda Therapeutics, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "foundedOn", "sentence": "The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "score": 0.64285, "arguments": [{"text": "Hospital, Inc. Acorda Therapeutics, Inc.", "location": [1748, 1788], "entities": [{"type": "Organization", "text": "Hospital, Inc. Acorda Therapeutics, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "1995", "location": [1804, 1808], "entities": [{"type": "Date", "text": "1995", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "locatedAt", "sentence": "The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.", "score": 0.993665, "arguments": [{"text": "Ardsley", "location": [1833, 1840], "entities": [{"type": "GeopoliticalEntity", "text": "Ardsley"}]}, {"text": "New York", "location": [1842, 1850], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "hasAttribute", "sentence": "About Denali Therapeutics Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.", "score": 0.858143, "arguments": [{"text": "candidates", "location": [1968, 1978], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "diseases", "location": [2001, 2009], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "employedBy", "sentence": "The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "score": 0.538499, "arguments": [{"text": "candidates", "location": [2106, 2116], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "LRRK2", "location": [2081, 2086], "entities": [{"type": "Organization", "text": "LRRK2"}]}]}, {"type": "partOfMany", "sentence": "The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.", "score": 0.803925, "arguments": [{"text": "DNL201", "location": [2128, 2134], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "candidates", "location": [2106, 2116], "entities": [{"type": "Person", "text": "candidates"}]}]}, {"type": "partOfMany", "sentence": "It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).", "score": 0.496175, "arguments": [{"text": "candidate", "location": [2401, 2410], "entities": [{"type": "Person", "text": "DNL201"}]}, {"text": "candidates", "location": [2302, 2312], "entities": [{"type": "Person", "text": "candidates"}]}]}], "keywords": [{"text": "Denali Therapeutics", "sentiment": {"score": -0.349853, "label": "negative"}, "relevance": 0.921253}, {"text": "Acorda Therapeutics", "sentiment": {"score": 0.385954, "label": "positive"}, "relevance": 0.862444}, {"text": "Denali Therapeutics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.738762}, {"text": "clinical trial", "sentiment": {"score": -0.351121, "label": "negative"}, "relevance": 0.522519}, {"text": "Acorda Therapeutics Daily", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517713}, {"text": "company markets Ampyra", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418804}, {"text": "biopharmaceutical company", "sentiment": {"score": 0.295141, "label": "positive"}, "relevance": 0.415271}, {"text": "SPR Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412455}, {"text": "Ib clinical trial", "sentiment": {"score": -0.224941, "label": "negative"}, "relevance": 0.41214}, {"text": "inhibitor product candidate", "sentiment": {"score": -0.385933, "label": "negative"}, "relevance": 0.406789}, {"text": "inhibitor product candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406524}, {"text": "lower price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404043}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403698}, {"text": "United States", "sentiment": {"score": -0.27797, "label": "negative"}, "relevance": 0.402189}, {"text": "leucine-rich repeat kinase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40141}, {"text": "serine/threonine protein kinase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400912}, {"text": "molecule product candidate", "sentiment": {"score": -0.593559, "label": "negative"}, "relevance": 0.400619}, {"text": "primary sclerosing cholangitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400565}, {"text": "Astellas Pharma Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399917}, {"text": "Biogen International GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399604}, {"text": "ARCUS drug delivery", "sentiment": {"score": -0.524542, "label": "negative"}, "relevance": 0.399564}, {"text": "small molecule", "sentiment": {"score": -0.489746, "label": "negative"}, "relevance": 0.398084}, {"text": "Rush-Presbyterian St. Luke", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.397104}, {"text": "brain-penetrant small molecule", "sentiment": {"score": -0.385933, "label": "negative"}, "relevance": 0.394673}, {"text": "Canadian Spinal Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394636}, {"text": "enzyme transport vehicle", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39315}, {"text": "amyotrophic lateral sclerosis", "sentiment": {"score": -0.385933, "label": "negative"}, "relevance": 0.391877}, {"text": "lysosomal storage disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39172}, {"text": "concise daily summary", "sentiment": {"score": 0.468303, "label": "positive"}, "relevance": 0.390587}, {"text": "replacement therapy program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390364}, {"text": "antibody transport vehicle", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39003}, {"text": "Forschungs-Und Entwicklungsges M.B.H", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388744}, {"text": "South San Francisco", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388465}, {"text": "F-star Gamma Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388421}, {"text": "various seed program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387895}, {"text": "F-star Biotechnology Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.385499}, {"text": "Phase", "sentiment": {"score": -0.413371, "label": "negative"}, "relevance": 0.362045}, {"text": "post-herpetic neuralgia", "sentiment": {"score": -0.646371, "label": "negative"}, "relevance": 0.359773}, {"text": "clinical trials", "sentiment": {"score": -0.600121, "label": "negative"}, "relevance": 0.358217}, {"text": "bispecific program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356702}, {"text": "inhaled triptan", "sentiment": {"score": -0.358366, "label": "negative"}, "relevance": 0.355738}, {"text": "higher earnings", "sentiment": {"score": 0.315973, "label": "positive"}, "relevance": 0.355533}, {"text": "acute treatment", "sentiment": {"score": -0.524542, "label": "negative"}, "relevance": 0.354821}, {"text": "lower revenue", "sentiment": {"score": -0.349853, "label": "negative"}, "relevance": 0.354675}, {"text": "disease-related dementia", "sentiment": {"score": -0.442489, "label": "negative"}, "relevance": 0.353972}, {"text": "dermal patch", "sentiment": {"score": -0.646371, "label": "negative"}, "relevance": 0.35392}, {"text": "neuropathic pain", "sentiment": {"score": -0.646371, "label": "negative"}, "relevance": 0.353783}, {"text": "therapeutic candidates", "sentiment": {"score": -0.222293, "label": "negative"}, "relevance": 0.352899}, {"text": "therapeutic candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352359}]}, "extracted_metadata": {"sha1": "5859ef354f31593ce3be225938292f4592301dfd", "filename": "1541452403184.zip-1169c35e7907257845f37d5a133b8fcb.xml", "file_type": "json"}, "title": "Financial Review: Acorda Therapeutics (ACOR) and Denali Therapeutics (DNLI)", "forum_title": "WKRB News"}, {"id": "GID363EOjxYGEKVEpGVmRwfvFNRzMa48-QbAVYu3zSZpYSIFLLfsAUe2cxLnrYYX", "result_metadata": {"score": 31.711607}, "author": "Asif Suria", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Arbitrage", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Arbitrage"}, {"text": "Risk arbitrage", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Risk_arbitrage"}], "categories": [{"score": 0.984504, "label": "/business and industrial/company/merger and acquisition"}], "relations": [], "keywords": [{"text": "Merger Arbitrage Mondays", "sentiment": {"score": 0.41854, "label": "positive"}, "relevance": 0.904572}]}, "crawl_date": "2018-11-06T14:13:18Z", "url": "https://seekingalpha.com/article/4218601-merger-arbitrage-mondays-november-5-2018", "host": "seekingalpha.com", "text": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd.", "main_image_url": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T08:53:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "LSC Communications", "relevance": 0.366666, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Encana Corporation", "relevance": 0.362452, "type": "Company", "disambiguation": {"subtype": [], "name": "Encana", "dbpedia_resource": "http://dbpedia.org/resource/Encana"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Penn Virginia", "relevance": 0.352492, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denbury", "relevance": 0.347576, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Penn Virginia Corporation", "relevance": 0.324702, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WildHorse Resource Development Corporation", "relevance": 0.313807, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chesapeake Energy Corporation", "relevance": 0.301375, "type": "Company", "disambiguation": {"subtype": [], "name": "Chesapeake Energy", "dbpedia_resource": "http://dbpedia.org/resource/Chesapeake_Energy"}}, {"count": 2, "sentiment": {"score": -0.296495, "label": "negative"}, "text": "T-Mobile", "relevance": 0.298584, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.296495, "label": "negative"}, "text": "US", "relevance": 0.293908, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KapStone Paper and Packaging Corporation", "relevance": 0.292131, "type": "Company", "disambiguation": {"subtype": [], "name": "Kapstone", "dbpedia_resource": "http://dbpedia.org/resource/Kapstone"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Newfield Exploration Company", "relevance": 0.290252, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Penn Virginia", "relevance": 0.27953, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TMUS", "relevance": 0.279523, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denbury Resources", "relevance": 0.279479, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sprint Corporation", "relevance": 0.269129, "type": "Company", "disambiguation": {"subtype": [], "name": "Sprint Nextel", "dbpedia_resource": "http://dbpedia.org/resource/Sprint_Nextel"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WildHorse", "relevance": 0.267508, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Electro Scientific Industries", "relevance": 0.264579, "type": "Company", "disambiguation": {"subtype": [], "name": "Electro Scientific Industries", "dbpedia_resource": "http://dbpedia.org/resource/Electro_Scientific_Industries"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chesapeake", "relevance": 0.262856, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Newfield", "relevance": 0.261333, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0.405847, "label": "positive"}, "text": "LifePoint Health", "relevance": 0.251176, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Newfield", "relevance": 0.249284, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KLA-Tencor Corporation", "relevance": 0.248921, "type": "Company", "disambiguation": {"subtype": [], "name": "KLA Tencor", "dbpedia_resource": "http://dbpedia.org/resource/KLA_Tencor"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senomyx", "relevance": 0.247932, "type": "Company", "disambiguation": {"subtype": [], "name": "Senomyx", "dbpedia_resource": "http://dbpedia.org/resource/Senomyx"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.24719, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reliance Industries Limited", "relevance": 0.246084, "type": "Company", "disambiguation": {"subtype": [], "name": "Reliance Industries", "dbpedia_resource": "http://dbpedia.org/resource/Reliance_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nevsun Resources", "relevance": 0.241635, "type": "Company", "disambiguation": {"subtype": [], "name": "Nevsun Resources", "dbpedia_resource": "http://dbpedia.org/resource/Nevsun_Resources"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pacific Biosciences of California", "relevance": 0.241452, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DNR", "relevance": 0.239353, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zijin Mining Group", "relevance": 0.2388, "type": "Company", "disambiguation": {"subtype": [], "name": "Zijin Mining", "dbpedia_resource": "http://dbpedia.org/resource/Zijin_Mining"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Firmenich", "relevance": 0.237466, "type": "Company", "disambiguation": {"subtype": [], "name": "Firmenich", "dbpedia_resource": "http://dbpedia.org/resource/Firmenich"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WestRock Company", "relevance": 0.236958, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RLJ Entertainment", "relevance": 0.23547, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teamsport Parent Limited", "relevance": 0.235046, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RCCH HealthCare Partners", "relevance": 0.23296, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IK Healthcare Investment Limited", "relevance": 0.232573, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LKSD", "relevance": 0.232566, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China Oceanwide Holdings Group Co.", "relevance": 0.23142, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AMC Networks", "relevance": 0.229344, "type": "Company", "disambiguation": {"subtype": [], "name": "AMC Networks", "dbpedia_resource": "http://dbpedia.org/resource/AMC_Networks"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ILMN", "relevance": 0.22689, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LPNT", "relevance": 0.226753, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zijin", "relevance": 0.222368, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CHK", "relevance": 0.217914, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nevsun", "relevance": 0.21721, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NSU", "relevance": 0.214934, "type": "Company", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Nova Southeastern University", "dbpedia_resource": "http://dbpedia.org/resource/Nova_Southeastern_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MKS Instruments", "relevance": 0.213547, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.210542, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "IBM", "relevance": 0.209555, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dominion Energy, Inc.", "relevance": 0.207246, "type": "Company"}], "sentiment": {"document": {"score": 0.448765, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Merger activity", "keywords": [{"text": "Merger activity"}]}, "sentence": "Merger activity increased last week with seven new deals announced and three pending deals closing.", "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "You"}, "sentence": " You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours.", "object": {"text": "all the active deals listed below", "keywords": [{"text": "active deals"}]}, "action": {"verb": {"text": "find", "tense": "future"}, "text": "can find", "normalized": "can find"}}, {"subject": {"text": "our Merger Arbitrage Tool", "keywords": [{"text": "Merger Arbitrage Tool"}]}, "sentence": " You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours.", "object": {"text": "itself"}, "action": {"verb": {"text": "update", "tense": "present"}, "text": "updates", "normalized": "update"}}, {"subject": {"text": "shareholders of Penn Virginia", "keywords": [{"text": "Penn Virginia"}, {"text": "shareholders"}], "entities": [{"type": "Company", "text": "Penn Virginia"}]}, "sentence": " Under the terms of the definitive merger agreement, shareholders of Penn Virginia will receive, subject to proration, a combination of 12.4 shares of Denbury common stock and $25.86 of cash for each share of Penn Virginia common stock.", "object": {"text": "a combination of 12.4 shares of Denbury common stock and $25.86 of cash for each share of Penn Virginia common stock", "keywords": [{"text": "Denbury common stock"}, {"text": "Virginia common stock"}, {"text": "combination"}, {"text": "Penn"}], "entities": [{"type": "Company", "text": "Denbury"}, {"type": "Location", "text": "Penn Virginia", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$25.86"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "Penn Virginia shareholders", "keywords": [{"text": "Penn Virginia"}, {"text": "shareholders"}], "entities": [{"type": "Location", "text": "Penn Virginia", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Penn Virginia shareholders will be permitted to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash.", "object": {"text": "permitted to elect all cash, all stock or a mix of stock and cash, subject to proration", "keywords": [{"text": "cash"}, {"text": "stock"}, {"text": "mix"}, {"text": "proration"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash", "keywords": [{"text": "aggregate issuance"}, {"text": "Denbury shares"}, {"text": "cash"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Denbury"}, {"type": "Quantity", "text": "$400 million"}]}, "sentence": " Penn Virginia shareholders will be permitted to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash.", "object": {"text": "Penn Virginia shareholders", "keywords": [{"text": "Penn Virginia"}, {"text": "shareholders"}], "entities": [{"type": "Location", "text": "Penn Virginia", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "permit", "tense": "future"}, "text": "permitted", "normalized": "permit"}}, {"subject": {"text": "proration", "keywords": [{"text": "proration"}]}, "sentence": " Penn Virginia shareholders will be permitted to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash.", "object": {"text": "in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash", "keywords": [{"text": "aggregate issuance"}, {"text": "Denbury shares"}, {"text": "payment"}, {"text": "cash"}], "entities": [{"type": "Company", "text": "Denbury"}, {"type": "Quantity", "text": "$400 million"}]}, "action": {"verb": {"text": "result", "tense": "future"}, "text": "will result", "normalized": "will result"}}, {"subject": {"text": "We"}, "sentence": " We are treating this as a cash plus stock type of deal.", "object": {"text": "treating this as a cash plus stock type of deal", "keywords": [{"text": "stock type"}, {"text": "cash"}, {"text": "deal"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We are treating this as a cash plus stock type of deal.", "object": {"text": "this"}, "action": {"verb": {"text": "treat", "tense": "present"}, "text": "are treating", "normalized": "be treat"}}, {"subject": {"text": "LSC Communications shareholders", "keywords": [{"text": "LSC Communications shareholders"}], "entities": [{"type": "Company", "text": "LSC Communications"}]}, "sentence": " Under the terms of the agreement, LSC Communications shareholders will receive 0.625 shares of Quad Class A common stock for each LSC Communications share they own.", "object": {"text": "0.625 shares of Quad Class A common stock", "keywords": [{"text": "Quad Class"}, {"text": "common stock"}, {"text": "shares"}], "entities": []}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "they"}, "sentence": " Under the terms of the agreement, LSC Communications shareholders will receive 0.625 shares of Quad Class A common stock for each LSC Communications share they own.", "object": {"text": "each LSC Communications share", "keywords": [{"text": "LSC Communications share"}], "entities": [{"type": "Company", "text": "LSC Communications"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "own", "normalized": "own"}}, {"subject": {"text": "Newfield shareholders", "keywords": [{"text": "Newfield shareholders"}], "entities": [{"type": "Location", "text": "Newfield", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Under the terms of the merger agreement, Newfield shareholders will receive 2.6719 Encana common shares for each share of Newfield common stock.", "object": {"text": "2.6719 Encana common shares", "keywords": [{"text": "Encana common shares"}], "entities": [{"type": "Company", "text": "Encana Corporation", "disambiguation": {"subtype": [], "name": "Encana", "dbpedia_resource": "http://dbpedia.org/resource/Encana"}}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "LifePoint Health ( LPNT )", "keywords": [{"text": "LifePoint Health"}, {"text": "LPNT"}], "entities": [{"type": "Company", "text": "LifePoint Health"}, {"type": "Organization", "text": "LPNT"}]}, "sentence": " On October 29, 2018, LifePoint Health ( LPNT ) announced that its stockholders approved the proposed agreement to merge LifePoint and RCCH HealthCare Partners.", "object": {"text": "that its stockholders approved the proposed agreement to merge LifePoint and RCCH HealthCare Partners", "keywords": [{"text": "RCCH HealthCare Partners"}, {"text": "LifePoint"}, {"text": "stockholders"}, {"text": "agreement"}], "entities": [{"type": "Company", "text": "RCCH HealthCare Partners"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "T-Mobile US ( TMUS )", "keywords": [{"text": "TMUS"}], "entities": [{"type": "Company", "text": "T-Mobile"}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "TMUS"}]}, "sentence": " On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company\u2019s previously announced merger with Sprint Corporation ( S ).", "object": {"text": "that it has received shareholder approval on proposals related to the company\u2019s previously announced merger with Sprint Corporation ( S )", "keywords": [{"text": "shareholder approval"}, {"text": "Sprint Corporation"}, {"text": "proposals"}, {"text": "merger"}], "entities": [{"type": "Company", "text": "Newfield Exploration Company"}, {"type": "Company", "text": "Sprint Corporation", "disambiguation": {"subtype": [], "name": "Sprint Nextel", "dbpedia_resource": "http://dbpedia.org/resource/Sprint_Nextel"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "previously announced merger", "keywords": [{"text": "merger"}]}, "sentence": " On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company\u2019s previously announced merger with Sprint Corporation ( S ).", "object": {"text": "with Sprint Corporation ( S )", "keywords": [{"text": "Sprint Corporation"}], "entities": [{"type": "Company", "text": "Sprint Corporation", "disambiguation": {"subtype": [], "name": "Sprint Nextel", "dbpedia_resource": "http://dbpedia.org/resource/Sprint_Nextel"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "merger", "keywords": [{"text": "merger"}]}, "sentence": " On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company\u2019s previously announced merger with Sprint Corporation ( S ).", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Nevsun Resources ( NSU )", "keywords": [{"text": "Nevsun Resources"}], "entities": [{"type": "Company", "text": "Nevsun Resources", "disambiguation": {"subtype": [], "name": "Nevsun Resources", "dbpedia_resource": "http://dbpedia.org/resource/Nevsun_Resources"}}, {"type": "Company", "text": "NSU", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Nova Southeastern University", "dbpedia_resource": "http://dbpedia.org/resource/Nova_Southeastern_University"}}]}, "sentence": " On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "object": {"text": "that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun", "keywords": [{"text": "friendly takeover bid"}, {"text": "required regulatory approvals"}, {"text": "Zijin Mining Group"}], "entities": [{"type": "Company", "text": "Zijin Mining Group", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Zijin Mining", "dbpedia_resource": "http://dbpedia.org/resource/Zijin_Mining"}}, {"type": "Company", "text": "Zijin"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Zijin", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Nevsun", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "object": {"text": "advised"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by Zijin Mining Group", "keywords": [{"text": "Zijin Mining Group"}], "entities": [{"type": "Company", "text": "Zijin Mining Group", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Zijin Mining", "dbpedia_resource": "http://dbpedia.org/resource/Zijin_Mining"}}]}, "sentence": " On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "object": {"text": "it"}, "action": {"verb": {"text": "advise", "tense": "past"}, "text": "has been advised", "normalized": "have be advise"}}, {"subject": {"text": "Zijin", "keywords": [{"text": "Zijin"}], "entities": [{"type": "Location", "text": "Zijin", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "object": {"text": "friendly takeover bid of Nevsun", "keywords": [{"text": "friendly takeover bid"}], "entities": [{"type": "Location", "text": "Nevsun", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "propose", "tense": "past"}, "text": "proposed", "normalized": "propose"}}, {"subject": {"text": "It"}, "sentence": " It took 93 days for this deal to be completed.", "object": {"text": "93 days", "entities": [{"type": "Quantity", "text": "93 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}]}, "sentence": " It took 93 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 277 days for this deal to be completed.", "object": {"text": "277 days", "entities": [{"type": "Quantity", "text": "277 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}]}, "sentence": " It took 277 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 46 days for this deal to be completed.", "object": {"text": "46 days", "entities": [{"type": "Quantity", "text": "46 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}]}, "sentence": " It took 46 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Please"}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "object": {"text": "your own"}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "any securities", "keywords": [{"text": "securities"}]}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "action": {"verb": {"text": "mention", "tense": "past"}, "text": "mentioned", "normalized": "mention"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "not warrant the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "warrant", "tense": "present", "negated": true}, "text": "warrant", "normalized": "warrant"}}, {"subject": {"text": "the content or data", "keywords": [{"text": "content"}, {"text": "data"}]}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "I am/we"}, "sentence": " Disclosure: I am/we are long TWLO,COL,P,RSYS,CALL.", "object": {"text": "long TWLO,COL,P,RSYS,CALL", "keywords": [{"text": "long TWLO,COL,P,RSYS,CALL"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "myself"}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "it"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "my own opinions", "keywords": [{"text": "opinions"}]}, "action": {"verb": {"text": "express", "tense": "present"}, "text": "expresses", "normalized": "express"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "not receiving compensation for it", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "compensation", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "receive", "tense": "present", "negated": true}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "I"}, "sentence": " I have no business relationship with any company whose stock is mentioned in this article.", "object": {"text": "no business relationship with any company whose stock is mentioned in this article", "keywords": [{"text": "business relationship"}, {"text": "company"}, {"text": "stock"}, {"text": "article"}], "entities": [{"type": "Company", "text": "Newfield Exploration Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}], "concepts": [{"text": "Stock", "relevance": 0.964337, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.853389, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Shareholder", "relevance": 0.822883, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Share", "relevance": 0.80233, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Chesapeake Energy", "relevance": 0.669405, "dbpedia_resource": "http://dbpedia.org/resource/Chesapeake_Energy"}, {"text": "Zijin Mining", "relevance": 0.539419, "dbpedia_resource": "http://dbpedia.org/resource/Zijin_Mining"}, {"text": "Mergers and acquisitions", "relevance": 0.51524, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Aubrey McClendon", "relevance": 0.437511, "dbpedia_resource": "http://dbpedia.org/resource/Aubrey_McClendon"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.423212, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Names of large numbers", "relevance": 0.420205, "dbpedia_resource": "http://dbpedia.org/resource/Names_of_large_numbers"}, {"text": "Fiduciary", "relevance": 0.412743, "dbpedia_resource": "http://dbpedia.org/resource/Fiduciary"}, {"text": "Arbitrage", "relevance": 0.399493, "dbpedia_resource": "http://dbpedia.org/resource/Arbitrage"}, {"text": "Security", "relevance": 0.392689, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Deals", "relevance": 0.3916, "dbpedia_resource": "http://dbpedia.org/resource/Deals"}, {"text": "Reliance Industries", "relevance": 0.390831, "dbpedia_resource": "http://dbpedia.org/resource/Reliance_Industries"}, {"text": "Stakeholder", "relevance": 0.358467, "dbpedia_resource": "http://dbpedia.org/resource/Stakeholder_(corporate)"}], "categories": [{"score": 0.790396, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.36566, "label": "/finance/financial news"}, {"score": 0.315089, "label": "/finance/investing"}], "relations": [{"type": "timeOf", "sentence": "Merger activity increased last week with seven new deals announced and three pending deals closing.", "score": 0.864687, "arguments": [{"text": "last week", "location": [26, 35], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "announced", "location": [57, 66], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Under the terms of the merger agreement, Newfield shareholders will receive 2.6719 Encana common shares for each share of Newfield common stock.", "score": 0.48557, "arguments": [{"text": "shareholders", "location": [2332, 2344], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Newfield", "location": [2323, 2331], "entities": [{"type": "Organization", "text": "Newfield Exploration Company"}]}]}, {"type": "timeOf", "sentence": "Deal Updates: On October 29, 2018, LifePoint Health ( LPNT ) announced that its stockholders approved the proposed agreement to merge LifePoint and RCCH HealthCare Partners.", "score": 0.811546, "arguments": [{"text": "October 29, 2018", "location": [2574, 2590], "entities": [{"type": "Date", "text": "October 29, 2018"}]}, {"text": "announced", "location": [2618, 2627], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On October 29, 2018, LifePoint Health ( LPNT ) announced that its stockholders approved the proposed agreement to merge LifePoint and RCCH HealthCare Partners.", "score": 0.962099, "arguments": [{"text": "LifePoint Health", "location": [2592, 2608], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}, {"text": "announced", "location": [2618, 2627], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On October 29, 2018, LifePoint Health ( LPNT ) announced that its stockholders approved the proposed agreement to merge LifePoint and RCCH HealthCare Partners.", "score": 0.844025, "arguments": [{"text": "LPNT", "location": [2611, 2615], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}, {"text": "announced", "location": [2618, 2627], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.597158, "arguments": [{"text": "October 30, 2018", "location": [2734, 2750], "entities": [{"type": "Date", "text": "October 30, 2018"}]}, {"text": "announced", "location": [2773, 2782], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.964944, "arguments": [{"text": "T-Mobile US", "location": [2752, 2763], "entities": [{"type": "Organization", "text": "T-Mobile US, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TMUS", "location": [2766, 2770], "entities": [{"type": "Ticker", "text": "TMUS"}]}]}, {"type": "employedBy", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.435151, "arguments": [{"text": "shareholder", "location": [2804, 2815], "entities": [{"type": "Person", "text": "Illumina"}]}, {"text": "it", "location": [2788, 2790], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}]}, {"type": "agentOf", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.744494, "arguments": [{"text": "company", "location": [2853, 2860], "entities": [{"type": "Organization", "text": "Newfield Exploration Company"}]}, {"text": "announced", "location": [2874, 2883], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.581283, "arguments": [{"text": "company", "location": [2853, 2860], "entities": [{"type": "Organization", "text": "Newfield Exploration Company"}]}, {"text": "merger", "location": [2884, 2890], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "On October 30, 2018, T-Mobile US ( TMUS ) announced that it has received shareholder approval on proposals related to the company's previously announced merger with Sprint Corporation ( S ).", "score": 0.444108, "arguments": [{"text": "Sprint Corporation", "location": [2896, 2914], "entities": [{"type": "Organization", "text": "Sprint Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "merger", "location": [2884, 2890], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.758365, "arguments": [{"text": "November 1, 2018", "location": [2925, 2941], "entities": [{"type": "Date", "text": "November 1, 2018"}]}, {"text": "announced", "location": [2968, 2977], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Under the terms of the definitive merger agreement, shareholders of Penn Virginia will receive, subject to proration, a combination of 12.4 shares of Denbury common stock and $25.86 of cash for each share of Penn Virginia common stock.", "score": 0.418566, "arguments": [{"text": "shareholders", "location": [691, 703], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Penn Virginia", "location": [707, 720], "entities": [{"type": "Organization", "text": "Penn Virginia Corporation"}]}]}, {"type": "employedBy", "sentence": "Penn Virginia shareholders will be permitted to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash.", "score": 0.427464, "arguments": [{"text": "shareholders", "location": [889, 901], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Penn Virginia", "location": [875, 888], "entities": [{"type": "Organization", "text": "Penn Virginia Corporation"}]}]}, {"type": "agentOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.914637, "arguments": [{"text": "Nevsun Resources", "location": [2943, 2959], "entities": [{"type": "Organization", "text": "Nevsun Resources", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [2968, 2977], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.788868, "arguments": [{"text": "NSU", "location": [2962, 2965], "entities": [{"type": "Organization", "text": "Nevsun Resources", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [2968, 2977], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.552294, "arguments": [{"text": "it", "location": [2983, 2985], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}, {"text": "advised", "location": [2995, 3002], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.764343, "arguments": [{"text": "Zijin Mining Group", "location": [3006, 3024], "entities": [{"type": "Organization", "text": "Zijin Mining Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "advised", "location": [2995, 3002], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "partOf", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.728114, "arguments": [{"text": "People's Republic of China", "location": [3108, 3134], "entities": [{"type": "Organization", "text": "People's Republic of China"}]}, {"text": "Zijin", "location": [3139, 3144], "entities": [{"type": "Organization", "text": "Zijin"}]}]}, {"type": "locatedAt", "sentence": "On November 1, 2018, Nevsun Resources ( NSU ) announced that it has been advised by Zijin Mining Group that Zijin has received the second of three required regulatory approvals from the People's Republic of China for Zijin's proposed friendly takeover bid of Nevsun.", "score": 0.730737, "arguments": [{"text": "Zijin", "location": [3139, 3144], "entities": [{"type": "Organization", "text": "Zijin"}]}, {"text": "Nevsun", "location": [3181, 3187], "entities": [{"type": "GeopoliticalEntity", "text": "Nevsun"}]}]}, {"type": "affectedBy", "sentence": "Closed Deals: The acquisition of RLJ Entertainment ( RLJE ) by AMC Networks ( AMCX ) on October 31, 2018.", "score": 0.450733, "arguments": [{"text": "RLJ Entertainment", "location": [3222, 3239], "entities": [{"type": "Organization", "text": "RLJ Entertainment"}]}, {"text": "acquisition", "location": [3207, 3218], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Closed Deals: The acquisition of RLJ Entertainment ( RLJE ) by AMC Networks ( AMCX ) on October 31, 2018.", "score": 0.530616, "arguments": [{"text": "AMC Networks", "location": [3252, 3264], "entities": [{"type": "Organization", "text": "AMC Networks", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [3207, 3218], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Closed Deals: The acquisition of RLJ Entertainment ( RLJE ) by AMC Networks ( AMCX ) on October 31, 2018.", "score": 0.864875, "arguments": [{"text": "October 31, 2018", "location": [3277, 3293], "entities": [{"type": "Date", "text": "October 31, 2018"}]}, {"text": "acquisition", "location": [3207, 3218], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Closed Deals: The acquisition of RLJ Entertainment ( RLJE ) by AMC Networks ( AMCX ) on October 31, 2018.", "score": 0.914795, "arguments": [{"text": "AMC Networks", "location": [3252, 3264], "entities": [{"type": "Organization", "text": "AMC Networks", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AMCX", "location": [3267, 3271], "entities": [{"type": "Ticker", "text": "AMCX"}]}]}, {"type": "timeOf", "sentence": "The acquisition of KapStone Paper and Packaging Corporation ( KS ) by WestRock Company ( WRK ) on November 2, 2018.", "score": 0.878226, "arguments": [{"text": "November 2, 2018", "location": [3440, 3456], "entities": [{"type": "Date", "text": "November 2, 2018"}]}, {"text": "acquisition", "location": [3346, 3357], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Penn Virginia shareholders will be permitted to elect all cash, all stock or a mix of stock and cash, subject to proration, which will result in the aggregate issuance of approximately 191.6 million Denbury shares and payment of $400 million in cash.", "score": 0.531897, "arguments": [{"text": "Denbury", "location": [1074, 1081], "entities": [{"type": "Person", "text": "Denbury"}]}, {"text": "$400 million", "location": [1104, 1116], "entities": [{"type": "Money", "text": "$400 million"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Senomyx ( SNMX ) by Firmenich on November 2, 2018.", "score": 0.549931, "arguments": [{"text": "Firmenich", "location": [3545, 3554], "entities": [{"type": "Organization", "text": "Firmenich", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [3510, 3521], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of Senomyx ( SNMX ) by Firmenich on November 2, 2018.", "score": 0.826325, "arguments": [{"text": "November 2, 2018", "location": [3558, 3574], "entities": [{"type": "Date", "text": "November 2, 2018"}]}, {"text": "acquisition", "location": [3510, 3521], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Senomyx ( SNMX ) by Firmenich on November 2, 2018.", "score": 0.900991, "arguments": [{"text": "Senomyx", "location": [3525, 3532], "entities": [{"type": "Organization", "text": "Senomyx"}]}, {"text": "SNMX", "location": [3535, 3539], "entities": [{"type": "Ticker", "text": "SNMX"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.417899, "arguments": [{"text": "Oceanwide Holdings Group Co., Ltd.", "location": [3782, 3816], "entities": [{"type": "Organization", "text": "Oceanwide Holdings Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW", "location": [3658, 3764], "entities": [{"type": "Organization", "text": "Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.794051, "arguments": [{"text": "Oceanwide Holdings Group Co., Ltd.", "location": [3782, 3816], "entities": [{"type": "Organization", "text": "Oceanwide Holdings Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3776, 3781], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.39848, "arguments": [{"text": "KANG", "location": [3861, 3865], "entities": [{"type": "Person", "text": "KANG"}]}, {"text": "IK Healthcare Investment Limited", "location": [3877, 3909], "entities": [{"type": "Organization", "text": "IK Healthcare Investment Limited"}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.462331, "arguments": [{"text": "EHIC", "location": [3958, 3962], "entities": [{"type": "Organization", "text": "EHIC"}]}, {"text": "04/06/2018", "location": [3963, 3973], "entities": [{"type": "Web", "text": "04/06/2018"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.564677, "arguments": [{"text": "Teamsport Parent Limited", "location": [3974, 3998], "entities": [{"type": "Organization", "text": "Teamsport Parent Limited"}]}, {"text": "EHIC", "location": [3958, 3962], "entities": [{"type": "Organization", "text": "EHIC"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.604825, "arguments": [{"text": "Dominion Energy, Inc.", "location": [4060, 4081], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SCG", "location": [4045, 4048], "entities": [{"type": "Organization", "text": "SCG"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.612924, "arguments": [{"text": "Reliance Industries Limited", "location": [4144, 4171], "entities": [{"type": "Organization", "text": "Reliance Industries Limited"}]}, {"text": "RSYS", "location": [4128, 4132], "entities": [{"type": "Organization", "text": "RSYS"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of WildHorse Resource Development Corporation ( WRD ) by Chesapeake Energy Corporation ( CHK ) for $3.977 billion in a cash plus stock deal.", "score": 0.425027, "arguments": [{"text": "WildHorse Resource Development Corporation", "location": [1145, 1187], "entities": [{"type": "Organization", "text": "WildHorse Resource Development Corporation"}]}, {"text": "acquisition", "location": [1130, 1141], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol Announced Date Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.16 12/01/2018 30.53% 428.58% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.97 10/31/2018 21.39% -1561.52% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $11.45 12/31/2018 17.90% 116.70% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $46.76 $40.01 12/31/2018 16.86% 109.90% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.52 12/31/2018 13.16% 85.76% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.18 $55.3 12/31/2018 12.45% 81.12% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.03 $", "score": 0.97086, "arguments": [{"text": "T-Mobile US, Inc.", "location": [4314, 4331], "entities": [{"type": "Organization", "text": "T-Mobile US, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TMUS", "location": [4334, 4338], "entities": [{"type": "Ticker", "text": "TMUS"}]}]}, {"type": "employedBy", "sentence": "6.27 06/30/2019 12.06% 18.58% SHPG 05/08/2018 Takeda Pharmaceutical Company Limited ( TKPYY ) $194.74 $176.28 06/30/2019 10.47% 16.13% RHT 10/28/2018 IBM ( IBM ) $190.00 $172.24 12/31/2019 10.31% 8.94% STC 03/16/2018 Fidelity National Financial, Inc. ( FNF ) $46.14 $41.86 06/30/2019 10.22% 15.74% Disclaimer: I hold positions in Twilio ( TWLO ), Rockwell Collins ( COL ), Pandora ( P ), Radisys ( RSYS ) and magicJack VocalTec ( CALL ).", "score": 0.491072, "arguments": [{"text": "SHPG", "location": [4378, 4382], "entities": [{"type": "Person", "text": "SHPG"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [4394, 4431], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "6.27 06/30/2019 12.06% 18.58% SHPG 05/08/2018 Takeda Pharmaceutical Company Limited ( TKPYY ) $194.74 $176.28 06/30/2019 10.47% 16.13% RHT 10/28/2018 IBM ( IBM ) $190.00 $172.24 12/31/2019 10.31% 8.94% STC 03/16/2018 Fidelity National Financial, Inc. ( FNF ) $46.14 $41.86 06/30/2019 10.22% 15.74% Disclaimer: I hold positions in Twilio ( TWLO ), Rockwell Collins ( COL ), Pandora ( P ), Radisys ( RSYS ) and magicJack VocalTec ( CALL ).", "score": 0.482357, "arguments": [{"text": "RHT", "location": [4483, 4486], "entities": [{"type": "Person", "text": "RHT"}]}, {"text": "IBM", "location": [4498, 4501], "entities": [{"type": "Organization", "text": "IBM", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "6.27 06/30/2019 12.06% 18.58% SHPG 05/08/2018 Takeda Pharmaceutical Company Limited ( TKPYY ) $194.74 $176.28 06/30/2019 10.47% 16.13% RHT 10/28/2018 IBM ( IBM ) $190.00 $172.24 12/31/2019 10.31% 8.94% STC 03/16/2018 Fidelity National Financial, Inc. ( FNF ) $46.14 $41.86 06/30/2019 10.22% 15.74% Disclaimer: I hold positions in Twilio ( TWLO ), Rockwell Collins ( COL ), Pandora ( P ), Radisys ( RSYS ) and magicJack VocalTec ( CALL ).", "score": 0.563286, "arguments": [{"text": "Fidelity National Financial, Inc.", "location": [4565, 4598], "entities": [{"type": "Organization", "text": "Fidelity National Financial, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "STC", "location": [4550, 4553], "entities": [{"type": "Organization", "text": "STC"}]}]}, {"type": "agentOf", "sentence": "I wrote this article myself, and it expresses my own opinions.", "score": 0.996992, "arguments": [{"text": "I", "location": [5033, 5034], "entities": [{"type": "Person", "text": "myself"}]}, {"text": "wrote", "location": [5035, 5040], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "employedBy", "sentence": "I have no business relationship with any company whose stock is mentioned in this article.", "score": 0.536126, "arguments": [{"text": "whose", "location": [5185, 5190], "entities": [{"type": "Person", "text": "myself"}]}, {"text": "company", "location": [5177, 5184], "entities": [{"type": "Organization", "text": "Newfield Exploration Company"}]}]}, {"type": "employedBy", "sentence": "Under the terms of the agreement, at the election of each WildHorse common shareholder, the consideration will consist of either 5.989 shares of Chesapeake common stock or a combination of 5.336 shares of Chesapeake common stock and $3 in cash, in exchange for each share of WildHorse common stock.", "score": 0.391074, "arguments": [{"text": "shareholder", "location": [1358, 1369], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "WildHorse", "location": [1341, 1350], "entities": [{"type": "Organization", "text": "WildHorse Resource Development Corporation"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Electro Scientific Industries ( ESIO ) by MKS Instruments ( MKSI ) for $1 billion or $30.00 per share in cash.", "score": 0.426743, "arguments": [{"text": "Electro Scientific Industries", "location": [1657, 1686], "entities": [{"type": "Organization", "text": "Electro Scientific Industries"}]}, {"text": "acquisition", "location": [1642, 1653], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of LSC Communications ( LKSD ) by Quad/Graphics ( QUAD ) for $1.4 billion in an all stock deal.", "score": 0.465217, "arguments": [{"text": "Quad", "location": [1818, 1822], "entities": [{"type": "Organization", "text": "Quad Class A", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1772, 1783], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Intersections ( INTX ) by WC SACD One Parent for $131.78 million or $3.68 per share in cash.", "score": 0.525518, "arguments": [{"text": "WC SACD One Parent", "location": [2090, 2108], "entities": [{"type": "Organization", "text": "WC SACD One Parent"}]}, {"text": "acquisition", "location": [2049, 2060], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Intersections ( INTX ) by WC SACD One Parent for $131.78 million or $3.68 per share in cash.", "score": 0.807379, "arguments": [{"text": "Intersections", "location": [2064, 2077], "entities": [{"type": "Organization", "text": "Intersections"}]}, {"text": "INTX", "location": [2080, 2084], "entities": [{"type": "Ticker", "text": "INTX"}]}]}], "keywords": [{"text": "common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.982519}, {"text": "Deals Cash Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.873}, {"text": "stock deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.839774}, {"text": "Penn Virginia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.752454}, {"text": "Chesapeake common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.742146}, {"text": "Total Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725211}, {"text": "new deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.700685}, {"text": "Denbury common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.693933}, {"text": "Total Deal Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.681868}, {"text": "LSC Communications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.67676}, {"text": "WildHorse common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676106}, {"text": "Newfield common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.666278}, {"text": "Pending Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.665262}, {"text": "Virginia common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.665196}, {"text": "Stock Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.659892}, {"text": "WildHorse common shareholder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.630259}, {"text": "acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629598}, {"text": "definitive merger agreement", "sentiment": {"score": 0.634471, "label": "positive"}, "relevance": 0.628268}, {"text": "Merger Arbitrage Tool", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.628229}, {"text": "Penn Virginia shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.623241}, {"text": "LSC Communications shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618178}, {"text": "Penn Virginia Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616794}, {"text": "Deals Not Completed", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612561}, {"text": "Newfield Exploration Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611532}, {"text": "Encana common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609566}, {"text": "active deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609393}, {"text": "LSC Communications share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.608898}, {"text": "WildHorse Resource Development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607504}, {"text": "Chesapeake Energy Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601245}, {"text": "Deal Statistics", "sentiment": {"score": 0.467484, "label": "positive"}, "relevance": 0.58851}, {"text": "Electro Scientific Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578565}, {"text": "Company Closing Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578309}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5764}, {"text": "RCCH HealthCare Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572911}, {"text": "Zijin Mining Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572888}, {"text": "required regulatory approvals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569746}, {"text": "friendly takeover bid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567438}, {"text": "Price Closing Date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567161}, {"text": "China Oceanwide Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563166}, {"text": "Deal Updates", "sentiment": {"score": 0.488589, "label": "positive"}, "relevance": 0.562967}, {"text": "Fidelity National Financial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557673}, {"text": "Annualized Profit GNW", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557543}, {"text": "Denbury shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54706}, {"text": "stock type", "sentiment": {"score": 0.660664, "label": "positive"}, "relevance": 0.546892}, {"text": "Newfield shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542096}, {"text": "Denbury Resources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536734}]}, "extracted_metadata": {"sha1": "7813a6e343969ee4dab03e3241a993bc36d74748", "filename": "1541513598645.zip-8cc38afde8d0994b0e3a4b6b3e891aef.xml", "file_type": "json"}, "external_links": ["https://www.sec.gov/Archives/edgar/data/1123979/000119312518316786/d648759d8k.htm", "http://finance.yahoo.com/q?s=RHT", "https://finance.yahoo.com/quote/ESIO?p=ESIO", "https://finance.yahoo.com/quote/DNR/?p=DNR", "http://finance.yahoo.com/q?s=STC", "https://finance.yahoo.com/quote/CHK/?p=CHK", "https://finance.yahoo.com/news/amc-networks-inc-completes-acquisition-163300020.html", "https://www.sec.gov/Archives/edgar/data/1669812/000119312518313019/d646301dex991.htm", "https://finance.yahoo.com/quote/WRD?p=WRD", "https://finance.yahoo.com/quote/ILMN/?p=ILMN", "http://finance.yahoo.com/q?s=KLAC", "https://finance.yahoo.com/quote/AMCX/?p=AMCX", "http://finance.yahoo.com/q?s=D", "https://finance.yahoo.com/quote/MKSI/?p=MKSI", "https://finance.yahoo.com/quote/LKSD?p=LKSD", "https://finance.yahoo.com/quote/LPNT/?p=LPNT", "https://www.sec.gov/Archives/edgar/data/912750/000119312518315278/d648700d425.htm", "https://finance.yahoo.com/quote/WRK/?p=WRK", "https://finance.yahoo.com/quote/NSU/?p=NSU", "http://finance.yahoo.com/q?s=KANG", "http://finance.yahoo.com/q?s=TKPYY", "http://finance.yahoo.com/q?s=TMUS", "https://finance.yahoo.com/quote/TMUS/?p=TMUS", "https://finance.yahoo.com/quote/S/?p=S", "https://finance.yahoo.com/news/nevsun-announces-second-chinese-regulatory-115000514.html", "http://finance.yahoo.com/q?s=EHIC", "http://finance.yahoo.com/q?s=ORBK", "https://finance.yahoo.com/news/lifepoint-health-stockholders-approve-merger-144900933.html", "https://finance.yahoo.com/quote/PACB?p=PACB", "http://finance.yahoo.com/q?s=IBM", "http://finance.yahoo.com/q?s=SHPG", "https://finance.yahoo.com/quote/QUAD/?p=QUAD", "http://finance.yahoo.com/q?s=S", "https://www.insidearbitrage.com/merger-arbitrage/", "https://www.sec.gov/Archives/edgar/data/1095277/000114036118041900/ex99_1.htm", "https://finance.yahoo.com/quote/INTX?p=INTX", "https://www.sec.gov/Archives/edgar/data/726514/000072651418000046/exhibit991q219release.htm", "https://finance.yahoo.com/news/westrock-completes-acquisition-kapstone-210200590.html", "https://finance.yahoo.com/quote/ECA?p=ECA", "http://finance.yahoo.com/q?s=FNF", "https://www.sec.gov/Archives/edgar/data/1681714/000110465918064708/a18-38251_1ex99d2.htm", "http://finance.yahoo.com/q?s=SCG", "https://www.sec.gov/Archives/edgar/data/101830/000119312518314106/d616444d425.htm", "https://www.sec.gov/Archives/edgar/data/77159/000119312518310686/d645994dex991.htm", "https://finance.yahoo.com/quote/PVAC/?p=PVAC", "http://finance.yahoo.com/q?s=RSYS", "https://finance.yahoo.com/quote/NFX?p=NFX", "http://investor.pacificbiosciences.com/news-releases/news-release-details/illumina-acquire-pacific-biosciences-approximately-12-billion", "http://finance.yahoo.com/q?s=GNW"], "title": "Merger Arbitrage Mondays - November 5, 2018", "forum_title": "All Articles on Seeking Alpha"}]}